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 Petrocortyne A was isolated from the marine sponge Petrosia sp. by Shin and Jung in 
1998 and 1999, respectively. Both groups assigned the absolute configuration of the natural 
product, but the assignments do not consistent with the reported optical rotations. Using the 
fluorous mixture synthesis (FMS), we have synthesized four stereoisomers of petrocortyne A to 
determine the absolute configuration. In the FMS, the stereoisomeric starting materials were 
tagged with different fluorous TIPS groups and mixed together. The resulting mixture was taken 
through a series of steps to make the fluorous-tagged products, which were separated by fluorous 
HPLC followed by desilylation to provide four pure products.  
Second-generation fluorous TIPS tags were synthesized and used in the FMS. Both 
Mosher and NMA ester methods were studied during the synthesis. The study showed that NMA 
ester method is superior to Mosher method for the assignment of absolute configuration of 
stereocenter C14. 
Comparison of optical rotations of the four synthetic and two natural samples showed 
that both natural samples had the C3-S configuration. Comparison of spectra of Mosher 
derivatives of the synthetic and natural samples showed that both natural samples had the 3S,14S 
configuration. At the same time, the use of the Mosher rule has been validated for assigning the 
challenging C14 stereocenter of petrocortyne A. A “shortcut” variant in which only one Mosher 
ester is made was developed and can also be used for assignment of this stereocenter. 
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1.0  FLUOROUS MIXTURE SYNTHESIS AND STRUCTURE ASSIGNMENT OF 
PETROCORTYNE A AND ITS STEREOISOMERS 
1.1 INTRODUCTION 
1.1.1 Fluorous Mixture Synthesis (FMS) 
Natural products are chemical compounds isolated from living organisms, and they 
usually have pharmacological and biological activities. Natural products play an important role 
in drug discovery and drug design.1 Recent reviews showed that natural products and their 
derivatives are significant sources of new drugs.2,3 The syntheses of libraries of biologically 
active natural product stereoisomers are important because they allow the unambiguous 
structural assignments of natural products whose stereoisomers may have similar or even 
identical spectra. Establishing the correct stereostructure is a prerequisite for the study of 
structure-activity relationships (SAR) in drug discovery. Furthermore, the syntheses of 
stereoisomer libraries provide samples for biological tests that help establish an SAR.  
As the complexity of isolated natural products increases, the structure assignment, 
especially the stereochemistry assignment, becomes more challenging. Total synthesis of all of 
the stereoisomers can provide enough samples that can be used to prove or disprove the structure 
assignment by comparison of various physical and spectral data of a natural product with 
1
  
synthetic products. The recent proof of structure of murisolin by its comparison with a library of 
its stereoisomers shows the power of having multiple isomers for comparison.4 
Synthetic chemists have always constructed compounds one at a time. It is time-
consuming work to synthesize multiple stereoisomers of natural products by traditional solution 
phase synthesis. For instance, in order to elucidate the structure of khafrefungin, Kobayashi and 
coworkers had to synthesize five stereoisomers of khafrefungin one by one.5  
The situation of synthesizing one stereoisomer at a time began to change in the 1990s as 
the revolution of solid-phase and combinatorial chemistry spread through synthetic laboratories.6 
Recently, Waldmann and coworkers reported the total syntheses of all isomers of cryptocarya 
diacetate on a polymeric carrier.7 Takahashi and coworkers also reported the combinatorial 
synthesis of a macrosphelide library on polymer support.8 However, compared to conventional 
solution-phase methods, solid-phase synthesis sacrifices the reactivity of the supported substrates 
because of unfavorable kinetics of heterogeneous reaction.9 To date, the scope of reactions 
developed for solid phase synthesis is still limited.  
Fluorous mixture synthesis (FMS), introduced in 2001, is the first solution phase 
technique that captures the efficiency inherent in mixing compounds yet still allows the reliable 
separation of the mixtures to provide individual pure target products in the end.10 A typical 
fluorous mixture synthesis consists of four stages: premix, mixture synthesis, demix, and detag, 
as shown in Figure 1.1. 
During the premix stage, a set of isomeric substrates (S1–Sn) is prepared individually by 
traditional methods. The configuration of each isomer is encoded with a corresponding set of 
homologous fluorous tags (F1–Fn) with increasing fluorine content. The fluorous-tagged 
precursors (S1F1–SnFn) are mixed together (M1) and taken through a multi-step synthesis 
2
  
(mixture stage) in one-pot reactions or split-parallel fashion. At the end of synthesis, the final 
mixture (M2) is demixed based on fluorine content by preparative fluorous HPLC. Molecules 
(F1P1–FnPn) with longer fluorous chains have longer retention time on the fluorous HPLC 
column. The order of elucidation of products can be predicted in advance by the original 
tag/substrate pairs (SF) based on the fluorine content. In the final stage, detagging is conducted 
to release the final products (P1–Pn). 
 
Premix Mixture synthesis Demix Detag
S1
.
.
.
Sn
F1
Fn SnFn
steps Fluorous HPLC
.
.
.
F1P1
FnPn
.
.
.
P1
Pn
PreparativeS
1F1
M1
.
.
.
M2
one-pot
/parallel
synthesis
S = substrate; F = f luorous tag; M1 = starting mixture; M2 = end mixture; P = product
 
Figure 1.1.  Schematic diagram of the concept of FMS 
 
Based on the nature of target, fluorous mixture synthesis has been applied to three 
different categories of compounds: enantiomers, diastereomers, and analogs (Scheme 1.1). When 
both enantiomers of a compound are needed, two enantiomeric precursors are tagged with 
different tags to make quasienantiomers, which are mixed together. The resulting mixture is 
conducted in the whole synthesis. After the steps of demixing and detagging, the two target 
enantiomers are obtained as pure compounds. The synthesis of both mappicine enantiomers 
highlights this application, which is called quasi-racemic synthesis (Scheme 1.1a).11 The 
synthesis of diastereomers of natural product is sometimes necessary for elucidation of structure. 
Fluorous mixture synthesis is a powerful tool to synthesize some or all diastereomers for 
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comparisons with an isolated natural product. This approach was taken in the synthesis and 
structure assignment of lagunapyrone B12 (Scheme 1.1b) and murisolin.4,13 Fluorous mixture 
synthesis can also be used to generate a library of analogs of a natural product with varying 
substituents. Recently, the syntheses of a 560-member library of mappicine analogs (Scheme 
1.1c) has been reported by Zhang and coworkers.14 
 
Scheme 1.1.  Representative natural products synthesized by FMS 
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 FMS has been proved to be a powerful tool to synthesize natural products, their isomers, 
and libraries. We now want to solve more challenging problem of stereocenter assignment for 
natural products with local symmetry. 
1.1.2 Petrocortyne A 
Many natural products with unique molecular architectures have been isolated from 
marine sponges.15 These natural products often display remarkable biological activities, making 
them lead structures for the development of new chemotherapeutic agents. Polyacetylenes have 
been revealed as abundant sources of marine sponge metabolites, which possess great novel and 
diverse long chain and functionalities. More than 50 biologically active polyacetylenes 
characterized by unbranched long alkyl chains were isolated from the marine sponge Petrosia sp.. 
Borrowing from the name of the sponge, the compounds were named like petrocortynes,16 
petroformynes,17 and petrosiacetylenes.16a,c One example of each type of substrate is shown in 
Figure 1.2. Most of these compounds modulate various biological activities such as anti-
inflammatory, antimicrobial, antitumor, antiviral, and antifungal effects. The compounds 
typically consist of a linear carbon skeleton of 30 to 47 carbons interspersed with functional 
groups including alkynes, E- and Z-alkenes, and hydroxyl groups. 
 
5
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Figure 1.2.  Representative polyacetylenes isolated from marine sponge Petrosia sp. 
 
Petrocortyne A, a novel lipid compound, was first isolated from the marine sponge 
Petrosia sp. collected in 1994 at Komun Island, Korea by Shin and coworkers in 1998.16a 
Approximately 70 mg of a linear tetraacetylene assigned as (3R,14R)-petrocortyne A 1.1RR 
(Figure 1.3) was isolated. The compound exhibited a modest inhibitory activity against the 
enzyme phospholipase A2 (PLA2) (31% at 50 μg/mL). 
 
OH
3
11
14
17 21 27
12
46
OH
1.1RR, 3R,14R (3R,14R)-petrocortyne A
1.1SS, 3S,14S (3S,14S)-petrocortyne A (not shown)  
Figure 1.3.  Structure of petrocortyne A 
 
In 1999, Jung and coworkers reported another petrocortyne A, assigned as (3S,14S)-
petrocortyne A 1.1SS (Figure 1.3), isolated from sponge Petrosia sp. collected in 1995 again off 
6
  
Komun Island.16c This time, about 142 mg of (3S,14S)-petrocortyne A 1.1SS was obtained.  
Jung’s petrocortyne 1.1SS inhibited the production of tumor necrosis factor (TNF)-α from 
lipopolysaccharide (LPS)-stimulated murine macrophages RAW264.7 in a concentration-
dependent manner with an IC50 of 2.35 μM. Similarly, it inhibited the production of TNF-α from 
phorbol 12-myristate 13-acetate (PMA)/LPS treated U937 cells at the transcriptional level (46% 
inhibition at 5 μM). (3S,14S)-Petrocortyne A 1.1SS also blocked NO release from either LPS- or 
interferon (INF)-γ-treated RAW267.4 cells. It selectively blocked the expression of hepatocyte 
growth factor/scatter factor (HGF/SF), which plays an important role in regulating infiltration of 
immune or inflammatory cells into inflamed tissue. Compound 1.1SS also induced U937 
homotypic aggregation. Since homotypic aggregation is considered a potential tool for negative 
modulation of inflammatory cell migration,18b the pro-aggregative effect of this compound may 
reinforce its anti-inflammatory function. Therefore, (3S,14S)-petrocortyne A 1.1SS inhibits 
cellular inflammatory processes and immune cell migration to inflamed tissue, which makes it a 
potential anti-inflammatory drug.18 
The constitutions of these two samples 1.1RR and 1.1SS were assigned by a battery of 
spectroscopic methods. By the combination of HRMS, IR, 1H NMR, and 13C NMR analysis, 
petrocortyne A 1.1RR or 1.1SS consists of four isolated double bonds and a long alkyl chain 
without methyl groups or other branches. Several partial structures (Figure 1.4) were identified 
based on the study of 2D NMR spectra (COSY, HETCOR, HMQC, and HMBC). The COSY 
data revealed that none of the partial structures was directly connected to another, so the partial 
structures were considered to be linked by linear alkyl chains. The lengths of alkyl chains and 
connectivities of partial structures were determined by the combination of chemical degradation, 
detailed NMR analysis with the addition of Eu(fod)3, a lanthanide-induced shift reagent, and 
7
  
EIMS analysis. The geometry of four isolated double bonds was determined by NMR 
spectroscopy. The double bonds at C4 and C43 were assigned as E and Z, based on the coupling 
constants between the olefinic protons. However, the geometry of those at C21 and C27 were 
unable to be determined by coupling constants, because signals of the olefinic protons 
overlapped. However, the geometry of both double bonds was assigned as Z on the basis of 
chemical shift of allylic carbons in the 13C NMR spectrum.19 
 
OH
OH  
Figure 1.4.  Partial structures of petrocortyne A 
 
The absolute configurations of the two remote stereocenters at C3 and C14 were assigned 
by the advanced Mosher ester method.20 The configurations were assigned as 3R,14R for Shin’s 
petrocortyne A 1.1RR, and 3S,14S for Jung’s petrocortyne A 1.1SS, respectively. Thus, these 
two natural products are enantiomers. However, the values of optical rotations of petrocortyne A 
1.1RR (+ 6.4, MeOH, c = 0.25) and (3S,14S)-petrocortyne A 1.1SS (+ 10.8, MeOH, c = 1.9) do 
not meet the expectation that enantiomers should give optical rotations with opposite sign and 
equal magnitude. Accordingly, the assignment of the absolute configuration of one or even both 
of these two natural products may be incorrect. 
In the murisolin family of acetogenins with very remote stereocenters, we have found the 
diastereomers exhibit substantially identical spectra.4 Similarly, petrocortynes also have remote 
stereocenters. Would the (3S,14S)/(3R,14R) pair of enantiomers (syn diastereomer) exhibit the 
same spectra as the (3R,14S)/(3S,14R) pair (anti diastereomer)? If the spectra are the same, then 
how can the diastereomers be differentiated? The configuration of the stereocenter at C3 can be 
8
  
assigned by making a pair of diastereomeric Mosher esters and analyzing their 1H NMR spectra 
by the advanced Mosher method. But, is the application of the advanced Mosher analysis a 
reliable tactic for assigning the configuration of the stereocenter at C14 of petrocortyne A? This 
center is difficult to assign because there is a local symmetry plane at C14 and because there are 
no protons directly attached to the carbons adjacent to the stereocenter. 
Despite the novel skeleton and uncertain configuration, there have not been any reports of 
synthetic efforts toward the petrocortynes and similar compounds. Our goals of this project are to 
prepare all four individual pure stereoisomers of petrocortyne A by fluorous mixture synthesis, to 
compare the data of synthetic and natural samples and their Mosher derivatives, and thereby to 
prove the assignment of absolute configuration of these natural products. 
9
  
 
1.2 RESULTS AND DISCUSSION 
1.2.1 Retrosynthetic analysis of petrocortyne A 
In the fluorous mixture synthesis, diisopropyl(perfluoroalkylethyl)silyl groups (TIPSF) 
and triisopropylsilyl group are used as tags because they are stable under most reaction 
conditions and easily deprotected.12,21 TIPSF group is not a “true” TIPS group because it has a 
1°-alkyl(diisopropyl)silyl group while TIPS group has a triisopropylsilyl group. In the following 
schemes, TIPSFn is used as an abbreviation of fluorous TIPS group; n is the number of certain 
fluorine content (the regular TIPS group is displayed as TIPSF0). The structures of TIPSF0 group 
and two fluorous tags, C3F7(CH2)2(iPr)2Si– (TIPSF7) and C4F9(CH2)2(iPr)2Si– (TIPSF9), used in 
the following synthesis are shown in Figure 1.5. Compounds bearing different TIPSF groups will 
be mixed, and in the numbering the following text, all samples bearing the “M” prefix are 
mixtures of fluorous-tagged quasiisomers. 
 
Si
Rf
TIPSF7 (Rf = C3F7): diisopropyl(3,3,4,4,5,5,5-heptafluoropentyl)silyl TIPSF0 : triisopropylsilyl
TIPSF9 (Rf = C4F9): diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyl
Si
 
Figure 1.5.  The structure of TIPSF groups used in the following synthesis 
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The retrosynthesis and tagging strategy of FMS to assemble the backbone of the target 
structure 1.1 are shown in Scheme 1.2. Petrocortyne A 1.1 can be constructed from the two large 
fragments, aldehyde M-1.2 and triphenylphosphonium salt 1.3, by Wittig reaction22 followed by 
demixing over fluorous HPLC and desilylation. Because fragment M-1.2 has two stereocenters, 
we planned to make M-1.2 as quasiisomer mixture of four stereoisomers with configurations 
encoded by fluorous tags in the protecting group (TIPSF). Fragment M-1.2 can be assembled 
from alkyne M-1.4 and aldehyde 1.5 by asymmetric alkynylation under Carreira’s condition.23 
 
Scheme 1.2.  The retrosynthesis of petrocortyne A 1.1 
OH
3
11
14
17 21
27 12
46
OH
1.1(RR, SS, RS, SR), four isomers
OTIPSFn
3
11
14
17 21
OTIPSFn
O
27 12
46
Ph3P
M-1.2, one mixture of 4 quasiisomers 1.3
Wittig Rxn
TBS
TMS
Br
asymmetric
alkynylation
OTIPFFn
11
14
17 21
O
H
TMS
OPMB
M-1.4, one mixture of 2 1.5
quasienantiomers
3
+
 
 
 As shown in Scheme 1.3, both enantiomers of fragment M-1.4 at C3 can be formed by 
enantioselective reduction of α,β-unsaturated ketone 1.6 using Alpine–Borane,24 followed by 
silylation with different fluorous tags. Ketone 1.6 can be constructed from aldehyde 1.7 by 
alkynylation followed by oxidation. Aldehyde 1.7 can be synthesized from aldehyde 1.8 by 
11
  
Wittig olefination22 followed by reduction of ester to alcohol and oxidation of alcohol to 
corresponding aldehyde.  Finally, we plan to prepare aldehyde 1.8 from commercially available 
3-nonyn-1-ol 1.9 by a zipper reaction,25 followed by Swern oxidation.26 
 
Scheme 1.3.  The retrosynthesis of M-1.4 
11
H
O
OH
O
11
TMS
1.8 1.9 3-nonyn-1-ol
OTIPSFn
11
TMS
M-1.4, one mixture of 2 1.6 1.7
quasienantiomers
3 3
11
H
O
3
 
 
Aldehyde 1.5 can be constructed from the reaction between DMF and alkyne 1.10, which 
can be derived from commercially available 3-heptyn-1-ol 1.11 by another zipper reaction 
followed by PMB protection (Scheme 1.4). 
 
Scheme 1.4.  The retrosynthesis of aldehyde 1.5 
17 21
OPMB OH14
17 21
O
H
1.5 1.10 1.11 3-heptyn-1-ol
OPMB
 
 
 The synthesis of triphenylphosphonium salt 1.3 can start from a smaller 
triphenylphosphonium salt 1.12 and aldehyde 1.13 by Wittig reaction followed by deprotection, 
halogenation, and reaction with triphenylphosphine (Scheme 3). Aldehyde 1.13 can be obtained 
from a Sonagashira coupling reaction27 between commercially available tert-
12
  
butyldimethylsilylacetylene and vinyl bromide 1.14, which will be synthesized from 16-
hydroxyhexadecanoic acid 1.15. 
 
Scheme 1.5.  The retrosynthesis of triphenylphosphonium salt 1.3 
27
PMBO
PPh3
Br 12
46 TBS
Br
12
H
MeO
HO
O
OH14
1.14 1.15 16-hydroxyhexadecanoic acid
O
O
27 12
46
Ph3P
TBS
Br
1.3 1.12 1.13
+
 
 
1.2.2 Synthesis of C1–C13 fragment 1.4R 
Prior to starting the FMS of petrocortyne A, the partial synthesis of one isomer was 
performed. The first aim for this synthesis was to validate that every step could work for FMS. 
The second aim was to provide some fragments of petrocortynes with known configurations to 
validate that the Mosher method is a reliable tactic for assigning the absolute configurations at 
C3 and C14 of petrocortynes. 
The work began with the preparation of propargylic alcohol 1.18R (C1–C13), as 
summarized in Scheme 1.6. Internal alkyne 1.9 was first subjected to an acetylene zipper 
reaction with sodium hydride in warm ethylene diamine to provide a terminal alkyne28 in 68% 
yield. Subsequent Swern oxidation of the primary alcohol of the above alkynol afforded 
aldehyde 1.829 in 90% yield. This intermediate is unstable toward oxygen and can only be stored 
for prolonged periods when kept under argon. Aldehyde 1.8 was reacted with commercially 
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available Wittig reagent 1.16 to give (E)-α,β-unsaturated ester 1.17 as a single isomer in 80% 
isolated yield after flash chromatography. Reduction of ester 1.17 with DIBAL-H cleanly 
provided the alcohol in 87% yield. This was oxidized to α,β-unsaturated aldehyde 1.7 in 90% 
yield by Swern oxidation. 
 
Scheme 1.6.  Synthesis of propargylic alcohol 1.18R 
HO
TMS1. n-BuLi, , 88%
TMS
(R)-Alpine Borane
neat, overnight
OH
TMS
R
1.9 3-nonyn-1-ol 1.8
1. H2NCH2CH2NH2, NaH, 68%
2. Swern Oxidation, 88%
H
Ph3P=CHCO2Et 1.16
EtO
O
2. Swern Oxidation, 90%
O
1. DIBAL-H, 87%
2. Swern Oxidation, 90%
H
O
O
1.17 1.7
1.6 1.18R, 58%, 93% ee
80%
 
 
Trimethylsilylacetylene was treated with n-BuLi to generate 
((trimethylsilyl)ethynyl)lithium, which was reacted with aldehyde 1.7 to give the racemic alcohol 
in 88% yield. Swern oxidation of this alcohol provided ketone 1.6, which was isolated as yellow 
oil in 88% yield after rapid chromatographic purification. This ketone could only be stored for a 
short time; hence, it was used as quickly as possible. Ketone 1.6 was treated with neat (R)-
Alpine–Borane at room temperature overnight to generate (R)-propargylic alcohol 1.18R in 58% 
yield. The ee of compound 1.18R was determined by 19F NMR analysis of the crude Mosher 
esters (see following text for synthesis). Each crude Mosher ester exhibited three peaks in its 19F 
NMR spectrum, one from excess MTPA  acid (α-methoxytrifluorophenylacetic acid) (−71.0 
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ppm), and the others from two diastereomeric MTPA  esters of −72.1 (major peak for 1.19RR 
and minor peak for 1.19RS) and −72.3 ppm (minor peak for 1.19RR and major peak in 1.19RS). 
Integration of the latter pair of peaks provided the ee of alcohol 1.18R as 93%. 
The absolute configuration of major compound 1.18R could be predicted based on the 
model provided by Midland and coworkers (Scheme 1.7).30 They proposed that the high 
enantioselectivity in this reduction originated from a cyclic, boat-like transition state due to the 
preferential syn-1,3-steric interaction between 2-methyl group of Alpine-Borane and the smaller 
group of the approaching ketone. In the case of reduction of ketone 1.6, the acetylene acts as the 
smaller group, and the alcohol 1.18R is predicted to form through the favored transition state. 
The configuration of compound 1.18R can be confidently assigned from Midland model, so 
alcohol 1.18R is a suitable substrate to validate the advanced Mosher method. 
 
Scheme 1.7.  Midland’s transition state model for the asymmetric reduction of ketone 1.6 with (R)-alpine 
borane 
Me
H
OBO
TMS
1.6
+
B
(R)-Alpine borane
favored
Me
H
OB
unfavored
H
R
R
OH
TMS
OH
TMS
R
S
1,3-syn
interaction
1,3-syn
interaction
≠
≠
1.18R major
1.18S, minor
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The advanced Mosher method was developed by Kusumi and Kakisawa in 1991.20 They 
proposed that the carbinyl proton, ester carbonyl and trifluoromethyl groups of MTPA moiety lie 
in the same plane. This idealized conformation is depicted in Figure 1.6a. Due to the anisotropic 
effect of the benzene ring, the resonances of protons HA, HB, HC of the (R)-MTPA ester should 
appear upfield relative to those of the (S)-MTPA ester. The reverse should be true for protons HX, 
HY, HZ. Therefore, for the differences in chemical shifts as defined ΔδH = δS − δR, protons on the 
right side of the MTPA plane (Figure 1.6b) will have positive values (ΔδH > 0) and protons on 
the left side of the MTPA plane will have negative values (ΔδH < 0). The magnitude of ΔδH will 
be proportional to the distance of the protons from MTPA moiety, with closer protons exhibit 
bigger ΔδΗ. Consequently, based on this model, the absolute configuration of the compound can 
be assigned.  
 
H
O
O
CF3
Ph OMe
HAHC
HZHYHX
HB
MTPA plane
a
C
OMTPA
H
HB
HA
HC
HY
HX
HZ
b
Δδ < 0 Δδ > 0
(S)-MTPA
ΔδH = δS - δR
Where ΔδH = the difference in chemical shift of a peaks of related protonsδS = the chemical shift of proton in (S)-MTPA esterδR = the chemical shift of proton in (R)-MTPA ester
Side View Front View
 
Figure 1.6.  (a) An ideal conformation of an (S)-MTPA ester of a secondary alcohol. (b) Advanced Mosher 
model for assigning the absolute configuration of a secondary alcohol from ΔδΗ values of Mosher ester.20 
 
The Mosher esters of alcohol 1.18R were then synthesized by treatment with (S)- and 
(R)-MTPA acid in CH2Cl2 in the presence of DCC and DMAP (Scheme 1.8). After removing the 
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solid byproducts by filtration, the corresponding crude esters 1.19RS and 1.19RR were obtained 
by solvent evaporation. These crude esters were used for assignment of absolute configuration of 
1.18R without further purification. Relevant chemical shifts of protons of esters 1.19RS, 1.19RR 
and their differences are listed in Table 1.1 in parts per million (ppm). The remote protons (H1') 
of the TMS group on one side of the stereocenter exhibited a small negative Δδ, while the 
protons H4, H5 and H6 on the other side exhibited a substantial positive Δδ. According to the 
advanced Mosher rule, the absolute configuration of C3 is R, as expected from the Midland 
transition state model. 
 
Scheme 1.8.  Synthesis of Mosher esters 1.19RS and 1.19RR 
OH
TMS
R (R)/(S)−MTPA acid
DCC, DMAP, DCM
OR/S-MTPA
TMS
R
1.18R 1.19RS: (S)-MTPA ester
1.19RR: (R)-MTPA ester  
 
Table 1.1.  Δδ (δ1.19RS − δ1.19RR) values (ppm) obtained from the MTPA esters of 1.19RS and 1.19RR 
OMTPA
Si
R 4
1'
6
1.19RS, (S)-MTPA ester
1.19RR, (R)-MTPA ester  
proton (H) 1' 4 5 6 
δ1.19RS 0.154 5.569 6.018 2.080 
δ1.19RR 0.174 5.472 5.960 2.045 
Δδ (δ1.19RS − δ1.19RR) −0.020 0.097 0.058 0.035 
 
Alcohol 1.18R was then tagged with fluorous tag 1.21 bearing a C3F7 group. The tag was 
synthesized from the corresponding perfluoroalkyl iodide 1.20 and chlorodiisopropylsilane in 
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77% yield.11 Fluorous silane 1.21 was reacted with trifluoromethansulfonic acid at 0 °C to 
generate the fluorous TIPSOTf reagent in situ,14 then alcohol 1.18R in the solution of CH2Cl2 
and 2,6-lutidine was slowly added at 0 °C. After stirring 2 h at room temperature followed by 
aqueous work up and flash chromatography, the desired product 1.4R was obtained in 82% yield 
(Scheme 1.9). 
 
Scheme 1.9.   Synthesis of fluorous tagged ether 1.4R 
C3F7
I
t-BuLi
H
Si
Cl
1.19 1.20, 77%
OH
TMS
OSi(iPr)2CH2CH2C3F7
TMS
Si H
C3F7 CF3SO3H
2,6-lutidine
Si OTf
C3F7
DCM
1.18R
1.4R, 82%  
 
1.2.3 Synthesis of aldehyde 1.5 (C14–C21 fragment) 
Aldehyde 1.5 was readily made in three steps (Scheme 1.10). Commercially available 3-
heptyn-1-ol 1.11 was treated with sodium hydride in warm ethylenediamine to provide alkynol 
1.2228 by a zipper reaction in 64% yield. Alkynol 1.22 was protected by para-methoxybenzyl 
chloride (PMBCl) in the presence of NaH and tetrabutylammonium iodide (TBAI) in DMF to 
generate the alkyne 1.10 in 92% yield. According to the procedure of Journet and Cai,32 alkyne 
1.10 was metallated with n-BuLi in THF, and the resulting lithium acetylide was formylated by 
DMF. Workup under mild acidic conditions (10% aqueous KHPO4) followed by flash 
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chromatography provided aldehyde 1.5 in 88% yield. Thus, about 2.5 g of aldehyde 1.5 was 
made by this sequence. 
 
Scheme 1.10.  Synthesis of aldehyde 1.5 
OH
H2NCH2CH2N2H
OH
NaH, PMBCl, TBAI
OPMB
n-BuLi, DMF OPMB
O
H
1.11 1.22, 64% 1.10, 92%
1.5, 2.5 g, 88%
14
17 21
NaH DMF
 
 
1.2.4 Model reaction towards the synthesis of fragment M-1.2 
Assorted methods have been described to make enantioenriched secondary alcohols with 
one alkynyl and one alkyl, vinyl or aryl substituent.32 However, very few methods to make 
enantioenriched dialkynyl carbinols have been reported. Carreira and co-workers reported one 
example of synthesizing enantioenriched dialkynyl methanol 1.25 by the asymmetric 
alkynylation of aldehyde 1.23 using chiral ligand (+)-N-methyl-ephedrine 1.24 (Scheme 1.10).23 
The product was obtained in 89% ee, but its configuration was not assigned. 
 
Scheme 1.11.  Carreira’s approach to synthesize dialkynyl methanol 1.25 
HO
Me
NMe2
PhEt3Si
+ H
O
OTBS
Zn(OTf)2, Et3N Et3Si
OH
OTBS
∗
1.23 1.25, 89% ee
1.24, toluene
1.24
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With the alkyne 1.4 and aldehyde 1.5 in hand, we initially investigated the Carreria 
method for asymmetric addition of alkynlides to alkynals by studying the reaction of 1-octyne 
1.26 with 2-octynal 1.27 (Scheme 1.12). Following the general procedure reported by Carreira 
and coworkers, a mixture of dried Zn(OTf)2, (+)-N-methyl-ephedrine 1.24 and Et3N in toluene 
was stirred at 23 °C for 2 h. The alkyne 1.26 was then added in one portion, and the resulting 
mixture was stirred at 23 °C for 15 min. A solution of aldehyde 1.27 in toluene was then added 
by syringe pump over 2.5 h, followed by stirring at 75 °C for 20 h. Unfortunately, no product 
1.28 was detected by 1H NMR spectroscopy. 
 
Scheme 1.12.  Unsuccessful model reaction between 1-octyne 1.26 with 2-octynal 1.27 
+ H
O OH
Zn(OTf)2 , Et3N
1.24, toluene, 75°C
1.26 1.27 1.28
× ∗
 
 
We also found several other examples of failed Carreira reactions on aliphatic 
aldehydes,33 which suggested that this type of chiral zinc acetylide addition reaction is sensitive 
to substrate structure.34 Due to the failure of Carreira asymmetric alkynylation, we had to revise 
the synthetic route for fragment M-1.2. 
 
1.2.5 Revised synthetic route of C1–C21 fragment M-1.2 
The revised retrosynthetic analysis of C1–C21 fragment M-1.2 is shown in Scheme 1.13. 
We divide fragment M-1.2 into two parts, iodide M-1.29 and dialkynyl methanol M-1.30, which 
can be made as quasiracemic mixtures with configurations encoded by fluorous tags in the 
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protecting groups (TIPSF). These two fragments then can be connected by a SN2 reaction to 
provide a mixture of four fluorous-tagged quasiisomers. This kind of double tagging strategy was 
recently reported in the synthesis of passifloricin A21 and lagunapyrone B.12  
 
Scheme 1.13.  Revised retrosynthesis of fragment M-1.2 
OTIPSF
3
11
14
17 21
OTIPSRf
O
M-1.2, one mixture of 4 isomers
TBS
I
OTIPSF
11
14
17 21
TBS
OPMB
M-1.29 quasiracemic mixture M-1.30 quasiracemic mixture
3
SN2 reaction
OTIPSF
+
 
 
Iodide M-1.29 can be constructed from ketone 1.31 by performing enantioselective 
reduction of α,β-unsaturated ketone 1.31 with chiral oxazaborolidine (CBS) catalyst (Scheme 
1.14).35 Ketone 1.31 can be synthesized from the addition of commercially available tert-
butyldimethylsilylacetylene to Weinreb amide 1.32, which can be obtained from aldehyde 1.33 
by Horner-Wadsworth-Emmons (HWE) olefination.36 Aldehyde 1.33 can be prepared from 
commercially available 1,7-heptanediol 1.34. 
 
Scheme 1.14.  The retrosynthesis of iodide M-1.29 
I
OTIPSF
11
M-1.29 1.31
OPMB
O
11
OPMB
O
11
N
1.32 1.33 1.34 1,7-heptanediol
OMe
OPMB
11
H
TBS TBS
OH
11
HO
O
3 3
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Dialkynyl methanol M-1.30 can be synthesized by enantioselective addition of terminal 
alkyne to aldehyde 1.5 followed by protection and encoding with TIPSF groups. 
 
Scheme 1.15.  The retrosynthesis of fragment M-1.30 
14
17 21
OTIPSF
OPMB
17 21
OPMB
O
H+
M-1.30 terminal alkyne 1.5
R
 
 
1.2.6 Synthesis of iodide M-1.29 (fragment C1–C11) 
The synthesis of iodide M-1.29 begins with the preparation of common intermediate 
ketone 1.31 (Scheme 1.16). Commercially available 1,7-heptanediol 1.34 was treated with 
sodium hydride (1.0 equiv) and PMBCl (1.0 equiv) in THF to provide the mono-PMB ether37 in 
49% yield after isolation by flash chromatography. Swern oxidation of the remaining primary 
alcohol afforded aldehyde 1.3337 in 98% yield. Weinreb amide 1.32 was accessed by a Horner-
Wadsworth-Emmons (HWE) olefination of aldehyde 1.33 with commercially available 
phosphonate 1.35 in THF with 91 % yield. Nucleophilic addition of tert-
butyldimethylsilylacetylene 1.36 to Weinreb amide 1.32 gave the ketone 1.31 in 89% yield. 
Conveniently, ketone 1.31 is stable and could be stored in refrigerator for 2 weeks without any 
decomposition.  
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Scheme 1.16.  Synthesis of ketone 1.31 
OHHO
1. NaH, PMBCl, TBAI, THF
OPMB
1.34 1,7-heptanediol 1.33, 48% (2 steps)
NaH, THF, 0 °C→rt
OPMB
O
N
OMe
Me
N
OMe
Me
O
(EtO)2P
O
1.35
1.32, 91% 1.31, 89%
TBS
THF, -78 °C
OPMB
O
TBS
1.36 , n-BuLi
2. Swern oxidation
H
O
 
 
The sample of ketone 1.31 was split into half and each portion was subjected to CBS 
asymmetric reduction (Scheme 1.17).35 Reduction with BH3 in the presence of the catalyst (R)-
CBS was proceeded to provide (R)-alcohol 1.37R in 70% yield. Similarly, (S)-alcohol 1.37S was 
generated by the reduction of alkynyl ketone 1.31 using (S)-CBS in 73% yield.  
 
Scheme 1.17.  Synthesis of alcohols 1.37R/S by CBS asymmetrical reduction 
(R)-CBS,
(S)-CBS, BH3• SMe2
OPMB
OH
TBS
1.37R, 70%, 93% ee
OPMB
OH
TBS
1.37S, 73%, 94%ee
R
S
BH3•SMe2
OPMB
O
TBS
split
1.31
 
 
According to the mechanism proposed by Corey and coworkers for analogous 
oxazaborolidine-mediated reactions,35b the absolute configurations of alcohols 1.37R and 1.37S 
were confidently assigned based on the transition state models in which the acetylenic moiety 
acts as the smaller group (scheme 1.18). 
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Scheme 1.18.  Corey’s transition state model for the CBS asymmetric reduction of ketone 1.31 
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O
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+
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OH
OPMB
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H
N
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O
B H
H H
Me
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Ph
H
TBS
H
BH3 SMe2•
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TBS
TBS
(S)-CBS
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 The corresponding Mosher esters of alcohols 1.37R and 1.37S were then synthesized for 
three reasons: 1) to determine the ees for the two alcohols; 2) to validate the Mosher method 
again, although we have done it using alcohol 1.18; 3) to compare the Mosher method and NMA 
(α-methoxy-2-naphthylacetic acid) ester method in the configuration assignment of secondary 
alcohol. After removal of the TBS group by TBAF in DCM, the corresponding alcohols 1.38R 
and 1.38S were obtained. Alcohol 1.38S was reacted with the R- and S-Mosher acid chloride 
(MTPACl = α-methoxy-α-trifluoromethylphenylacetic acid chloride) in dry pyridine to give the 
corresponding crude esters 1.39SS and 1.39SR after removing organic solvent under reduced 
pressure. Integration of the respective signals in 1H and 19F NMR spectra of the resulting crude 
samples provides the indicated ees (93% for 1.37R and 94% for 1.37S) for the CBS asymmetric 
reduction. After flash chromatography, the pure esters 1.39SS and 1.39SR were obtained and 
used in NMR experiments. All of the key protons of both compounds were assigned by a 
combination of 1H NMR and COSY data. Relevant chemical shifts of protons of esters 
1.39SS/SR and the differences of resonances of corresponding pairs (δS − δR) are listed in Table 
2. The proton (H1) on the left side of stereocenter exhibited a positive Δδ, while the protons H4–
24
  
H10 on the other side showed the substantial negative Δδs. According to the advanced Mosher 
rule, the absolute configuration of C3 is S, as expected from the Corey transition state model. 
 
Scheme 1.19.  Synthesis of Mosher esters 1.39SS and 1.39SR 
OPMB
OH
TBS 1.37S 1.38S, 95%
1.37R (not shown) 1.38R (not shown)
S
TBAF, DCM
OPMB
OH
S
OPMB
OS/R-MTPA
SOPMB
OH
1.38S 1.39SS (S)-MTPA ester
1.39SR (R)-MTPA ester
S
R/S-MTPACl, Py
 
 
Table 1.2.  Δδ (δ1.39SS − δ1.39SR) values (ppm) obtained from the MTPA esters of 1.39SS and 1.39SR 
O
OS/R-MTPA
H
O1
4 6
9 11 1'
2'
1.39SS, (S)-MTPA ester
1.39SR, (R)-MTPA ester
S
 
position 1 4 5 6 7 8 9 10 
δ1.39SS 2.629 5.496 6.002 2.044 1.368 1.260 1.338 1.578
δ1.39SR 2.589 5.606 6.063 2.085 1.400 1.312 1.364 1.589
Δδ (δ1.39SS − δ1.39SR ) 0.040 −0.110 −0.061 −0.041 −0.032 −0.052 −0.026 −0.011
 
During the model studies for the C14 stereocenter (see below), we needed to make α-
methoxy-2-naphthylacetic acid (2-NMA) esters to validate the Mosher results, so we also made 
the NMA ester with alcohols 1.38S and 1.38R. The use of α-methoxy-2-naphthylacetic acid as a 
chiral anisotropic reagent for determining the absolute configuration of long chain secondary 
alcohols was developed simultaneously by several groups in mid-1990s.38 Because the 
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anisotropic effect of 2-NMA is much greater than that of MTPA, Δδ values of 2-NMA esters are 
larger than those of MTPA esters. This makes assignment of absolute configuration both easier 
and more reliable.39 
Since we only had (S)-2-NMA in hand, our strategy was to synthesize the corresponding 
(S)-2-NMA esters 1.40SS and 1.40RS by the reaction of two enantiomers 1.38S and 1.38R with 
(S)-2-NMA in the presence of DCC and DMAP (Scheme 1.20). Ester 1.40RS is the enantiomer 
of ester 1.40SR obtained from the reaction of 1.38S with (R)-2-NMA acid. Consequently, 
ΔδH between esters 1.40SR and 1.40SS were obtained from 1H NMR data of esters 1.40RS and 
1.40SS. For NMA ester, the subtraction formula is reversed,39 ΔδH = δR − δS, due to the inverted 
CIP (Cahn–Ingold–Prelog) priority order of NMA ester compared to MTPA ester (δR is the 1H 
chemical shift of (R)-2-NMA ester, δS is the 1H chemical shift of (S)-2-NMA ester.). After 
purification by flash chromatography, esters 1.40SS and 1.40RS were studied by 1H NMR 
spectroscopy. All of the key protons of both compounds were unambiguously assigned by a 
combination of 1H NMR and COSY data. Relevant chemical shifts of protons of esters 1.40SS, 
1.40RS and their differences are listed in Table 1.3. For comparison, the Δδ values for the 
Mosher esters were also listed in the last row in Table 1.3. 
 
Scheme 1.20.  Synthesis of (S)-2-NMA esters 1.40SS and 1.40RS 
COOH
OCH3
S
OPMB
OH
DCC, DMAP, CH2Cl2 ,
rt, overnight
1.38S 1.40SS
1.38R (not shown) 1.40RS (not shown)
OPMB
O-S-NMA
(S)-2-NMA
S S
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Table 1.3.  Δδ (δ1.40RS − δ1.40SS) values (ppm) obtained from the (S)-2-NMA esters of 1.40RS and 1.40SS 
O
O-S-NMA
H
O1
4 6
9 11 1'
2'
1.40SS, from 1.38S
1.40RS, from 1.38R (not shown)
S
 
protons 1 4 5 6 7 8 9 10 11 
δ1.40RS 2.558 5.335 5.798 1.886 1.173 1.149 1.237 1.515 3.393
δ1.40SS 2.444 5.534 5.981 2.038 1.356 1.267 1.329 1.569 3.420
Δδ (δ1.40RS − δ1.40SS) 0.114 −0.199 −0.183 −0.152 −0.183 −0.118 −0.092 −0.054 −0.027
Δδ (δ1.39SS − δ1.39SR)∗ 0.040 −0.110 −0.061 −0.041 −0.032 −0.052 −0.026 −0.011 0.000
*MTPA ester 
 
First, the results showed that the NMA ester method works for configuration assignment 
of secondary alcohol. The results also showed that the differences of chemical shifts obtained 
with NMA esters are much larger than those obtained with MTPA esters. For instance, the 
difference of chemical shift of NMA esters at H6 is −0.152, but that of MTPA esters is only 
−0.041. The large ΔδH allowed us to confirm the C3 absolute configuration of alcohol 1.38S 
without ambiguity. The results also showed the long-range anisotropic effect of NMA. For NMA 
esters, the difference of chemical shift for H11 (nine atoms away from the stereocenter) is 
−0.027, but for MTPA esters, there is no measurable difference for this proton. Taken together, 
the results show that NMA esters are superior to MTPA esters for the assignment of absolute 
configuration. 
Alcohols 1.37R and 1.37S were then individually tagged with two different tags (Scheme 
1.21). The hydroxyl group of 1.37R was protected by silylation with in situ generated fluorous 
TIPS triflate bearing the C4F9 (F9) group to encode the 3R configuration in 1.41R. Likewise, 
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silylation of 1.37S with fluorous TIPS triflate bearing the C3F7 (F7) provided the 
quasienantiomer 1.41S with the 3S configuration encoded. Quasienantiomers 1.41R and 1.41S 
were weighed and mixed with 1:1 molar ratio to generate the first quasiracemate. Although not 
true racemates, the components of quasiracemates usually have nearly identical physical and 
spectroscopic properties and chemical reactivities toward achiral reagents.40 The quasiracemic 
mixture was deprotected by DDQ to afford alcohol M-1.42, which was then converted to iodide 
M-1.29 with iodine in the presence of triphenylphosphine and imidazole in CH2Cl2 with 49% 
yield over two steps. 
 
Scheme 1.21.  Synthesis of iodide M-1.29 
OPMB
OH
TBS
1.37R 1.41R, 87%
OPMB
OH
TBS
1.37S 1.41S, 90%
TIPSF9OTf
2,6-lutidine
2,6-lutidine
TIPSF7OTf
OPMB
OTIPSF9
TBS
OPMB
OTIPSF7
TBS
mix
DDQ, I2, PPh3, imid, DCM
OH
OTIPSF9,7
TBS
I
OTIPSF9,7
TBSDCM/H2O
M-1.42 M-1.29, 49% (2 steps)
R
S
R
S
11
3
Rf
Si
TIPSF9 (Rf = C4F9)
TIPSF7 (Rf = C3F7)
 
1.2.7 Synthesis of dialkynyl carbinols 1.57R and 1.57S 
The precursors for synthesis of fragment M-1.30, dialkynyl carbinols 1.54R and 1.54S, 
can be synthesized from aldehyde 1.5 and terminal alkyne by asymmetric alkynylation (Scheme 
1.22).  
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Scheme 1.22.  Proposed synthetic route for 1.57R/S 
H
OPMB
O
OPMB
OH
Si
Ph
R
17 21
14
OPMB
OH
S
17 21
14
1.5 1.54R 1.57S
1.54S (not shown) 1.57R (not shown)  
 
The key reaction in this transformation is constructing the stereocenter C14 
enantioselectively. After the failure of Carreira’s asymmetric alkynylation, we were attracted by 
a literature report published by Pu and co-workers.41 They described the asymmetric 
alkynylations of aldehydes (aromatic, alkyl and vinyl, but no alkynyl aldehyde) using chiral 
ligand (S)-BINOL with Ti(OiPr)4 in excellent yields and enantioselectivities. In Pu’s reaction 
(Scheme 1.23), a terminal alkyne is first reacted with Et2Zn to generate an alkynylzinc 
intermediate. This is then added to the aldehyde and the catalyst to form the chiral propargyl 
alcohol. 
 
Scheme 1.23.  Enantioselective synthesis of propargyl alcohols reported by Pu and coworkers 
R
R'CHO, (S)-BINOL
Ti(OiPr)4, rt
R
OH
R'∗
91-99% ee
R' = aryl, alkyl or
vinyl
Et2Zn
toluene, reflux
R ZnEt
≠ OH
OH
(S)-BINOL  
 
We set out to find whether Pu’s asymmetric addition was applicable to alkynals. We first 
studied the asymmetric reaction of phenylacetylene 1.43 with 2-octynal 1.27. A solution 
phenylacetylene 1.43 and diethylzinc in toluene was heated under argon atmosphere at reflux for 
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1 h. After the solution had cooled to room temperature, (R)-BINOL, Et2O, and Ti(OiPr)4 were 
added sequentially, and the resulting mixture was stirred for 1 h. 2-Octynal 1.27 was added and 
stirring was continued for an additional 4 h. After purification on silica gel, alcohol 1.44S was 
obtained (90–96% yield, Table 1.4). The absolute configuration of this alcohol was tentatively 
assigned as S by analogy to Pu’s results with other types of aldehydes.41 
 
Table 1.4.  Yields and ees of reactions of phenylacetylene 1.43 with 2-octynal 1.27 to give propargyl alcohol 
1.44S 
Ph
1. ZnEt2, toluene, reflux
1.43 1.44S
OH
Ph
S
2.
(R)-BINOL, Ti(OiPr)4, ether, rt
C5H11C CCHO, 1.27
 
 
entry 
alkyne 
(equiv) 
Et2Zn 
(equiv) 
[Et2Zn] 
(mol/L) 
Ti(OiPr)4 
(equiv) 
BINOL 
(equiv) 
yielda 
(%) 
eeb 
(%) 
1 4.0 4.0c 1.1 1.0 0.4 96 57 
2 4.0 4.0d 3.0 1.0 0.4 94 63 
3 6.0 6.0d 4.5 2.5 1.0 90 78 
4 8.0 8.0d 6.0 2.5 1.0 92 67 
aIsolated yield. bee determined by chiral HPLC (Chiralcel OD column, 4.6 × 200 mm, hexane/iPrOH = 9:1, 1.0 
mL/min). c15 % wt Et2Zn (1.1 M) in toluene was used. d95 % Et2Zn was used. 
 
Various conditions were explored for the reaction to optimizing enantioselectivity (Table 
1.4). The ee of propargyl alcohol 1.44S was determined by chiral HPLC. We first used 
commercially available Et2Zn solution (15 wt% in toluene ≈ 1.1 M) as source of zinc, but the ee 
of alcohol 1.44S was only 57% (entry 1). When 95% Et2Zn was used, the ee improved to 63% 
(entry 2). To further increase the ee, we increased the amount of all reagents. This increased the 
ee to 78% and provided a high yield (90%) (entry 3). In entry 4, we further increased the 
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amounts of diethylzinc and phenylacetylene 1.43 compared to the aldehyde 1.27. This decreased 
the ee to 67%, but still gave an excellent yield (92%). Finally, we chose the conditions of entry 3 
as the optimized conditions for this reaction. 
 
Table 1.5.  Enantioselective addition of alkynes and aldehyde 1.27 
(R)-BINOL, Ti(OiPr)4
1.44-1.46 1.47-1.49SH
O
OH
Ph
SR
Et2Zn
toluene, reflux
R ZnEt
≠
1.27  
entry R- SM product yield (%)a ee (%)b 
1 SiPh
 
1.45 1.48S 90c 78  
2 Si
Ph
Ph
 
1.46 1.49S 85c 80  
3 
TBSO
 
1.47 1.50S 86 90  
aIsolated yield. bee determined by chiral HPLC (Chiralcel OD column, 4.6 × 200 mm, hexane/iPrOH = 49:1, 0.6 
mL/min). cProduct was contaminated with BINOL. 
 
The optimized procedure was then applied to the reactions of several terminal alkynes 
with 2-octynal 1.27, and the results of this series of reactions are shown in Table 1.5. The ees of 
the products were again measured by chiral HPLC. Silylacetylenes generate products that can be 
easily converted to terminal alkynes by desilylation, so these were tested first. Reaction of 
dimethylphenylsilylacetylene 1.45 with aldehyde 1.27 gave alcohol 1.48S in 90% yield and 78% 
ee (entry 1). When methyldiphenylsilylacetylene 1.46 was used, the yield was 85% and the ee of 
product 1.49S was only increased to 80%. We rationalized this small increase due to the 
relatively long bond length of carbon-silicon bond (1.86 Å). Increasing the size of the silyl group 
had little impact on enantioselectivity. If an alkyne with shorter bond length between carbon and 
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R group is used in the reaction, then the enantioselectivity should be improved. 2-Methyl-3-
butyn-2-o1 1.47 is a suitable alkyne, because the bond length of carbon-carbon bonds (1.46 Å) is 
shorter than carbon-silicon bonds. The addition reaction followed by a facile fragmentation 
reaction provides an access to the enantioenriched terminal acetylene that could be a useful 
building block for synthesis of petrocortyne A. When alkyne 1.47 was subjected to this 
asymmetric addition reaction (entry 3), the product 1.50S was isolated in 90% ee and 86% yield.  
The next goal was to convert the compound 1.50S to the corresponding terminal 
acetylene. As a prelude, the model reaction using racemic alcohol rac-1.53 was performed. 
Compound rac-1.53 was prepared in three steps (Scheme 1.24). Alkyne 1.47 was treated with n-
BuLi to generate lithium acetylene in situ. This was reacted with aldehyde 1.27 to afford racemic 
propargylic alcohol rac-1.51 in 82% yield. Alcohol rac-1.51 was then converted to diol rac-1.52 
with acetyl chloride in MeOH in 91% yield. TIPS protection of the secondary alcohol of diol 
rac-1.52 afforded alcohol rac-1.53 in 87% yield. 
 
Scheme 1.24.  Synthesis of racemic alcohol rac-1.53 
TBSO
1.47 1.27 rac-1.51, 82%
TIPSOTf, 2,6-lutidine
OHC
n-BuLi, THF TBSO
OH
CH3COCl
MeOH
HO
OH
HO
OTIPS
rac-1.52, 91% rac-1.53, 87%  
 
The fragmentation reaction of alcohol rac-1.53 was conducted under a variety of 
conditions (Scheme 1.25). Reaction with 40 mol % of 18-crown-6 and K2CO3 in refluxing 
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toluene42 or under microwave irradiation resulted in decomposition. When the base was changed 
to KOH, no desired product was detected by TLC analysis and starting material was recovered. 
This reaction was then carried out in the KH solution of toluene with or without 18-crown-6 at 
room temperature, but only starting material was obtained.  
 
Scheme 1.25.  Unsuccessful fragmentation reaction of alcohol rac-1.53 
conditions×HO
OTIPS OTIPS
1. 40 mol % 18-crown-6, K2CO3, toluene reflux, decomposition
2. 40 mol % 18-crown-6, K2CO3, toluene microwave (30 min, 150 °C), decomposition
3. 40 mol % 18-crown-6, KOH, toluene reflux, recovered starting material
4. 40 mol % 18-crown-6, KH, toluene rt, recovered starting material
5. KH, toluene rt, recovered starting material
rac-1.53
 
 
 Because of the difficulty of performing a fragmentation reaction of rac-1.53, the product 
generated from dimethylphenylsilylacetylene 1.45 was chosen as the precursor to synthesize 
fragment M-1.30. Alcohol 1.54R was synthesized according to the optimized version of Pu’s 
procedure (Table 1.4 entry 3). Commercially available dimethylphenylsilylacetylene 1.45 was 
treated with Et2Zn in refluxing toluene for 1 h to afford the alkynylzinc intermediate. Aldehyde 
1.5 was then added with (S)-BINOL and Ti(OiPr)4 to form (R)-dialkynyl methanol 1.54R 
(Scheme 1.26). Alcohol 1.54R was contaminated with residual (S)-BINOL, which was difficult 
to remove by flash chromatography. Furthermore the ee of alcohol 1.54R, while a substantial 
(83% determined by chiral HPLC: Chiralcel OD column, 4.6 × 200 mm hexane:iPrOH = 9:1, 1.0 
mL/min), did not meet our target level of ee >90%. Enantiomeric impurities at this stage would 
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produce diastereomeric impurities downstream, and we did not know whether or how the 
impurities could be either separated or identified.  
In order to increase the ee and get rid of BINOL in alcohol 1.54R, purification by 
preparative HPLC was undertaken. The enantiomerically pure (>99% ee) alcohol 1.54R was 
obtained in 64% yield (269.3 mg) by using semi-preparative Chiralcel OD column (20 × 250 mm, 
hexane:iPrOH = 19 : 1, 8.0 mL/min, 1.0 mL (0.1 M in hexane)/injection, 320 mg of crude 
product). Similarly, (S)-dialkynyl methanol 1.54S (not shown) was obtained by addition of 
alkynylzinc to aldehyde 1.5 in the presence of (R)-BINOL and Ti(OiPr)4 in 83% ee too. After 
purification by HPLC (350 mg of crude product), the enantiomerically pure alcohol (>99% ee) 
1.54S was obtained in 70% yield (294.6 mg). 
 
Scheme 1.26.  Synthesis of alcohols 1.54R and 1.54S 
SiPh H
OPMB
O
1.45 1.5 1.54R, from (S)-BINOL, 64%, >99% ee
1.54S, from (R)-BINOL, 70%, >99% ee (not shown)
OPMB
OH
Si
Ph
R
Et2Zn, (S)/(R)-BINOL,Ti(OiPr)4
HPLC Purification
+
17 21
14
 
 With alcohols 1.54R/S in hand, we next used them as models to validate the Mosher 
method for assigning the configuration at C14. It is more difficult to assign the C14 stereocenter 
than C3 for two reasons. First, there are no protons directly attached to the carbons adjacent to 
the C14 stereocenter. Second, because there is a local plane symmetry, the peaks of protons at 
C10 and C17 in 1H NMR are overlap. Making the Mosher esters breaks this local symmetry and 
differentiates the protons at C10 and C17. It is essential to correctly assign the resonances for 
protons at C10 and C17 before applying the Mosher method. If the resonances are mis-assigned, 
then the stereocenter configuration will be mis-assigned. 
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 To unambiguously assign pairs of propargylic methylene protons, we chose dialkynyl 
carbinol 1.54R and/or 1.54S as a model system with only one propargylic methylene group. We 
then made both MTPA and 2-NMA esters of alcohol 1.54. Each of the pair of enantiomeric 
MTPA acid chlorides was reacted with 1.54R in dry pyridine to provide the pair of Mosher 
esters 1.55RS and 1.55RR, while the single (S)-2-NMA acid was reacted with the pair of 
enantiomers 1.54R and 1.54S to give the NMA esters pair 1.56RS and 1.56SS. All of key 
protons of two pairs of esters were assigned by a combination of 1H NMR and COSY spectra. 
The relevant chemical shifts of protons of Mosher esters 1.55RS/RR and NMA esters 
1.56RS/SS and the differences of resonances of corresponding pairs (δS − δR for Mosher esters 
and δR − δS for NMA esters) are listed in Table 1.6 and 1.7, respectively. The configuration of 
stereocenter C14 at alcohol 1.54R was assigned as R by applying either the Mosher method or 
NMA ester method. 
Although the differences of proton resonances of both Mosher ester pairs and NMA ester 
pairs have negative sign on one side of the stereocenter and positive sign on the other side, the 
magnitudes are very different. For example, the largest chemical shift difference in the Mosher 
esters is only 0.029 ppm for the protons at the C17, while in NMA esters, this difference is 0.158 
ppm. The large ΔδH allowed us to confirm the C14 absolute configuration of alcohol 1.54S 
without ambiguity. Besides the larger chemical shift differences, the NMA esters have a longer 
anistropic effect. No difference was measured for the benzylic protons H1'' (10 atoms away from 
the stereocenter) in Mosher esters, but the difference of 0.022 ppm was measured in NMA esters. 
Taken together, NMA esters are superior to MTPA esters for the assignment of configuration of 
stereocenters with local symmetry.  
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Table 1.6.  Δδ (δ1.55RS − δ1.55SS) values (ppm) obtained from the MTPA esters of 1.55RS and 1.55RR 
OPMB
OH
Si
Ph
R
17 21
14
R/S-MTPACl, Py
1.54R 1.55RS, (S)-MTPA ester
1.55RR, (R)-MTPA ester
O
OS/R-MTPA
Si
Ph
R
OCH3
1'
17 21 1''
 
position 1' 17 18 19 20 21 1'' 
δ1.55RS 0.405 2.242 1.534 1.444 1.598 3.415 4.410
δ1.55RR 0.428 2.213 1.511 1.420 1.587 3.413 4.410
Δδ (δ1.55RS − δ1.55RR) -0.023 0.029 0.023 0.024 0.011 0.002 0.000
 
Table 1.7.  Δδ (δ1.56SS − δ1.56RS) values (ppm) obtained from the MTPA esters of 1.56SS and 1.56RS 
OPMB
OH
Si
Ph
R
17 21
14
1.54R 1.56RS, (S)-NMA ester
1.54S (not shown) 1.56SS, (S)-NMA ester (not shown)
COOH
OCH3
S
DCC, DMAP, CH2Cl2,
rt, overnight
(S)-2-NMA
O
O-S-NMA
Si
Ph
OCH3
1'
17 21 1''
R
 
position 1' 17 18 19 20 21 1'' 
δ1.56SS 0.249 2.212 1.510 1.429 1.587 3.413 4.414
δ1.56RS 0.400 2.054 1.335 1.277 1.484 3.349 4.392
Δδ (δ1.56SS − δ1.56RS) –0.151 0.158 0.175 0.152 0.103 0.064 0.022
 
 From the above results, we validated the use of the Mosher method and the NMA ester 
method to assign the configuration at C14. Because of larger and longer anistropic effect of the 
NMA group, the NMA ester method is easier and more reliable to assign the configuration of the 
stereocenter, especially in a compound with local symmetry, such as petrocortyne A. 
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 Continuing the synthesis of 1.57S/R, silylacetylenes 1.54R and 1.54S were then treated 
with TBAF to generate terminal alkynes 1.57S and 1.57R in 85% and 89% yield, respectively 
(Scheme 1.27). 
 
Scheme 1.27.  Synthesis terminal alkynes 1.57S and 1.57R 
OPMB
OH
Si
Ph
R
17 21
14
1.54R 1.57S, 85%
1.54S (not shown) 1.57R, 89% (not shown)
OPMB
OH
17 21
STBAF, THF, rt
 
 
Before the alcohols 1.57S and 1.57R were individually tagged with different fluorous 
tags, several model reactions were carried out to make sure that every step could work for the 
synthesis of fragment M-1.2. 
1.2.8 Towards the synthesis of fragment M-1.2 with silyl ether rac-1.59 
After completing the syntheses of iodide M-1.29 and alcohols 1.57R/S, we initiated our 
task for the coupling reaction of iodide M-1.29 with alkyne M-1.30 derived from alcohols 1.57R 
and 1.57S. A model coupling reaction between commercially available iodide 1.58 and alkyne 
rac-1.59 was first conducted before the iodide M-1.29 and alcohol 1.57R/S were used in the 
coupling reaction.  
Terminal alkyne rac-1.59 was easily prepared in a three-step procedure (Scheme 1.28). 
Trimethylsilylacetylene was treated with n-BuLi to generate ((trimethylsilyl)ethynyl)lithium, 
which was reacted with aldehyde 1.5 to give a racemic alcohol in 89% yield. After removal of 
37
  
the TMS group with TBAF, the secondary alcohol rac-1.57 was protected with TIPS group to 
afford alkyne rac-1.59 in 90% yield. 
 
Scheme 1.28.  Synthesis terminal alkyne rac-1.59 
OPMB
OH
OPMB
O
HTMS
1. n-BuLi, THF, 89%
2. TBAF, THF, 91%
+
1.5 rac-1.57
OPMB
OTIPS
rac-1.59, 90%
TIPSOTf
 
 
The results of the model coupling reaction of iodide 1.58 (model for C1–C10 fragment) 
and alkyne rac-1.59 were shown in Scheme 1.29. After treatment of rac-1.59 with n-BuLi in 
THF at −78 °C for 1 h, a solution of iodide 1.58 in THF and HMPA was added. After workup 
and flash chromatography purification, three major products were isolated. The desired coupling 
product 1.60 was isolated in 16.5% yield along with the two undesired products 1.61 (2.5%) and 
1.62 (9.1%) (Structures were determinated by 1H NMR). The side products arrived from the 
deprotonation of the protected dialkynylcarbonol proton (proton at C14). Even if the alkylation at 
C14 could be prevented, this deprotonation still cause epimerization at C14 of substrates (rac-
1.59). 
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Scheme 1.29.  Model coupling reaction of iodide 1.58 and alkyne rac-1.59 
I
OPMB
OTIPS
+
OPMB
OTIPS
OPMB
OTIPS
OPMB
OTIPS
n-BuLi, HMPA
THF
1.60, 16.5%
1.58 rac-1.59
1.61, 2.5%
1.62, 9.1%
14
14
14
14
 
To suppress the undesired products and avoid the epimerization at the C14 stereocenter, 
we decided to conduct the coupling reaction on a dianion derived from free alcohol rac-1.57. 
Under the conditions for formation of dianion of rac-1.57 by its treatment with n-BuLi, there 
should be no anion formation at C14 to give a trianion.43 
 
1.2.9 Towards the synthesis of fragment M-1.2 by using dianion strategy 
The model dianion alkylation was performed between iodide 1.58 and free alcohol rac-
1.57 (Scheme 1.30). Alcohol rac-1.57 was treated with 2 equiv of n-BuLi to generate dianion in 
situ, which was then reacted with 2 equiv of iodide 1.58. In addition to the desired product rac-
1.63 (26% yield), O-alkylated product rac-1.64 was also isolated in 25% yield and its structure 
was confirmed by 1H NMR. The 19% of alcohol rac-1.57 was recovered (entry 1). In entry 2, 1:1 
ratio of alkyne and iodide were subjected to the reaction also gave byproduct rac-1.64 (10%) in 
addition to desired product rac-1.63 (13%). The starting material rac-1.57 was recovered in 51%. 
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When a 2:1 ratio of alkyne and iodide were used, only product rac-1.63 was obtained in 59% 
yield with 65% recovered rac-1.57 (entry 3). 
 
Scheme 1.30.  Model reaction of iodide 1.58 and alkyne rac-1.57 
I
OPMB
OH
+
OPMB
OH
n-BuLi, HMPA
THF
rac-1.63
1.58 rac-1.57
OPMB
rac-1.64
OC8H17
 
entry 1.58/equiv rac-1.57/equiv n-BuLi/equiv rac-1.63/% rac-1.64/% rac-1.57/% 
1 2.0 1.0 2.2 25 26 19 
2 1.0 1.0 2.2 13 10 51 
3 1.0 2.0 4.4 59 0 65 
 
 We then carried out the coupling reaction of iodide 1.29S with dialkynol rac-1.57 
(Scheme 1.31). Dialkynol rac-1.57 was treated with 2 equiv of n-BuLi to generate dianion in situ, 
then iodide 1.29S was added. Standard workup and chromatography provided coupled product 
1.65 in 35% yield. Substantial starting material rac-1.57 remained, and 1.65 was the only new 
product of the reaction. 
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Scheme 1.31.  Coupling reaction of iodide 1.29S and dialkynol rac-1.57 
OPMB
OHTBS
OTIPS
I +
n-BuLi, HMPA
THF
TBS
OTIPS
OH
OPMB
1.29S rac-1.57
1.65, 35%
 
 The coupling reaction of the iodide M-1.29 and dialkynol 1.57S was then performed 
(Scheme 1.32). The quasiracemate M-1.29 was added to the dianion derived from 1.57S. Again, 
a single new spot appeared on TLC analysis. However, this time the chromographically isolated 
product (30% yield) was not the pure quasiracemate M-1.66. Instead, this was contaminated by a 
substantial amount (about 50%) of a second component 1.67 resulting from transfer of the 
fluorous TIPS groups of M-1.29 to the terminal acetylide of 1.57S. These compounds were not 
separable, but the structure of 1.67 was secured by MS (m/z = 596.7 and 646.7) and NMR 
analysis of mixture. In particular, the 1H NMR spectrum of the mixture exhibited no terminal 
acetylide proton resonance, so the TIPSF group in alcohol 1.67 must be connected to the terminal 
acetylide and not to the alcohol. 
 Suspecting that this reaction provided the byproduct because of liability of the TIPSF 
under the nucleophilic environment, we conspired to block this side reaction by applying the new 
second-generation TIPSF tags with a propylene spacer, Rf(CH2)3Si(iPr)2, to reduce the 
electrophilic reactivity of TIPSF tags.44 
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Scheme 1.32.  Coupling reaction of iodide M-1.29 and dialkynol 1.57S 
OPMB
OH
TBS
I +
n-BuLi, HMPA
THF
TBS
OTIPSF7,9
OH
OPMB
M-1.29 1.57S
M-1.66 1.67
OTIPSF7,9
OPMB
OH
F7,9TIPS
+
 
1.2.10 Synthesis of the second-generation TIPSF tags and new iodide M-1.68 
The second-generation TIPSF tags 1.69 and 1.70 were synthesized from the 
corresponding perfluoroalkyl iodides and chlorodiisopropylsilane (Scheme 1.33).44 The perfluoro 
carbon units in the two fluorous tags are C3F7 (TIPSF7′) and C4F9 (TIPSF9′). The “prime(′)” in the 
formula represents the propylene spacer. 
 
Scheme 1.33.  Synthesis of the second-generation TIPSF 1.69 and 1.70 
C3F7 I
t-BuLi
H
Si
Cl
SiC3F7
1.69
C4F9 I
t-BuLi
H
Si
Cl
SiC4F9
1.70
H H
 
 
 The synthesis of new iodide M-1.68 starts from the common intermediate ketone 1.31 
(Scheme 1.34). Asymmetric reduction of ketone 1.31 using BH3 in the presence of the catalyst 
(R)-CBS proceeded in 70% yield with high enantiomeric selectivity (93%) to provide (R)-alcohol 
1.37R. Similarly, (S)-alcohol 1.37S was generated by the reduction of alkynyl ketone 1.31 using 
(S)-CBS in 73% yield with 94% ee. Fluorosilane 1.70 bearing C4F9 (TIPSF9′) group was treated 
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trifluoromethansulfonic acid at −78 °C to generate TIPSF9′OTf in situ. This was then reacted with 
the hydroxy group of 1.37R to encode the 3R configuration in 1.71R. Likewise, silylation of 
1.37S with general TIPS triflate provided the quasienantiomer 1.71S with the 3S configuration 
encoded by TIPS (TIPSF0) group. Quasienantiomers 1.71R and 1.71S were weighed and mixed 
with 1:1 molar ratio to generate the starting mixture. The mixture was deprotected by DDQ to 
afford alcohol, which was then converted to iodide M-1.68 with iodine in the presence of 
triphenylphosphine and imidazole in CH2Cl2 with 42% yield (5.62 g) over two steps. 
 
Scheme 1.34.  Synthesis of new iodide M-1.68 
OPMB
O
TBS
1. (R)-CBS,
OPMB
OTIPSF9 '
TBS
OPMB
OTIPSF0
TBS
mix
1. DDQ, DCM/H2O
2. I2, PPh3, DCM
I
OTIPSF0, 9'
TBS
R
S
M-1.68, 42% (2 steps)
1 mixture of 2 quasienantiomers
SiTIPS
F9' (Rf = C4F9)
TIPSF0 Si
BH3• SMe2
2. TIPSF9'OTf
1. (S)-CBS, BH3• SMe2
2. TIPSF0OTf
Rf
1.31
1.71R, 87%
1.71S, 90%
split
 
 
1.2.11 Unexpected difficulty of removal of PMB group in compound 1.65 
In parallel with the syntheses of the second-generation TIPSF tags and new iodide M-1.68, 
we also continued the pilot synthesis from compound 1.65. After protection of the hydroxyl 
group by TIPS, the resulting TIPS ether 1.72 was subjected to various conditions to remove the 
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PMB group (Scheme 1.35). We first tried DDQ deprotection in DCM with the pH 7 buffer, but 
many spots appeared on TLC analysis (entry 1). When the 3 equiv of ceric ammonium nitrate 
(CAN) was used in acetonitrile with pH 7 buffer, only 28% of desired alcohol 1.73 was obtained 
and 50% starting material was recovered (entry 2). When the amount of CAN was increased to 5 
equiv, the yield of product 1.73 did not change, but the recovered PMB ether 1.72 decreased to 
37% (entry 3). We suspected that the substrate, especially the alkynyl alkenyl carbinol unit, was 
not stable under oxidative cleavage conditions. We then turned to Lewis acids. When 
MgBr2·Et2O and Me2S were used,45 only starting material was recovered (room temperature) or 
decomposition occurred (refluxing) (entry 4). Sonication of a solution of PMB ether 1.72 in 
DCM at rt for 5 min also gave nothing but starting material (entry 5). 
 
Scheme 1.35.  Unsuccessful removal of PMB group 
TIPSOTf, 93%
R
OPMB conditions
R
OTIPS
OH
R
OH
OPMB
1.65 1.72
TBS
OTIPS
OTIPS
1.73
R =
 
 
entry conditions yield comments 
1 DDQ (1.2 + 0.3 equiv), pH7 buffer, DCM, rt / complex TLC 
2 CAN (3.0 equiv), pH7 buffer, CH3CN, rt 28% recovered SM 50% 
3 CAN (5.0 equiv), pH7 buffer, CH3CN, rt 27% recovered SM 37% 
4 MgBr2·Et2O, Me2S, DCM, rt/reflux / NR (rt), decomposition (reflux) 
5 Sonication 5 min, DCM, rt / NR 
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 Faced with difficulty of removal of the PMB group in compound 1.72, we considered 
other protecting group options. The protecting group should be easily removed after the 
precursor of fragment M-1.2 was obtained. In order to circumvent this issue, we chose to protect 
the hydroxyl group as MTM (methylthiomethyl) ether.46 So it was necessary to synthesize the 
new middle fragment as an MTM ether. 
 
1.2.12 Synthesis of middle fragment MTM ethers 1.74S and 1.74R 
The synthesis of alcohol 1.74S and 1.74R started from the commercially available 3-
heptyn-1-ol 1.11 (Scheme 1.36), which was treated with sodium hydride in warm 
ethylenediamine to provide alkynol 1.22 by a zipper reaction in 68% yield. Alcohol 1.22 was 
protected by reacting with DSMO in the presence of AcOH in Ac2O to generate MTM ether 
1.75.46b This was used directly in next step. According to the procedure of Journet and Cai,32 
MTM ether 1.75 was metallated with n-BuLi in THF, and resulting lithium acetylide was 
formylated by DMF. Workup under mild acidic conditions (10% aqueous KHPO4) provided 
aldehyde 1.76 in 71% yield over two steps. Treatment of aldehyde 1.76 with the lithium 
(dimethylphenylsilyl)alkynide 1.45 afforded racemic alcohol rac-1.77 in 97% yield.  
In analyzing the ees from Pu reactions, we have found that the enantiomers of products 
like rac-1.77 were well separated on a Chiralcel OD chiral column. Thus, instead doing two 
asymmetric alkyne additions and upgrading the ees of those enantiomeric products, we simply 
made racemic rac-1.77 on gram scale and resolved it. The racemic alcohol rac-1.77 was 
preparatively resolved by chiral HPLC to provide two enantiomerically pure alcohols 1.77R in 
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49% yield and 1.77S in 48% yield. Both samples had ees ≥ 99% by chiral HPLC analysis. The 
absolute configurations of two alcohols were assigned by advanced Mosher method. The 
terminal dimethylphenylsilyl group in 1.75R was removed by TBAF in THF to afford 1.74S in 
78% yield. Likewise, alcohol 1.74R was obtained in 95% yield from 1.75S. 
 
Scheme 1.36.  Synthesis of MTM ether 1.74S and 1.74R 
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1.2.13 Successful synthesis of fragment M-1.2 
We envisioned an SN2 nucleophilic addition to an iodide as the key coupling step to 
combine fragments M-1.68 and 1.74S/R (Scheme 1.37). In order to avoid racemization at C14 of 
1.74S/R, we decided to employ the dianion derived from 1.74S/R for its alkylation with iodide 
M-1.68 based on the results of the model reaction in Scheme 1.30. Formation of dianion of 
46
  
1.74S/R by its treatment with n-BuLi should be clean and there should be no deprotonation at 
C14 of 1.74S/R to give a trianion. We therefore prepared two quasi-diastereomeric compounds 
by dianion alkylation. Treatment of alcohol 1.74R in THF/HMPA with 2.2 equiv of n-BuLi 
generated the dinaion. This was alkylated with M-1.68 to provide the first quasi-diastereomeric 
product M-1.78R in 34% yield. The sample of M-1.78R was then tagged with a second-
generation fluorous TIPS triflate bearing the C4F9 group (TIPSF9′) to afford M-1.79R in 99% 
yield. Similarly, we prepared M-1.79S by alkylation of 1.74S with M-1.68 in 33% yield and 
tagged this with C3F7 variant of second-generation fluorous TIPS group (TIPSF7′) in 85% yield. 
Although the yields of alkylations were moderate, there was no evidence of silyl transfer from 
the M-1.68 to terminal acetylide of 1.74R/S. Thus, the propylene spacer did its job. 
Quasidiastereomers M-1.79R and M-1.79S were then mixed in a 1/1 ratio to provide the 
mixtures of four quasiisomers. MTM deprotection was accomplished under mild alkylation 
conditions (MeI, NaHCO3, aqueous acetone)46a to give alcohol M-1.80 in 90% yield, and 
subsequent treatment with Dess-Martin periodinane gave the aldehyde M-1.2 (338.5 mg) in 74% 
yield. 
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Scheme 1.37.  Synthesis of fragment M-1.2 
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1.2.14 Synthesis of C22–C46 fragment 1.3 
The synthesis of fragment 1.3 is summarized in Scheme 1.38. Commercially available 
1,6-hexanediol 1.81 was treated with sodium hydride (1.0 equiv) and PMBCl (1.0 equiv) in the 
presence of TBAI in THF to provide the mono-PMB ether 1.82 in 54% yield. Alcohol 1.82 was 
converted to bromide 1.83 with CBr4 in 89% yield.47 The corresponding phosphonium salt 1.12 
was derived from bromide 1.83 with triphenylphosphine in refluxing acetonitrile for 2 days.47 
Ester 1.84 was obtained from 16-hydroxyhexadecanoic acid 1.15 by the reaction with MeOH in 
the presence of p-toluenesulfonic acid with quantitative yield.48 Swern oxidation of ester 1.84 
provided aldehyde 1.85 in 98% yield.49 The gem-dibromoalkene 1.86 was obtained, in excellent 
yield (92%) by Wittig homologation of aldehyde 1.85 in the presence of PPh3 and CBr4. 
Stereoselective palladium-catalyzed hydrogenolysis of 1.86 with n-Bu3SnH was then 
performed, yielding the desired Z-vinyl bromide 1.14 quantitatively. Sonogashira cross-coupling 
reaction of 1.14 with tert-butyldimethylsilylacetylene 1.35 was successfully carried out with 
Pd(PPh3)2Cl2 and CuI in piperidine to furnish ester 1.87 in 87% yield. Conversion of ester 1.87 
to aldehyde 1.13 was effected by DIBAL reduction in 94% yield. Wittig olefination reaction of 
1.13 with the ylide derived from triphenylphosphonium salt 1.12 (NaHMDS, THF, -78 °C to rt) 
afforded olefin 1.88 in 99% yield with complete Z-selectivity. Deprotection of PMB ether 1.88 
with DDQ in DCM/H2O provided alcohol, which was directly brominated by CBr4 in the 
presence of PPh3 to furnish bromide 1.89 in 60% yield over two steps. The bromide 1.89 was 
then treated with excess PPh3 in refluxing acetonitrile for 2 days to provide corresponding 
triphenylphosphonium salt 1.3 (6.8 g). 
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Scheme 1.38.  Synthesis of triphenylphosphonium salt 1.3 
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1.2.15 Synthesis of four isomers of petrocortyne A 
With the two large fragments M-1.2 and 1.3 in hand, we finished the synthesis of four 
isomers of petrocortyne A as shown in Scheme 1.39. The mixture of four aldehydes M-1.2 was 
subjected to Wittig olefination with phosphonium salt 1.3 to afford final mixture M-1.90 in 44% 
isolated yield. The low yield of this reaction was caused by instability of M-1.90, which slowly 
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decomposed during the purification. The 1H NMR of M-1.90 showed that about 50% of the 
compound M-1.90 decomposed in one week at −20 °C. 
The mixture M-1.90 was quickly demixed into four individual quasiisomers by 
preparative fluorous HPLC. Demixing was conducted on a Waters high-performance liquid 
chromatograph by fluorous chromatography over a FluoroFlashTM PFC8 column (10 mL/min) 
with the following gradient: 0 to 45 min, 100% CH3CN up to 85% CH3CN/15% THF; 45 to 65 
min, keep 85% CH3CN/15% THF. A representative preparative HPLC demixing chromatogram 
of mixture M-1.90 is shown in Figure 1.7. The four mixture compounds (137.2 mg) were well 
separated and eluted in order of increasing fluorine content to give the four quaiisomers 
1.90[F0,7′] (41.3 mg) (represents the quasiisomer bearing TIPSF0 and TIPSF7′ groups), 
1.90[F0,9′] (39.5 mg), 1.90[F9′,7′] (16.0 mg) and 1.90[F9′,9′] (19.7 mg). The combined 
recovery of demixing was 85%. All four quaiisomers decomposed slightly during the demixing, 
so the compounds were subjected to the next step immediately. 
All four quasiisomers were then deprotected individually by exposure to TBAF in THF to 
provide four final products 1.1SS (11.4 mg), 1.1SR (10.4 mg), 1.1RS (2.1 mg) and 1.1RR (5.1 
mg) in 59%, 59%, 41% and 65% yields, respectively. The complete structures of these final 
products are shown in Figure 1.8 along with their optical rotations and the fluorous tagging 
scheme for reference. 
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Scheme 1.39.  Synthesis of petrocortyne A 1.1 
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Figure 1.7.  Representative HPLC demixing chromatogram 
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Figure 1.8.  Four isomer of petrocortyne A with optical rotations 
 
In a parallel, Mr. Edmund Yeh in our lab also finished the non-selective synthesis of a 
mixture of all four petrocortyne A isomers 1.1Mix. He used a strategy that somewhat similar to 
that outlined here, but there were no fluorous protecting groups and the stereocenters were 
generated non-selectively. 
We then compared four pure isomers of 1.1 with mixture 1.1Mix. 1H and 13C NMR 
spectra (600 and 151 MHz) of all four stereoisomers of 1.1 and mixture 1.1Mix were identical 
(Figure 1.9, only differences come from the peaks of free alcohols). This is expected for two 
pairs of compounds, 1.1SS/1.1RR and 1.1SR/1.1RS, because they are enantiomers. However, 
the spectra of the diastereomeric compounds were also identical, indicating that the long spacer 
between the two remote stereocenters C3 and C14 prohibits their communication, at least under 
these standard NMR recording conditions. This phenomenon was also observed in the syntheses 
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of libraries of murisolin4b and lagunapyrone B.12 Importantly, all of the spectra also matched 
very well with spectra for (3R,14R)-petrocortyne A (The 1H and 13C NMR data (CDCl3) were 
listed in Table 1.8 and 1.9, respectively) and (3S,14S)-petrocortyne A (The 1H and 13C NMR data 
(CD3OD) were listed in Table 1.10 and 1.11, respectively). Thus, based on the NMR spectra, we 
cannot assign the relative configuration of the natural products.  
 
 
Figure 1.9.  1H NMR spectra of mixture 1.1Mix and four pure stereoisomers of 1.1 (CDCl3) 
1.1Mix
1.1SS
1.1SR
1.1RS
1.1RR
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Table 1.8. 1H NMR data of 3R,14R-petrocortyne A, 1.1SS/SR and 1.1Mix (CDCl3) 
H 3R,14R-1.1a 1.1SSb 1.1SRb 1.1-Mixc 
1 2.56 (dd, 2.0, 1.0) 2.57 (d, 2.4) 2.57 (d, 2.4) 2.57 (d, 2.4) 
3 4.83 (br d, 5.9) 4.84 (t, 6.0) 4.84 (t, 6.0) 4.84 (br s) 
4 5.61 (dd, 15.6, 5.9) 5.62 (dd, 15.0, 6.0) 5.62 (dd, 15.0, 6.0) 5.62 (dd, 15.0, 6.0) 
5 5.90 (dt, 15.6, 7.0) 5.91 (dt, 15.0, 7.0) 5.91 (dt, 15.0, 7.0) 5.91 (dt, 15.6, 6.6) 
6 2.07 (dt, 7.0, 6.7) 2.08 (q, 7.2) 2.08 (q, 7.2) 2.08 (q, 7.2) 
7 1.39 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
8 1.32 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
9 1.37 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
10 1.50 (m) 1.52 (m) 1.52 (m) 1.52 (m) 
11 2.22 (br t, 6.3) 2.23 (qd, 6.0, 1.2) 2.23 (qd, 6.0, 1.2) 2.23 (qd, 6.6, 1.2) 
14 5.09 (br s) 5.09 (dt, 7.2, 1.8) 5.09 (dt, 7.2, 1.8) 5.09 (br s) 
17 2.23 (br t, 6.3) 2.23 (qd, 6.0, 1.2) 2.23 (qd, 6.0, 1.2) 2.23 (qd, 6.6, 1.2) 
18 1.53 (m) 1.52 (m) 1.52 (m) 1.52 (m) 
19 1.43 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
20 2.04 (m) 2.05–1.99 (m) 2.05–1.99 (m) 2.05–1.99 (m) 
21,22 5.36–5.32 (m) 5.39–5.31 (m) 5.38–5.32 (m) 5.39–5.31 (m) 
23 2.03 (m) 2.05–1.99 (m) 2.05–1.99 (m) 2.05–1.99 (m) 
24,25 1.35 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
26 2.02 (m) 2.05–1.99 (m) 2.05–1.99 (m) 2.05–1.99 (m) 
27,28 5.36–5.32 (m) 5.39–5.31 (m) 5.39–5.31 (m) 5.39–5.31 (m) 
29 2.02 (m) 2.05–1.99 (m) 2.05–1.99 (m) 2.05–1.99 (m) 
30–41 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 1.46–1.25 (m) 
42 2.32 (dt, 7.3, 7.3) 2.32 (q, 7.2) 2.32 (q, 7.2) 2.32 (q, 7.2) 
43 5.99 (dt, 10.7, 7.3) 6.00 (dt, 10.8, 7.2) 6.00 (dt, 10.8, 7.2) 6.00 (dt, 10.8, 7.8) 
44 5.43 (ddt, 10.7, 2.4, 1.0) 5.44 (dd, 10.8, 1.2) 5.44 (dd, 10.8, 1.2) 5.44 (dd, 10.8, 1.2) 
46 3.06 (d, 2.4) 3.07 (d, 1.8) 3.07 (d, 1.8) 3.07 (d, 1.2) 
aReported by Shin (500MHz), 16a bThis work (600 MHz), cMr. Yeh’s work (600 MHz). 
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Table 1.9. 13C NMR data of 3R,14R-petrocortyne A, 1.1SS/SR and 1.1Mix (CDCl3) 
C 3R,14R-1.1a 1.1SSb 1.1SRb 1.1-Mixc 
1 73.99 74.01 74.01 74.00 
2 83.29 83.26 83.26 83.27 
3 62.78 62.77 62.78 62.79 
4 128.54 128.52 128.51 128.55 
5 134.29 134.32 134.33 134.32 
6 31.77 31.76 31.77 31.77 
7 28.56 28.54 28.54 28.55 
8 29.70–28.51 29.68–28.49 29.68–28.50 29.60–28.50 
9 28.58 28.56 28.56 28.57 
10 28.22 28.19 28.20 28.21 
11d 18.67 18.64 18.65 18.64 
12e 85.02 85.02 85.03 85.03 
13f 78.14 78.10 78.09 78.13 
14 52.56 52.54 52.54 52.56 
15j 78.13 78.10 78.08 78.10 
16e 84.96 84.97 84.98 84.98 
17d 18.65 18.63 18.63 18.63 
18 27.95 27.92 27.91 27.93 
19 28.90 28.87 28.87 28.88 
20 g 26.68 26.65 26.65 26.66 
21h 129.64 129.65 129.65 129.66 
22h 130.20 130.21 130.21 130.22 
23g 27.11 27.09 27.09 27.10 
24 29.40 29.37 29.37 29.38 
25 29.70–28.51 29.68–28.49 29.68–28.50 29.68–28.50 
26i 27.25 27.23 27.23 27.24 
27j 130.06 130.07 130.07 130.07 
28j 129.30 129.31 129.31 129.31 
29i 27.15 27.13 27.13 27.14 
30–38 29.70–28.51 29.68–28.49 29.68–28.50 29.68–28.50 
39 29.45 29.44 29.44 29.44 
40 29.19 29.17 29.17 29.18 
41 29.70–28.51 29.68–28.49 29.68–28.50 29.68–28.50 
42 30.28 30.26 30.26 30.27 
43 146.27 146.31 146.32 146.31 
44 107.88 107.88 107.87 107.89 
45 80.58 80.58 80.58 80.58 
46 81.12 81.13 81.12 81.12 
a Reported by Shin (125MHz), 16a bThis work (151 MHz), cMr. Yeh’s work (151 MHz), d–jAssignments with the 
same superscript in the same column may be interchanged. 
56
  
 
Table 1.10.  1H NMR data of 3S,14S-petrocortyne A and 1.1SS/SR (CD3OD) 
H 3S,14S-1.1a 1.1SSb 1.1SRb 
1 2.83 (d, 2.2) 2.86 (d, 2.4) 2.87 (d, 2.4) 
3 4.74 (br d, 5.9) 4.74 (br d, 6.0) 4.75 (br d, 6.0) 
4 5.55 (ddt, 15.2, 5.9, 1.3) 5.55 (ddt, 15.0, 6.0, 1.2) 5.56 (ddt, 15.0, 6.0, 1.2) 
5 5.85 (dtd, 15.2, 6.0, 1.0) 5.84 (dtd, 15.6, 6.6, 1.2) 5.84 (dtd, 15.0, 6.6, 1.2) 
6 2.05–2.02 (m) 2.08–2.02 (m) 2.09–2.03 (m) 
7–10 1.51–1.30 (m) 1.53–1.29 (m) 1.54–1.30 (m) 
11 2.21 (td, 7.0, 2.0) 2.21 (td, 7.2, 2.4) 2.22 (td, 6.6, 1.8) 
14 5.01 (quint, 2.0) 5.00 (quint, 2.1) 5.01 (quint, 1.8) 
17 2.21 (td, 7.0, 2.0) 2.21 (td, 7.2, 2.4) 2.21 (td, 6.6, 1.8) 
18,19 1.51–1.30 (m) 1.53–1.29 (m) 1.54–1.30 (m) 
20 2.05–2.02 (m) 2.08–2.02 (m) 2.09–2.03 (m) 
21,22 5.38–5.33 (m) 5.38–5.32 (m) 5.39–5.33 (m) 
23 2.05–2.02 (m) 2.08–2.02 (m) 2.09–2.03 (m) 
24,25 1.51–1.30 (m) 1.53–1.29 (m) 1.54–1.30 (m) 
26 2.05–2.02 (m) 2.08–2.02 (m) 2.09–2.03 (m) 
27,28 5.38–5.33 (m) 5.38–5.32 (m) 5.39–5.33 (m) 
29 2.05–2.02 (m) 2.08–2.02 (m) 2.09–2.03 (m) 
30–41 1.51–1.30 (m) 1.53–1.29 (m) 1.54–1.30 (m) 
42 2.32 (q, 6.6) 2.31 (qd, 7.2, 1.2) 2.32 (qd, 7.2, 1.2) 
43 5.98 (dtd, 10.8, 7.4, 1.0) 5.99 (dtd, 10.8, 7.2, 0.6) 6.00 (dt, 10.2, 7.2) 
44 5.43 (ddt, 10.8, 2.0, 1.3) 5.44 (ddt, 10.8, 1.8, 1.2) 5.44 (ddt, 10.2, 1.8, 1.2) 
46 3.36 (d, 2.0) 3.39 (d, 2.4) 3.41 (d, 1.8) 
aReported by Jung (200 MHz),16c bThis work (600 MHz). 
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Table 1.11.  13C NMR data of 3S,14S-petrocortyne A and 1.1SS/SR (CD3OD) 
C 3S,14S-1.1a 1.1SSb 1.1SRb 
1 74.5 74.53 74.52 
2 84.8 84.77 84.77 
3 63.1 63.16 63.16 
4 130.5 130.56 130.56 
5 134.0 134.05 134.06 
6 32.9 32.93 32.93 
7–10 30.9–29.2 30.93–29.21 30.93–29.21 
11c 19.2 19.21 19.21 
12d 84.5 84.48 84.48 
13e 79.9 79.94 79.94 
14 52.6 52.62 52.61 
15e 79.8 79.86 79.86 
16d 84.3 84.36 84.36 
17c 19.3 19.28 19.28 
18,19 30.9–29.2 30.93–29.21 30.93–29.21 
20 f 27.8 27.72 27.71 
21g 130.7 130.74 130.74 
22g 131.1 131.10 131.10 
23 f 28.22 28.06 28.04 
24,25 30.9–29.2 30.93–29.21 30.93–29.21 
26h 28.2 28.04 28.02 
27i 131.0 130.99 130.99 
28i 130.7 130.76 130.76 
29h 28.1 28.15 28.14 
30–41 30.9–29.2 30.93–29.21 30.93–29.21 
42 31.2 31.14 31.13 
43 146.3 146.41 146.42 
44 109.4 109.34 109.34 
45 81.2 81.23 81.24 
46 82.8 82.72 82.72 
aReported by Jung (50 MHz),16c bThis work (151 MHz), c–iAssignments with the same superscript in the same 
column may be interchanged. 
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Furthermore, we could not obtain a natural sample of (3R,14R)- or (3S,14S)-petrocortyne 
A to do chiral HPLC analysis to assign the structure of the natural product. Accordingly, chiral 
HPLC analysis, such as used to assign the murisolin, was not possible. 
  
1.2.16 Structure assignment of petrocortyne A 
 In order to assign the stereo structure of petrocortyne A, we first looked at optical 
rotations. The optical rotations of these isomers are shown in Figure 1.8. Two pairs of 
diastereomer, 1.1RR/1.1RS and 1.1SS/1.1SR, have rotations that are too close to be 
differentiated in practice. So for the structure assignment purposes, the sign of the optical 
rotation can be used to assign the configuration of C3, but no information is provided about C14. 
Contributions to rotation from remote stereocenters are often approximately additive, so at this 
wavelength the C14 stereocenter apparently contributes an almost negligible amount to the total 
rotation. Thus, the four isomers could be partly differentiated by optical rotation. 
The optical rotations of Shin’s petrocortyne A (+6.4, c = 0.25 MeOH) and Jung’s sample 
(+10.8, c = 1.9 MeOH) match the measure optical rotations of either (3S,14R)-petrocrotyne A 
1.1SR (+9.5, c = 0.25 MeOH) or (3S,14S)-petrocortyne A 1.1SS (+10.5, c = 0.30 MeOH). The 
optical rotation of Jung’s sample happens to match that of the (3S,14S)-petrocortyne A very well, 
but as mentioned above, the magnitudes of the rotations of the two diastereomers 1.1SR/1.1SS 
are too close to be differentiated. So after the comparison of optical rotations, we can only assign 
the configuration of C3 as S. Accordingly, Jung’s assignment of this stereocenter is correct and 
Shin’s is incorrect. But we still cannot assign the absolute configuration of stereocenter at C14. 
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Since we have individual samples of all four isomers and have validated the Mosher ester 
analysis, in order to assign the absolute configuration of petrocortyne A, we turned to advanced 
Mosher ester derivatives. This was possible because Shin reported full 1H NMR data for Mosher 
esters of his samples and Jung did not report the full Mosher esters’ spectra, but he did report the 
differences of chemical shifts of the corresponding Mosher ester derivatives. After comparison 
of the reported and synthetic Mosher esters, we will confirm the assignment of the natural 
product. We then converted the pair of petrocortyne A diastereomers with the 3S configuration 
1.1SS, 1.1SR to both the bis-(R)- and bis-(S)-Mosher esters 1.91SSR, 1.91SSS, 1.92SRR, and 
1.92SRS, respectively (Scheme 1.40).  
 
Scheme 1.40.  Synthesis of Mosher esters of 1.1SS and 1.1SR 
R/S-MTPA acid
DCC, DMAP, DCM
OR/S-MTPA
OR/S-MTPA
12S S
11 17 21
OH
OH
12S S
11 17 21
1.1SS
1.91SSR (R)-MTPA ester
1.91SSS (S)-MTPA ester
R/S-MTPA acid
DCC, DMAP, DCM
OR/S-MTPA
OR/S-MTPA
12S R
11 17 21
OH
OH
12S R
11 17 21
1.1SR
1.92SRR (R)-MTPA ester
1.92SRS (S)-MTPA ester  
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A set of 1D and 2D 1H NMR spectra of these esters were recorded for assignment and 
analysis. The expansions of the spectra of 1.91SSR/SSS and 1.92SRR/SRS along with their 
precursors 1.1SS and 1.1SR are shown in Figure 1.10. Our expectations that all the 1D Mosher 
esters’ spectra might be substantially identical in the region of the C14 stereocenter (H11 and 
H17) proved to be wrong; there were small yet clear differences.  
 
                                    
Figure 1.10.  Expansions of the H11/H17 region of the 1H NMR spectra of 1.1SS/SR (top) Mosher esters of 
1.1SS/SR (middle and bottom) 
 
 Although the differences of the 1D 1H NMR spectra of each pair of Mosher esters, 
1.91SSR/SSS and 1.92SRR/SRS, were observed in Figure 1.10, how can we assign H11 and 
H17? The proper assignments of H11 and H17 are crucial for comparison of 1H NMR data of 
reported and synthetic Mosher esters. These assignments were made by TOCSY experiments. 
The expansions of the TOCSY spectra of 1.91SSS/SSR and 1.92SRS/SRR are shown in Figure 
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1.12 and 1.13, respectively. Accordingly, H11, H17 and related protons were assigned 
unambiguously. Only one cross-coupling peak between H21 and one of the two resonances in 
the H11 and H17 region was observed. H11 is too far away to communicate with H21, so this 
cross peak must be the result of interaction between protons H21 and H17.  
 
1.91SSS S-MTPA
17
21
11 11     17
21
1.91SSR R-MTPA
42
44 44
42
 
Figure 1.11.  Expansions of portions of the TOCSY spectra of Mosher esters 1.91SSS/SSR 
 
11     17
21
1.92SRS S-MTPA
17         11
21
1.92SRR R-MTPA
42
44 44
42
 
Figure 1.12.  Expansions of portions of the TOCSY spectra of Mosher esters 1.92SRS/SRR 
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 All four Mosher esters spectra of the petrocortyne A isomers were unique. To assign the 
natural product configuration, we do not need to apply the Mosher rule and just simply compared 
the 1D 1H NMR spectra of the synthetic Mosher esters with those reported by Shin and the 
differences of chemical shifts of the Mosher ester derivatives reported by Jung. The data of the 
Mosher esters 1.91SSS/SSR of synthetic product 1.1SS, 3S,14S-petrocortyne A, uniquely 
matched the data reported by both groups (Table 1.12, 1.13). We also disproved the compound 
1.1SR is the natural product by comparison of the data obtained from the Mosher ester 
1.92SRS/SRR with the reported data (Table 1.12, 1.13). All results showed that Shin’s and 
Jung’s samples are identical, not enantiomers, and that Jung’s assignment of the 3S,14S 
configuration is correct. Jung assigned H11 and H17 in the Mosher esters and applied the 
advanced Mosher method to assign the natural product correctly. Shin also assigned H11 and 
H17 correctly, but unfortunately, Shin and coworker forgot to reverse CIP priority of order of 
Mosher esters when using Mosher chlorides to synthesize Mosher esters. So their assignment of 
natural product is reversed.  
 
Table 1.12.  1H NMR data of reported and synthetic Mosher ester derivatives 
H (R)-MTPA estera 1.91SSRb 1.92SRRb 
1 2.59 (d, 2.0) 2.59 (d, 2.1) 2.59 (d, 2.1) 
3 6.01 (br dd, 6.8, 2.0) 6.01 (m) 6.01 (m) 
4 5.60 (br dd, 15.6, 6.8) 5.60 (ddt, 15.4, 7.0, 1.4) 5.60 (ddt, 15.4, 7.0, 1.4) 
5 6.06 (dt, 15.6, 6.8) 6.05 (dtd, 15.4, 7.0, 1.4) 6.06 (dtd, 15.4, 7.0, 1.4) 
6 2.08 (td, 7.3, 6.8)) 2.07 (q, 7.0) 2.08 (q, 7.0) 
11 2.22 (td, 7.3, 2.0) 2.22 (td, 7.0, 2.1) 2.19 (td, 7.0, 2.1) 
14 6.21 (t, 2.0) 6.21 (t, 2.1) 6.21 (t, 2.1) 
17 2.21 (td, 7.3, 2.0) 2.21 (td, 7.0, 2.1) 2.23 (td, 7.0, 2.1) 
42 2.33 (q, 7.3) 2.32 (qd, 7.7, 1.4) 2.32 (qd, 7.2, 1.2) 
43 6.00 (br dt, 10.7, 7.3) 6.01 (m) 6.00 (m) 
44 5.44 (ddt, 10.7, 2.0, 1.5) 5.44 (ddt, 10.5, 2.8, 1.4) 5.44 (ddt, 10.5, 2.8, 1.4) 
46 3.07 (d, 2.0) 3.06 (d, 2.1) 3.07 (d, 1.8) 
aReported by Shin (500 MHz),16a bThis is work (700 MHz) 
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Table 1.13.  ΔδS-MTPA ester − R-MTPA ester value (ppm) of reported and synthetic Mosher ester derivatives 
H 1 4 5 6 11 17 18 
ΔδS − Ra 0.04 −0.10 −0.06 −0.04 −0.03 0.03 NA 
Δδ1.91SSS - 1.91SSR 0.04 −0.10 −0.06 −0.04 −0.03 0.03 0.02 
Δδ1.92SRS - 1.92SRR 0.04 −0.11 −0.06 −0.04 0.02 −0.03 −0.03 
aReported by Jung 16c 
 
With the optical rotations and Mosher esters spectra, we can confirm that the 3S,14S 
configuration of petrocortyne A is correct. This assignment of the 3S,14S-petrocortyne A is 
rigorous and is based solely on comparison of data derived from natural and synthetic samples 
and Mosher ester derivatives; it does not depend on applying Mosher rules. 
 
1.2.17 “Shortcut” Mosher Ester Method50 
Because the local symmetry at C14, the pairs of methylene protons (H11, H17) in the 
alcohols 1.1SS/SR are chemical equivalent but can be differentiated in the Mosher ester 
derivatives 1.91SSS/SSR and 1.92SRS/SRR. Subtraction of the pair of resonances from each 
other in one Mosher ester (rather than from the corresponding resonances in the two Mosher 
esters as advanced Mosher method mentioned) will provide the absolute configuration of the 
alcohol. We call this “shortcut” Mosher ester method. 
Since we have synthesized and unambiguously assigned Mosher esters 1.91SSS/SSR for 
alcohol 1.1SS and Mosher esters 1.92SRS/SRR for 1.1SR. We next analyzed the Mosher esters 
spectra by applying the standard advanced method and the shortcut method. In the advanced 
Mosher method, the differences of chemical shifts of corresponding protons (δS − δR) in (R)- and 
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(S)-Mosher esters need to be used. The chemical shift of key protons and their differences 
between two Mosher esters are listed in Table 1.14. The differences of chemical shift of protons 
at both sides of the stereocenters have the opposite sign, based on the advanced Mosher method, 
and the absolute configurations of stereocenters at C3 and C14 were assigned as 3S,14S for 
1.1SS and 3S,14R for 1.1SR, respectively.  
 In the shortcut Mosher method, we only use the difference of a symmetry-related pairs of 
protons (δH11 − δH17 or δH17 − δH11) in one single Mosher ester.  Here we use subtraction (δH11 − 
δH17) to assign the absolute configuration of stereocenter at C14. The subtraction data of Mosher 
esters of 1.1SS and 1.1SR are listed in Table 1.4. The signs of the subtractions are the opposite 
for stereocenters 14R and 14S, so both analyses correctly indicate the known configuration of the 
compounds. This validates the applicability of the shortcut Mosher method. 
 The shortcut Mosher method can be used to assign the petrocortyne A like natural 
products with local symmetry dialkynyl carbinol unit (other petrocortynes). Only one Mosher 
ester derivative is needed, after comparison of the natural product derivative with our results, the 
absolute configuration of the carbinol can be assigned. The shortcut method can also be 
generally applicable to assign any stereocenters with local symmetry. The method conserves 
valuable natural product, especially when only small amounts of natural product are isolated. 
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Table 1.14.  Selective chemical shifts in Mosher esters and application of the advanced and shortcut Mosher 
methods 
config. H# δS-MTPA δR-MTPA δS − δRa δH11 − δH17b 
3S,14R (1.1SR) 1 2.632 2.591 +0.041c 
 4 5.490 5.601 −0.111c 
 11 2.214 2.190 +0.024d −0.043d 
 17 2.204 2.233 −0.029d 
   
3S,14S (1.1SS) 1 2.628 2.590 +0.038c 
 4 5.494 5.594 −0.100c 
 11 2.185 2.219 −0.034e +0.015e 
 17 2.220 2.204 +0.026e 
aThe standard advanced Mosher method. bThe shortcut Mosher method with the R-MTPA ester. cIndicates 3S. 
dIndicates 14R. eIndicates 14S. 
 
1.3 CONCLUSIONS 
Fluorous mixture synthesis was applied to the total synthesis of petrocortyne A and its 
isomers. This technique features the tagging and mixing of enantiomers of the chiral starting 
material with different fluorous TIPS groups. The resulting mixture is taken through a series of 
steps to make the fluorous-tagged products, which are separated by fluorous HPLC in the 
demixing stage to provide the final enantiomerically pure products. The extra effort in making 
precursors in enantiopure form and tagging them with fluorous tags paid dividends in the end 
with easy separation and identification by fluorous dimixing. 
The second-generation fluorous TIPS tags were synthesized and used in the synthesis. 
Both Mosher and NMA derivatization methods were developed during the synthesis. Because 
the Mosher esters of petrocortyne A are known, we used Mosher method to assign the absolute 
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configuration of the natural product. However, the study showed that NMA ester method is 
superior to Mosher method for the assignment of absolute configuration of stereocenter C17. 
NMA ester method should be a better choice for future natural product isolation work.  
Comparison of optical rotations of the four synthetic and two natural samples showed 
that both natural samples had the C3-S configuration. Comparison of spectra of Mosher 
derivatives of the synthetic and natural samples showed that both natural samples had the 3S,14S 
configuration. At the same time, the use of the Mosher rule has been validated for assigning the 
challenging C14 stereocenter of petrocortyne A. As we showed above, a “shortcut” variant in 
which only one Mosher ester is made can also be used for assignment of this stereocenter. 
In summary, the petrocortyne A and its isomers were synthesized and the two natural 
products were proved to be the same compound, 3S,14S-petrocortyne A. 
 
1.4 EXPERIMENTAL 
General Information: 
All reactions were performed under an atmosphere of argon unless otherwise noted. 
Reaction solvents were freshly dried either by distillation or by passing through an activated 
alumina column. THF and toluene were freshly distilled from Na/benzophenone. Methylene 
chloride and Et2O were dried by activated alumina according to literature.51 All other reagents 
were purchased commercially and used without further purification unless stated otherwise. 
Reaction mixtures were magnetically stirred and reaction progress was monitored by TLC with 
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0.25 mm E. Merck precoated silica gel plates. Flash chromatography was performed with silica 
gel 60 (particle size 0.040–0.063 mm) supplied by Sorbent Technologies.  
Products and reactions were analyzed by 1H NMR, 13C NMR, COSY, 19F NMR, FT-IR, 
high and low resolution mass spectroscopy, and HPLC. NMR spectra were taken on a Bruker 
WH-300, IBM AF-300, a Bruker AvanceTM 500 NMR, a Bruker AvanceTM 600 NMR, and a 
Bruker AvanceTM 700 NMR spectrometer. Spectra were recorded at room temperature in the 
indicated deuteriated solvents and chemical shifts were reported in parts per million (ppm) 
downfield relative to TMS using the residual solvent proton resonance of CDCl3 (7.26 ppm) or 
central CDCl3 carbon peak (77.0 ppm) as the internal standard. In reporting spectral data, the 
following abbreviations were used: s = singlet, d = doublet, t = triplet, q = quartet, quin = 
quintuplet, m = multiplet, dd = doublet doublet, dt = doublet triplet, td = triplet doublet, qd = 
quartet doublet, ddt = doublet doublet triplet, dtd = doublet triplet double. Infrared spectra were 
taken on a Mattson Genesis Series FTIR using thin film on NaCl plate. Peaks are reported in 
wavenumbers (cm-1). Low resolution mass spectra were obtained on Fision Autospec. High 
resolution mass spectra were obtained on a V/G 70/70 double focusing machine and were 
reported in units of m/e. Optical rotations were measured on a Perkin-Elmer 241 polarimeter at 
the Na D-line (λ = 589 nm) using a 1 dm cell. HPLC analyses were performed on a Waters 600 E 
system with a Waters 2487 dual λ absorption detector. 
 
HO  
Non-8-yn-1-ol:29 
 NaH (2.85 g, 60 wt% in mineral oil, 71.3 mmol) was added to a 250 ml of three-neck 
flask containing ethylenediamine (35 mL) at 0 °C. The resulting suspension was stirred at room 
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temperature for 1 h and then warmed to 60 °C. After being stirred at 60 °C for 1 h, the deep blue-
black mixture was cooled to 45 °C and 3-nonyn-1-ol 1.9 (2.5 g, 17.8 mmol) was added dropwise. 
After complete addition, the resulting mixture was warmed back to 60 °C and was stirred for 
further 1 h. Upon slowly cooling to 0 °C, 1 M HCl (15 mL) was added. The organic layer was 
separated and the aqueous layer was extracted with Et2O (3 × 40 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by column chromatography (pentane/Et2O = 1:3 followed by 1:1) to afford title 
compound  (1.71 g, 68%) as the colorless oil: 1H NMR (300 MHz, CDCl3) δ 3.63 (t, J = 6.5 Hz, 
2 H), 2.18 (td, J = 6.8, 2.6 Hz, 2 H), 1.92 (t, J = 2.6 Hz, 1 H), 1.63–1.48 (m, 4 H), 1.45–1.28 (m, 
6 H). 
 
H
O
 
Non-8-ynal (1.8):30 
A solution of DMSO (2.13 mL, 30 mmol) in CH2Cl2 (17 mL) was slowly added to a 
solution of oxalyl chloride (1.72 mL, 20 mmol) in CH2Cl2 (85 mL) at –78 °C. After 15 min at the 
same temperature, a solution of non-8-yn-1-ol (1.40 g, 10 mmol) in CH2Cl2 (17 mL) was then 
added dropwise. The resulting mixture was stirred for 15 min and Et3N (6.97 mL, 50 mmol) was 
added slowly. The reaction was maintained at –78 °C for 15 min, then allowed to warm to 0 °C, 
the stirring continued for further 30 min. Water was added and the mixture was diluted with Et2O. 
The organic layer was separated and washed with brine. The combined aqueous layers were 
extracted with Et2O (3 × 30 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash chromatography 
(pentane/Et2O = 9:1) to afford the title compound 1.8 (1.24 g, 90%) as colorless oil: 1H NMR 
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(300 MHz, CDCl3) δ 9.75 (t, J = 1.8 Hz, 1 H), 2.42 (td, J = 7.3, 1.8 Hz, 2 H), 2.17 (td, J = 6.8, 
2.6 Hz, 2 H), 1.93 (t, J = 2.6 Hz, 1 H), 1.68–1.27 (m, 8 H). 
 
O
EtO  
(E)-Ethyl undec-2-en-10-ynoate (1.17): 
 Ethyl (triphenylphosphoranylidene)acetate 1.16 (3.21 g, 9.2 mmol) was added to a 
solution of aldehyde 1.8 (1.06 g, 7.7 mmol) in CH2Cl2 (20 mL) at room temperature. After being 
stirred overnight, the organic solvent was removed in vacuo, the residue was washed with petane 
and filtered through Celite®. The filtrate was concentrated under reduced pressure. The crude 
product was purified by column chromatography (pentane/Et2O = 30:1) to afford the title 
compound 1.17 as (1.27 g, 80%) colorless oil: 1H NMR (300 MHz, CDCl3) δ 6.95 (dt, J = 15.6, 
6.9 Hz, 1 H), 5.80 (dt, J = 15.6, 1.6 Hz, 1 H), 4.17 (q, J = 7.1 Hz, 2 H), 2.23–2.14 (m, 4 H), 1.93 
(t, J = 2.6 Hz, 1 H), 1.56–1.23 (m, 8 H) 1.28 (t, J = 7.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 
166.7, 149.2, 121.3, 84.5, 68.2, 60.1, 32.1, 28.5, 28.4, 28.3, 18.3, 14.2. 
 
HO  
(E)-Undec-2-en-10-yn-1-ol: 
 DIABL-H (12.5 mL, 1.0 M solution in hexane, 12.5 mmol) was added to a solution of 
ester 1.17 (1.04 g, 5.0 mmol) in CH2Cl2 (50 mL) over 10 min at –78 °C. After 30 min at the 
same temperature, the mixture was poured into a solution of saturated aqueous sodium potassium 
tartrate (125 mL) and Et2O (125 mL), the resultant cloudy mixture was then vigorously stirred 
for 1 h, at which time the organic layer cleared. The organic layer was separated and washed 
with brine. The combined aqueous layers were extracted with Et2O (2 × 25 mL). Then the 
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combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by column chromatography (pentane/Et2O = 3:1) to afford the title compound (0.82 g, 
99%) as colorless oil: 1H NMR (300 MHz, CDCl3) δ 5.71–5.55 (m, 2 H), 4.05 (t, J = 5.1, 2 H), 
2.16 (td, J = 6.9, 2.6 Hz, 2 H), 2.02 (q, J = 6.3 Hz, 2 H), 1.92 (t, J = 2.6 Hz, 1 H), 1.65 (t, J = 5.7 
Hz, 1 H), 1.57–1.23 (m, 8 H); 13C NMR (75 MHz, CDCl3) δ 133.1, 128.9, 84.6, 68.1, 63.6, 32.0, 
28.9, 28.5, 28.4, 28.3, 18.3. 
 
H
O
 
(E)-Undec-2-en-10-ynal (1.7): 
 A solution of DMSO (0.96 mL, 13.5 mmol) in CH2Cl2 (7.5 mL) was slowly added to a 
solution of oxalyl chloride (0.77 mL, 9 mmol) in CH2Cl2 (42 mL) at –78 °C. After 15 min at the 
same temperature, a solution of (E)-undec-2-en-10-yn-1-ol (0.75 g, 4.5 mmol) in CH2Cl2 (7.5 
mL) was then added dropwise. The resulting mixture was stirred for 15 min and Et3N (3.14 mL, 
22.5 mmol) was added slowly. The reaction was maintained at –78 °C for 15 min, then allowed 
to warm to 0 °C, the stirring continued for further 30 min. Water was added and the mixture was 
diluted with Et2O. The organic layer was separated and washed with brine. The combined 
aqueous layers were extracted with Et2O (3 × 15 mL). The combined organic layers were dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (pentane/Et2O = 9:1) to afford the title compound 1.7 (0.66 g, 90%): 1H NMR 
(300 MHz, CDCl3) δ 9.48 (d, J = 7.9 Hz, 1 H), 6.83 (dt J = 15.6, 6.8 Hz, 1 H), 6.09 (ddt, J = 15.6, 
7.9, 1.4 Hz, 1 H), 2.33 (qd, J = 7.1, 1.4 Hz, 2 H), 2.17 (td, J = 6.8, 2.6 Hz, 2 H), 1.93 (t, J = 2.6 
Hz, 1 H), 1.56–1.28 (m, 8 H); 13C NMR (75 MHz, CDCl3) δ 193.9, 158.5, 133.0, 84.4, 68.2, 32.5, 
28.5, 28.3, 28.3, 27.6, 18.3. 
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OH
TMS  
(E)-1-(Trimethylsilyl)trideca-4-en-1,12-diyn-3-ol: 
 A solution of n-BuLi (3.15 mL, 1.6 M solution in hexane, 5.0 mmol) was added to a 
solution of trimethylsilylacetylene (0.8 mL, 5.5 mmol) in THF (20 mL) at –78 °C. After 10 min, 
a solution of aldehyde 1.7 (554 mg, 3.4 mmol) in THF (5 mL) was added dropwise. The 
resulting mixture was stirred for further 10 min at this temperature and allowed to warm to room 
temperature. The mixture was poured into pH 7 phosphate buffer (20 mL) and extracted with 
Et2O (3 × 20mL). The organic layer was washed with brine, dried over MgSO4 and concentrated 
in vacuo. The residue was purified by column chromatography (hexane/CH2Cl2 = 1:2) to afford 
the title compound as pale yellow oil (775 mg, 88%): 1H NMR (300 MHz, CDCl3) δ 5.87 (dtd J 
= 15.2, 6.7, 1.0 Hz, 1 H), 5.59 (ddt, J = 15.3, 6.2, 1.4 Hz, 1 H), 4.82 (t, J = 6.1 Hz, 1 H), 2.19 (td, 
J = 6.9, 2.6 Hz, 2 H), 2.07 (q, J = 7.0 Hz, 2 H), 1.94 (t, J = 2.6 Hz, 1 H), 1.79 (d, J = 6.0 Hz, 1 H), 
1.55–1.26 (m, 8H), 0.17 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 134.3, 129.1, 105.3, 90.9, 84.9, 
68.4, 63.6, 32.1, 29.0, 28.9, 28.8, 28.7, 18.7, 0.14. 
 
O
TMS  
(E)-1-(trimethylsilyl)trideca-4-en-1,12-diyn-3-one (1.6): 
 To a solution of oxalyl chloride (0.26 mL, 3 mmol) in CH2Cl2 (14 mL) was slowly added 
a solution of DMSO (0.32 mL, 4.5 mmol) in CH2Cl2 (2.5 mL) at –78 °C. After 15 min at the 
same temperature, a solution of (E)-1-(trimethylsilyl)trideca-4-en-1,12-diyn-3-ol (0.40 g, 1.5 
mmol) in CH2Cl2 (2.5 mL) was then added dropwise. The resulting mixture was stirred for 15 
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min and Et3N (1.05 mL, 7.5 mmol) was added slowly. The reaction was maintained at –78 °C for 
15 min, then allowed to warm to 0 °C, the stirring continued for further 30 min. Water was added 
and the mixture was diluted with Et2O. The organic layer was separated and washed with brine. 
The combined aqueous layers were extracted with Et2O (3 × 5 mL). The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (hexane/CH2Cl2 = 1:1) to afford the title compound 1.6 (347.8 
mg, 88%) as pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 7.18 (dt, J = 15.7, 6.8 Hz, 1H), 6.15, 
(dt, J = 15.7, 1.4 Hz, 1H), 2.30 (qd, J = 6.6, 1.4 Hz, 2H), 2.19 (td, J = 6.8, 2.6 Hz, 2H), 1.95 (t, J 
= 2.6 Hz, 1H), 1.55–1.36 (m, 8H), 0.26 (s, 9H). 
 
OH
TMS  
(R,E)-1-(Trimethylsilyl)trideca-4-en-1,12-diyn-3-ol (1.18R): 
 (R)-Alpine borane (7.2 mL, 0.5 M solution in THF, 3.6 mmol) was placed in a round 
bottle flask, the solvent was removed under vacuum and the flask was refilled with Ar. To it 
ketone 1.6 (315.0 mg, 1.2 mmol) was added slowly at 0 °C. After stirring at room temperature 
for 15 h, a solution of acetaldehyde (1.15 mL, 20 mmol)) in THF (2.4 mL) was added and the 
mixture was then stirred at room temperature for 6 h before removing the solvent in vacuo. To 
the residue a solution of ethanolamine (0.16 mL) in Et2O (2.4 mL) was added. After 1 h, the 
white precipitate was filtered and washed with Et2O. The organic layer was dried over MgSO4 
and concentrated under reduced pressure. The crude compound was purified by column 
chromatography (hexane/CH2Cl2 = 1:2) to afford the title compound 1.18R (183.6 mg, 58%, 
93% ee): 1H NMR (500 MHz, CDCl3) δ 5.87 (dtd, J = 15.3, 7.4, 0.9 Hz, 1H), 5.58, (dd, J = 15.3, 
6.2 Hz, 1H), 4.82 (t, J = 5.9 Hz, 1H), 2.18 (td, J = 7.0, 2.6 Hz, 2H), 2.07 (q, J = 7.2 Hz, 2H), 1.94 
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(t, J = 2.6 Hz, 1H), 1.83 (d, J = 6.0 Hz, 1H), 1.55–1.49 (m, 2H), 1.44–1.37 (m, 4H), 1.34–1.28 
(m, 2H), 0.18 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 134.1, 128.7, 104.9, 90.9, 84.9, 68.1, 63.4, 
31.8, 29.6, 28.6, 28.5, 28.4, 18.4, –0.16; MS (EI) m/z 262 (M+); HRMS (EI) m/z (M+) calcd for 
C16H26OSi 262.1753, found 262.1747. 
 
O
TMS
O
H3CO
F3C
R
S
 
(S)-((R,E)-1-(Trimethylsilyl)trideca-4-en-1,12-diyn-3-yl) 3,3,3-trifluoro-2-methoxy-2-phenyl 
propanoate (1.19RS): 
 (S)-MTPA acid (23.5 mg, 0.10 mmol), DCC (24.8 mg, 0.12 mmol), and DMAP (0.6 mg, 
0.005mmol) was added to a solution of alcohol 1.18R (13.1 mg, 0.05 mmol) in CH2Cl2 (0.7 ml)  
at room temperature. The resulting mixture was stirred at the same temperature overnight. The 
mixture was then filtered through a pad of Celite ®, the filtrate was concentrated in vacuo. The 
crude product 1.19RS was obtained: 1H NMR (300 MHz, CDCl3) δ 7.54-7.51 (m, 2H), 7.43-7.36 
(m, 3H), 6.02 (dtd, J = 15.7, 7.1, 0.7 Hz, 1H), 6.00 (d, J = 6.8 Hz, 1H), 5.57 (ddt, J = 15.3, 6.9, 
1.2 Hz, 1H), 3.54 (s, 3H), 2.17 (td, J = 6.8, 2.6 Hz, 2H), 2.08 (q, J = 6.6 Hz, 2H), 1.93 (t, J = 2.6 
Hz, 1H), 1.58–1.23 (m, 8H), 0.15 (s, 9H). 
 
O
TMS
O
F3C
H3CO
R
R
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(R)-((R,E)-1-(Trimethylsilyl)trideca-4-en-1,12-diyn-3-yl)3,3,3-trifluoro-2-methoxy-2-phenyl 
propanoate (1.19RR): 
 Following the same procedure as above, except for using (R)-MTPA acid rather than (S)-
MTPA acid, the title compound 1.19RR was obtained: 1H NMR (300 MHz, CDCl3) δ 7.54-7.51 
(m, 2H), 7.43-7.36 (m, 3H), 6.02 (dtd, J = 15.7, 7.1, 0.7 Hz, 1H), 6.00 (d, J = 6.8 Hz, 1H), 5.57 
(ddt, J = 15.3, 6.9, 1.2 Hz, 1H), 3.54 (s, 3H), 2.17 (td, J = 6.8, 2.6 Hz, 2H), 2.08 (q, J = 6.6 Hz, 
2H), 1.93 (t, J = 2.6 Hz, 1H), 1.58–1.23 (m, 8H), 0.15 (s, 9H). 
 
Si H
C3F7
 
(3,3,4,4,5,5,5-Heptafluoropentyl)diisopropylsilane (1.21): 
 t-BuLi (10.4 mL, 1.7 M solution in pentane, 17.6 mmol) was added by syringe pump in 
40 min to a solution of iodide 1.20 (3.80 g, 11.7 mmol) in Et2O (20 mL) at –78 °C. After 10 min 
at the same temperature, the mixture was warmed to –15 °C and stirred for further 10 min. The 
mixture was recooled to –78 °C. Chlorodiisopropylsilane (1.10 mL, 6.5 mmol) was added to the 
above solution in 15 min. The resulting mixture was then warmed to room temperature and 
stirred overnight. Water (2 mL) was added at 0 °C, followed by 1 M HCl (20 mL). The mixture 
was extracted with Et2O (3 × 30 mL). The organic layer was washed with water (2 × 20 mL), 
dried over MgSO4, and concentrated under reduced pressure. The residue was purified by 
column chromatography (100% hexane) to afford the title compound 25 (1.56 g, 77%): 1H NMR 
(300 MHz, CDCl3) δ 3.49 (s, 1H), 2.20–2.04 (m, 2H), 1.05 (s, 14H), 0.88–0.82 (m, 2H). 
 
OSi(iPr)2CH2CH2C3F7
TMS  
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(R,E)-(3,3,4,4,5,5,5-Heptafluoropentyl)diisopropyl(1-(trimethylsilyl)trideca-4-en-1,12- diyn-
3-yloxy)silane (1.4R): 
 Trifluoromethanesulfonic acid (neat, 75.0 mg, 0.50 mmol) was slowly added to silane 25 
(neat, 203.0 mg, 0.65 mmol) at 0 °C. After being stirred for 5 min at the same temperature, the 
mixture was warmed to room temperature and stirred for 15 h. To it a solution of alcohol 23 
(131.2 mg, 0.50 mmol) in CH2Cl2 and 2,6-lutidine (116.0 μL, 1.00 mmol) were added at 0 °C. 
The resulting mixture was warmed to room temperature and stirred for further 2 h. Saturated 
aqueous NH4Cl (1 mL) was then added to quench the reaction at 0 °C. The mixture was extracted 
with Et2O (3 × 10 mL), the organic layers were combined and washed with water, dried over 
MgSO4, and concentrated in vacuo. The crude product was purified by column chromatography 
(100% hexane) to afford the title compound 1.4R (135.9 mg, 82%): 1H NMR (300 MHz, CDCl3) 
δ 5.77 (dtd, J = 15.2, 6.7, 1.1 Hz, 1H), 5.34 (ddt, J = 15.2, 5.7, 1.3 Hz, 1H), 4.88 (dd, J = 5.7, 1.0 
Hz, 1H), 2.18 (td, J = 6.9, 2.6 Hz, 2H), 2.05 (q, J = 6.9 Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.55-
1.25 (m, 10H), 1.10–1.03 (m, 12H), 0.93–0.87 (m, 2H), 0.15 (s, 9H); MS (EI) m/z 572 (M+); 
HRMS (EI) m/z (M+) calcd for C27H43F7OSi2 572.2741, found 572.2744. 
 
OH  
Hept-6-yn-1-ol (1.22):29 
 NaH (3.75g, 60 wt% in mineral oil, 93.8 mmol) was added to a 250 ml of three-neck 
flask containing ethylenediamine (37.5 mL) at 0 °C. The resulting suspension was stirred at 
room temperature for 1 h and then warmed to 60 °C. After being stirred at 60 °C for 1 h, the deep 
blue-black mixture was cooled to 45 °C and 3-heptyn-1-ol 1.10 (2.1 g, 18.8 mmol) was added 
dropwise. After complete addition, the resulting mixture was warmed back to 60 °C and was 
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stirred for further 1 h. Upon slowly cooling to 0 °C, 1 M HCl (20 mL) was added. The organic 
layer was separated and the aqueous layer was extracted with Et2O (3 × 50 mL). The combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by column chromatography (pentane/Et2O = 1:3) to afford compound 1.22 
(1.35 g, 64%) as the colorless oil: 1H NMR (300 MHz, CDCl3) δ 3.64 (t, J = 6.2 Hz, 2H), 2.20 
(td, J = 6.7, 2.6 Hz, 2H), 1.94 (t, J = 2.6 Hz, 1H), 1.63–1.41 (m, 6H); 13C NMR (75 MHz, CDCl3) 
δ 84.3, 68.2, 62.4, 32.0, 28.1, 24.8, 18.2. 
 
OPMB  
1-((Hept-6-ynyloxy)methyl)-4-methoxybenzene (1.10) 
 Alcohol 1.22 (1.34 g, 12 mmol) was added  dropwise to a suspension of NaH (0.60 g, 60 
wt% in mineral oil, 15 mmol) in DMF (25 mL) at 0 °C. After being stirred for 30 min at the 
same temperature, PMBCl (2.06 g, 13 mmol) was slowly added followed by addition of TBAI 
(44 mg, 0.12 mmol). The resulting mixture was stirred at room temperature for 18 h. Cold water 
(20 mL) was added to quench the reaction. The resulting mixture was extracted with Et2O (3 × 
30 mL). The organic layer was washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The crude product was purified by column chromatography (hexane/Et2O = 
9:1) to afford the title compound 1.10 (2.55 g, 92%) as colorless oil: 1H NMR (300 MHz, CDCl3) 
δ 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.46 (s,2H), 3.80 (s, 3H), 3.44 (t, J = 6.4 Hz, 
2H), 2.19 (td, J = 6.8, 2.6 Hz, 2H), 1.94 (t, J = 2.6 Hz, 1H), 1.66–1.41 (m, 6H); 13C NMR (75 
MHz, CDCl3) δ 159.1, 130.7, 129.2, 113.7, 84.5, 72.5, 69.9, 68.2, 55.2, 29.2, 28.3, 25.4, 18.4. 
 
OPMB
O
H
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8-(4-Methoxybenzyloxy)oct-2-ynal (1.5) 
n-BuLi (6.8 mL, 1.6 M solution in hexane, 10.8 mmol) was slowly added to a solution of 
alkyne 1.10 (2.50 g, 10.8 mmol) in THF (27 mL) at –40 °C. After completion of addition, DMF 
(1.67 mL, 21.6 mmol) was added. The mixture was then warmed to room temperature. After 
being stirred for 30 min at the same temperature, the resulting mixture was poured into a solution 
of 10% acquous solution KH2PO4 (58 mL) and methyl tert-butyl ether (MTBE) (54mL) at 0 °C. 
The organic layer was separated and the aqueous layer was extracted with MTBE (3 × 40 mL). 
The combined organic layers was washed with water, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography (hexane/Et2O = 3:1) to afford the 
title compound 1.5 (2.46 g, 88%) as pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 9.17 (s, 1H), 
7.26 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.43 (s,2H), 3.81 (s, 3H), 3.45 (t, J = 6.2 Hz, 
2H), 2.42 (t, J = 6.5 Hz, 2H), 1.67–1.46 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 177.1, 159.0, 
130.5, 129.1, 113.7, 99.0, 81.6, 72.5, 69.6, 55.2, 29.1, 27.3, 25.5, 19.0; IR (film) 2935, 2858, 
2279, 1667, 1612, 1512, 1462, 1246, 1173, 1095, 1033, 817 cm-1; MS (EI) m/z 260 (M+); HRMS 
(EI) m/z (M+) calcd for C16H20O3 260.1412, found 260.1410. 
 
HO OPMB  
7-(4-Methoxybenzyloxy)heptan-1-ol:37 
 1,7–Heptanediol 1.34 (17.00 g, 128.6 mmol) was added dropwise to a suspension of 
NaH (5.15 g, 60 wt% in mineral oil, 128.8 mmol) in THF (490 mL) at 0 °C. PMBCl (17.50 mL, 
128.9 mmol) was then added dropwise followed by addition of TBAI (5.22 g, 14.1 mmol). After 
warm to room temperature and stirring for 1 h, the reaction mixture was heated to 60 °C for 15 h. 
After being cooled to room temperature, the resulting mixture was poured into a solution of 
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saturated NaHCO3 and vigorously stirred. The organic layer was separated and the aqueous layer 
was extracted with EtOAc (3 × 150 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash chromatography (hexane/EtOAc = 
7:3) to afford the title compound (15.93 g, 49%) as colorless oil: 1H NMR (300 MHz, CDCl3) δ 
7.26 (d, J = 8.6 Hz, 2 H), 6.87 (d, J = 8.6 Hz, 2 H), 4.42 (s, 2 H), 3.80 (s, 3 H), 3.61 (t, J = 6.6 Hz, 
2 H), 3.43 (t, J = 6.6 Hz, 2 H), 1.62–1.50 (m, 4 H), 1.40–1.33 (m, 6 H); 13C NMR (75 MHz, 
CDCl3) δ 159.0, 130.7, 129.2, 113.7, 72.5, 70.1, 62.9, 55.2, 32.6, 29.6, 29.2, 26.1, 25.6; IR (film) 
3428, 2935, 2859, 1612, 1513, 1465, 1247, 1092, 908, 734, 650 cm-1; MS (EI) m/z 252 (M+); 
HRMS (ESI) m/z (M+) calcd for C15H24O3 252.1725, found 252.1730. 
 
O OPMB  
7-(4-Methoxybenzyloxy)heptanal (1.33):37 
 A solution of DMSO (13.0 mL, 183.0 mmol) in CH2Cl2 (76 mL) was slowly added to a 
solution of oxalyl chloride (10.5 mL, 122.0 mmol) in CH2Cl2 (350 ml) at –78 °C. After 15 min at 
the same temperature, a solution of 7-(4-Methoxybenzyloxy)heptan-1-ol (15.40 g, 61.0 mmol) in 
CH2Cl2 (76 mL) was then added dropwise. The resulting mixture was stirred for 15 min and 
Et3N (42.6 mL, 305.6 mmol) was added slowly. The reaction was maintained at -78 °C for 15 
min, then allowed to warm to 0 °C, the stirring continued for further 30 min. Water was added 
and the mixture was diluted with Et2O. The organic layer was separated and washed with brine. 
The combined aqueous layers were extracted with Et2O (3 × 120 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (Hexane/EtOAc = 5:1) to afford the title compound 1.33 
(15.01 g, 98%) as colorless oil: 1H NMR (300 MHz, CDCl3) δ 9.76 (t, J = 1.8 Hz, 1 H) 7.26 (d, J 
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= 8.5 Hz, 2 H), 6.88 (d, J = 8.6 Hz, 2 H), 4.42 (s, 2 H), 3.80 (s, 3 H), 3.43 (t, J = 6.5 Hz, 2 H), 
2.42 (td, J = 7.3, 1.7 Hz, 2 H), 1.67–1.55 (m, 4 H), 1.44–1.28 (m, 6 H); 13C NMR (75 MHz, 
CDCl3) δ 202.7, 159.0, 130.6, 129.1, 113.6, 72.4, 69.8, 55.1, 43.7, 29.4, 28.8, 25.9, 21.9; IR (film) 
2937, 2860, 1722, 1612, 1512, 1464, 1248, 1093, 1036, 908, 731, 650 cm-1; MS (EI) m/z 250 
(M+); HRMS (ESI) m/z (M+) calcd for C15H22O3 250.1569, found 250.1572. 
 
OPMBN
O
OMe  
(E)-N-Methoxy-9-(4-methoxybenzyloxy)-N-methylnon-2-enamide (1.32): 
 The diethyl N-methoxy-N-methylphosphonoacetamide 1.35 (15.1 mL, 73.2 mmol) was 
added to a suspension of NaH (3.30 g, 60 wt% in mineral oil, 82.5 mmol) in THF (400 mL) at 0 
°C. The resulting mixture was stirred for 30 min, then a solution of aldehyde 1.33 (15.01 g, 60.0 
mmol) in THF (100 mL) was added dropwise. The mixture was stirred for 1 h at room 
temperature before saturated aqueous NH4Cl solution (120 mL) and Et2O (120 mL) were added. 
The organic layer was separated and the aqueous layer was extracted with Et2O (3 × 120 mL). 
The combined organic layers were washed with brine, dried over MgSO4, and concentrated in 
vacuo. The crude product was purified by column chromatography (hexane/EtOAc = 6:4) to 
afford the title compound 1.32 (18.30 g, 91%) as colorless oil: 1H NMR (300 MHz, CDCl3) δ 
7.26 (d, J = 8.6 Hz, 2 H), 6.97 (dt, J = 15.4, 7.0 Hz, 1 H), 6.88 (d, J = 8.7 Hz, 2 H), 6.38 (dt, J = 
15.4, 1.3 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 H), 3.69 (s, 3 H), 3.43 (t, J = 6.6 Hz, 2 H), 3.23 (s, 3 
H), 2.23 (qd, J = 7.0, 1.3 Hz, 2 H), 1.64–1.55 (m, 4 H), 1.50–1.25 (m, 6 H); 13C NMR (75 MHz, 
CDCl3) δ 167.0, 159.0, 147.8, 130.7, 129.1, 118.6, 113.7, 72.4, 70.0, 61.6, 55.2, 32.3, 32.2, 29.6, 
28.9, 28.2, 25.9; IR (film) 2932, 2855, 1664, 1633, 1613, 1513, 1463, 1442, 1413, 1380, 1247, 
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1173, 1097, 1053, 998, 820 cm-1; MS (EI) m/z 335 (M+); HRMS (ESI) m/z (M+) calcd for 
C19H29NO4 335.2097, found 335.2099. 
 
O
OPMB
TBS  
(E)-1-(tert-Butyldimethylsilyl)-11-(4-methoxybenzyloxy)undec-4-en-1-yn-3-one (1.31): 
 n-BuLi (72.0 mL, 1.6 M solution in hexane, 115.2 mmol) was added to a solution of tert-
butyldimethylsilylacetylene 1.36 (20.5 mL, 109.8 mmol) in THF (300 ml) at –78 °C. After 20 
min, the solution of amide 1.32 (18.30 g, 54.6 mmol) in THF (100 mL) was added. The resulting 
mixture was stirred for further 1 h at –78 °C. The mixture was poured into a saturated aqueous 
NH4Cl solution and extracted with Et2O (3 × 150 mL). The combined organic extracts were dried 
over MgSO4 and concentrated under reduced pressure. The residue was purified by column 
chromatography (hexane/EtOAc = 10:1) to afford the title compounds 1.31 (20.17 g, 89%) as 
pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.5 Hz, 2 H), 7.19 (dt, J = 15.5, 7.0 
Hz, 1 H), 6.88 (d, J = 8.5 Hz, 2 H), 6.15 (dt, J = 15.5, 1.3 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 H), 
3.43 (t, J = 6.5 Hz, 2 H), 2.29 (qd, J = 7.0, 1.0 Hz, 2 H), 1.60 (quin, J = 6.9 Hz, 2 H), 1.50 (quin, 
J = 7.4 Hz, 2 H), 1.4–1.34 (m, 4 H), 0.98 (s, 9 H), 0.20 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 
178.0, 159.0, 154.6, 132.1, 130.6, 129.1, 113.6, 101.1, 96.7, 72.4, 69.9, 55.1, 32.4, 29.5, 28.9, 
27.8, 25.9, 25.8, 16.5, –5.2; IR (film) 2933, 2859, 1641, 1620, 1513, 1465, 1363, 1301, 1248, 
1174, 1095, 1037, 1008, 976, 910, 841, 780, 734 cm-1; MS (EI) m/z 437 (M+ + Na); HRMS (ESI) 
m/z (M+) calcd for C25H39O3Si 415.2668, found 415.2669. 
 
OH
OPMB
TBS  
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(R,E)-1-(tert-Butyldimethylsilyl)-11-(4-methoxybenzyloxy)undec-4-en-1-yn-3-ol (1.37R): 
 A solution of compound 1.31 (10.62 g, 25.6 mmol) in THF (90 ml) was added dropwise 
in 10 min to a solution of (R)-CBS (7.10 g, 25.6 mmol) and BH3·SMe2 (2.8 mL, 29.5 mmol) in 
THF (30 mL) at 0 °C under Ar. Upon completion of addition, reaction was cautiously quenched 
by slow addition of MeOH (30 mL) at 0 °C. The resulting solution was stirred for 15 min at 
room temperature and most organic solvent was removed under reduced pressure. The residue 
was purified by column chromatography (hexane/EtOAc = 17:3) to afford the title compound 
1.37R (7.48 g, 70%, 93% ee), [α]D 25 = –21.7 (c = 1.30, CHCl3), 1H NMR (300 MHz, CDCl3) δ 
7.26 (d, J = 8.4 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.90 (dtd, J = 15.3, 6.6，0.9 Hz, 1 H), 5.59 
(ddt, J = 15.3, 5.7, 1.4 Hz, 1 H), 4.82 (t, J = 6.0 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 H), 3.43 (t, J = 
6.6 Hz, 2 H), 2.06 (q, J = 6.6 Hz, 2 H), 1.80 (d, J = 6.3 Hz, 1 H), 1.63–1.55 (m, 2 H), 1.45–1.28 
(m, 6 H), 0.94 (s, 9 H), 0.12 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 158.9, 133.7, 130.6, 129.1, 
128.8, 113.6, 105.8, 88.4, 72.3, 69.9, 63.0, 55.1, 31.7, 29.5, 28.8, 28.7, 26.0, 25.9, 16.4, –4.8; IR 
(film) 3593, 3419, 2932, 2858, 1612, 1513, 1465, 1363, 1301, 1249, 1091, 1034, 909, 827, 777, 
734 cm-1; HRMS (ESI) m/z (M+ + Na) calcd for C25H40O3NaSi 439.2644, found 439.2620. 
 
OH
OPMB
TBS  
(S,E)-1-(tert-Butyldimethylsilyl)-11-(4-methoxybenzyloxy)undec-4-en-1-yn-3-ol (1.37S): 
 Following the same procedure for 1.37R, ketone 1.31 (9.50 g, 22.9 mmol) was reacted 
with (S)-CBS (6.35 g, 22.9 mmol), BH3·SMe2 (2.5 mL, 26.4 mmol), the title compound 1.37S 
(6.99 g, 73%, 94% ee) was obtained. [α]D 25 = +22.1 (c = 1.17, CHCl3), 1H NMR (300 MHz, 
CDCl3) δ 7.26 (d, J = 8.1 Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 5.89 (dt, J = 15.0, 6.9 Hz, 1 H), 
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5.59 (dd, J = 15.0, 5.7 Hz, 1 H), 4.82 (t, J = 6.0 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 H), 3.43 (t, J = 
6.6 Hz, 2 H), 2.05 (q, J = 6.6 Hz, 2 H), 1.86 (d, J = 6.3 Hz, 1 H), 1.63–1.54 (m, 2 H), 1.45–1.28 
(m, 6 H), 0.94 (s, 9 H), 0.12 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 159.0, 133.9, 130.7, 129.2, 
128.8, 113.7, 105.7, 88.7, 72.4, 70.0, 63.2, 55.2, 31.8, 29.6, 28.9, 28.7, 26.0(2C), 16.4, –4.7; IR 
(film) 3405, 2931, 2857, 1613, 1513, 1464, 1362, 1302, 1249, 1091, 1035, 910, 828, 776, 733 
cm-1; MS (EI) m/z 439 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for C25H40O3NaSi 
439.2644, found 439.2640. 
 
OPMB
OH
 
(S,E)-11-(4-methoxybenzyloxy)undec-4-en-1-yn-3-ol (1.38S): 
 TBAF (0.77 mL, 1.0 M solution in THF, 0.77 mmol) was added to a solution of 43b 
(216.3 mg, 0.52 mmol) in THF (10 mL) at –20 °C. The mixture then was stirred for 30 min at 
this temperature and quenched with saturated aqueous NH4Cl. The resulting mixture was 
extracted with CH2Cl2 (3 × 10 mL). The organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified by column 
chromatography (hexane/EtOAc = 9 : 1) to give compound 1.38S (149.1 mg, 95%) as pale 
yellow oil. [α]D 25 = +17.9 (c = 1.14, CHCl3). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 
2H), 6.88 (d, J = 8.7 Hz, 2H), 5.90 (dtd, J = 15.3, 6.7，1.1 Hz, 1H), 5.60 (ddt, J = 15.3, 6.1, 1.4 
Hz), 4.83 (m, 1H), 4.43 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.5 Hz, 2H), 2.56 (d, J = 2.2 Hz, 1H), 
2.06 (q, J = 6.5 Hz, 2H), 1.89 (d, J = 6.2 Hz, 1H), 1.64–1.54 (m, 2H), 1.45–1.23 (m, 6H); 13C 
NMR (75 MHz, CDCl3) δ 159.0, 134.1, 130.6, 129.2, 128.5, 113.7, 83.4, 73.8, 72.4, 69.9, 62.5, 
55.2, 31.7, 29.5, 28.9, 28.6, 25.9; IR (film) 3591, 3416, 3306, 3004, 2935, 2858, 1613, 1513, 
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1465, 1248, 1090, 908, 732, 650 cm-1; MS (EI) m/z 302 (M+); HRMS (EI) m/z (M+) calcd for 
C19H26O3 302.1882, found 302.1872. 
 
OPMB
OH
 
(R,E)-11-(4-methoxybenzyloxy)undec-4-en-1-yn-3-ol (1.38R): 
 Following the same procedure for 1.38S, alcohol 1.37R (207.6 mg, 0.50 mmol) was 
reacted with TBAF (0.75 mL, 1.0 M solution in THF, 0.75 mmol), the title compound 1.38R 
(150.2 mg, 95%) was obtained. [α]D 25 = –18.1 (c = 1.37, CHCl3), 1H NMR (300 MHz, CDCl3) δ 
7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.90 (dtd, J = 15.2, 6.7，1.1 Hz, 1H), 5.60 
(ddt, J = 15.3, 6.1, 1.4 Hz), 4.83 (m, 1H), 4.43 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.56 
(d, J = 2.2 Hz, 1H), 2.06 (q, J = 6.7 Hz, 2H), 1.89 (d, J = 6.2 Hz, 1H), 1.63–1.55 (m, 2H), 1.45–
1.23 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 158.9, 133.9, 130.5, 129.1, 128.5, 113.6, 83.4, 73.7, 
72.3, 69.9, 62.4, 55.1, 31.7, 29.4, 28.8, 28.6, 25.8; IR (film) 3591, 3417, 3306, 3004, 2934, 2858, 
1613, 1513, 1465, 1248, 1090, 905, 731, 650 cm-1; MS (EI) m/z 302 (M+); HRMS (EI) m/z (M+) 
calcd for C19H26O3 302.1882, found 302.1871. 
 
OPMB
O O
H3CO
F3C
S
S
 
(S)-((S,E)-11-(4-Methoxybenzyloxy)undec-4-en-1-yn-3-yl)3,3,3-trifluoro-2-methoxy-2- 
phenylpropanoate (1.39SS): 
 Alcohol 1.38S (11.0 mg, 0.04 mmol) was added to a solution of (R)-MTPA-Cl (20.4 μL, 
0.11 mmol) in pyridine (0.4 mL) at room temperature. After 4 h, the organic solvent was 
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removed under reduced pressure. The residue was purified by column chromatography 
(hexane/EtOAc = 19:1) to afford the title compound 1.39SS (14.5 mg, 78%).  1H NMR (300 
MHz, CDCl3) δ 7.54-7.51 (m, 2H), 7.41-7.36 (m, 3H), 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.6 
Hz, 2H), 6.00 (d, J = 6.8 Hz, 1H), 6.03 (dtd, J = 15.3, 6.9, 0.9 Hz, 1H), 5.49 (ddt, J = 15.1, 6.9, 
1.4 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.59 (s, 3H), 3.42 (t, J = 6.6 Hz, 2H), 2.63 (d, J = 2.2 Hz, 
1H), 2.04 (q, J = 7.0 Hz, 2H), 1.63–1.53 (m, 2H), 1.41–1.23 (m, 6H). 
 
OPMB
O O
F3C
H3CO
R
S  
(R)-((S,E)-11-(4-Methoxybenzyloxy)undec-4-en-1-yn-3-yl)3,3,3-trifluoro-2-methoxy-2- 
phenylpropanoate (1.39SR) 
Following the same procedure as above, except for using (S)-MTPA-Cl rather than (R)-
MTPA-Cl, the title compound 1.39SR (15.0 mg, 80%) was obtained. 1H NMR (300 MHz, CDCl3) 
δ 7.54-7.52 (m, 2H), 7.43-7.37 (m, 3H), 7.26 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 6.07 
(dt, J = 15.3, 6.9 Hz, 1H), 6.00 (d, J = 6.8 Hz, 1H), 5.60 (ddt, J = 15.4, 6.9, 1.2 Hz, 1H), 4.42 (s, 
2H), 3.80 (s, 3H), 3.55 (s, 3H), 3.43 (t, J = 6.5 Hz, 2H), 2.59 (d, J = 2.2 Hz, 1H), 2.09 (q, J = 6.9 
Hz, 2H), 1.64–1.54 (m, 2H), 1.45–1.23 (m, 6H). 
 
OPMB
O O
OCH3
S
S  
(S)-((S,E)-11-(4-Methoxybenzyloxy)undec-4-en-1-yn-3-yl)2-methoxy-2-(naphthalen-2-yl) 
acetate (1.40SS): 
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 (S)-NMA acid (16.0 mg, 0.07 mmol), DCC (18.3, 0.09 mmol), and DMAP (0.9 mg, 
0.007mmol) was added to a solution of alcohol 43a (11.2 mg, 0.04 mmol) in CH2Cl2 (0.7 ml) at 
room temperature. The resulting mixture was stirred at the same temperature overnight. The 
mixture was then filtered through a pad of Celite ®, the filtrate was concentrated in vacuo. The 
crude product was purified by column chromatography (hexane/EtOAc = 17:3) to afford the tiltle 
compound 1.40SS (14.2 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 7.93 (s, 1H), 7.86-7.82 (m, 
3H), 7.56 (dd, J = 8.5, 1.5 Hz, 1H), 7.51-7.47 (m, 2H), 7.26 (d, J = 8.5 Hz, 2H),  6.88 (d, J = 8.5 
Hz, 2H), 5.98 (dtd, J = 15.0, 7.0, 1,0 Hz, 1H), 5.87 (dd, J = 6.5, 1.0 Hz, 1H), 5.53 (ddt, J = 15.0, 
6.5, 1.5 Hz, 1H), 4.96 (s, 1H), 4.43 (s, 2H), 3.80 (s, 3H), 3.46 (s, 3H), 3.42 (t, J = 6.5 Hz, 2H), 
2.45 (d, J = 2.0 Hz, 1H), 2.04 (q, J = 7.0 Hz, 2H), 1.61–1.55 (m, 2H), 1.39–1.23 (m, 6H). 
 
OPMB
O O
OCH3
S
R  
(S)-((R,E)-11-(4-Methoxybenzyloxy)undec-4-en-1-yn-3-yl) 2-methoxy-2-(naphthalen-2-yl) 
acetate (1.40RS): 
 Following the same procedure as above, except for using alcohol 1.38R rather than 1.38S, 
the title compound 1.40RS (15.7 mg, 85%) was obtained. 1H NMR (500 MHz, CDCl3) δ 7.92 (s, 
1H), 7.86-7.81 (m, 3H), 7.54 (dd, J = 8.5, 1.5 Hz, 1H), 7.50-7.47 (m, 2H), 7.26 (d, J = 8.5 Hz, 
2H),  6.88 (d, J = 8.5 Hz, 2H), 5.89 (dd, J = 6.5, 1.0 Hz, 1H), 5.79 (dtd, J = 15.0, 7.0, 1.0 Hz, 
1H), 5.34 (ddt, J = 15.0, 6.5, 1.5 Hz, 1H), 4.97 (s, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.47 (s, 3H), 
3.39 (t, J = 7.0 Hz, 2H), 2.56 (d, J = 2.5 Hz, 1H), 1.89 (q, J = 6.5 Hz, 2H), 1.52 (m, 2H), 1.27–
1.12 (m, 6H). 
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(R,E)-tert-Butyl(3-(diisopropyl(3,3,4,4,5,5,6,6,6-nonafluorohexyl)silyloxy)-11-(4-
methoxybenzyloxy)undec-4-en-1-ynyl)dimethylsilane (1.41R): 
 Trifluoromethanesulfonic acid (neat, 2.9 mL, 33.2 mmol) was slowly added to silane 
C4F9(CH2)2(iPr)2SiH (neat, 15.1 g, 41.5 mmol) at 0 °C. After being stirred for 20 min at the same 
temperature, the mixture was warmed to room temperature and stirred for 15 h. CH2Cl2 (30 mL) 
was added to above mixture at –60 °C, followed by a solution of alcohol 1.37R (6.92 g, 16.6 
mmol) in CH2Cl2 (42 mL) and 2,6-lutidine (5.8 mL, 49.8 mmol). The resulting mixture was 
warmed to room temperature and stirred for further 2 h. Saturated aqueous NH4Cl (100 mL) was 
then added to quench the reaction at 0 °C. The mixture was extracted with Et2O (3 × 150 mL), 
the organic layers were combined and washed with water, dried over MgSO4, and concentrated 
in vacuo. The crude product was purified by column chromatography (hexane/EtOAc = 19:1) to 
afford the title compound 1.41R (11.23 g, 87%) as colorless oil. [α]D 25 = +1.13 (c = 1.20, 
CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.79 
(dtd, J = 15.3, 6.6, 0.9 Hz, 1 H), 5.51 (dd, J = 15.0, 5.7 Hz, 1 H), 4.89 (d, J = 5.4 Hz, 1 H), 4.43 
(s, 2 H), 3.80 (s, 3 H), 3.43 (t, J = 6.3 Hz, 2 H), 2.23–2.01 (m, 4 H), 1.61–1.54 (m, 2 H), 1.43–
1.28 (m, 6 H), 1.06 (br s, 14 H), 0.93–0.86 (m, 11 H), 0.09 (s, 6 H); 13C NMR (75 MHz, CDCl3) 
δ 159.1, 132.5, 130.8, 129.4, 129.2, 113.8, 106.0, 88.4, 72.5, 70.2, 64.1, 55.3, 31.7, 29.7, 29.0, 
28.9, 26.0, 25.9, 25.4 (t, JCF = 23.2 Hz, 1 C), 17.5 (2 C), 17.4 (2 C) 16.5, 12.7, 12.6, 0.3 –4.9; IR 
(film) 3020, 2934, 1640, 1514, 1474, 1424, 1216, 1133, 1036, 929, 755 cm-1; HRMS (ESI) m/z 
(M+ + H) calcd for C37H58O3Si2F9 777.3793, found 777.3781. 
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(S,E)-tert-Butyl(3-((3,3,4,4,5,5,5-heptafluoropentyl)diisopropylsilyloxy)-11-(4-
methoxybenzyloxy)undec-4-en-1-ynyl)dimethylsilane (1.41S): 
 Trifluoromethanesulfonic acid (neat, 2.7 mL, 30.8 mmol) was slowly added to silane 
C3F7(CH2)2(iPr)2SiH (neat, 12.1 g, 39.5 mmol) at 0 °C. After being stirred for 20 min at the same 
temperature, the mixture was warmed to room temperature and stirred for 15 h. CH2Cl2 (23 mL) 
was added to above mixture at –60 °C, followed by a solution of alcohol 1.37R (6.44 g, 15.4 
mmol) in CH2Cl2 (39 mL) and 2,6-lutidine (5.4 mL, 46.2 mmol). The resulting mixture was 
warmed to room temperature and stirred for further 2 h. Saturated aqueous NH4Cl (90 mL) was 
then added to quench the reaction at 0 °C. The mixture was extracted with Et2O (3 × 150 mL), 
the organic layers were combined and washed with water, dried over MgSO4, and concentrated 
in vacuo. The crude product was purified by column chromatography (hexane/EtOAc = 19:1) to 
afford the title compound 1.41S (10.11 g, 90%) as colorless oil. [α]D 25 = -1.09 (c = 0.92, CHCl3), 
1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.79 (dtd, J = 
15.3, 6.9, 0.6 Hz, 1 H), 5.51 (dd, J = 15.3, 5.7 Hz, 1 H), 4.89 (d, J = 5.7 Hz, 1 H), 4.43 (s, 2 H), 
3.80 (s, 3 H), 3.43 (t, J = 6.6 Hz, 2 H), 2.23–2.01 (m, 4 H), 1.61–1.53 (m, 2 H), 1.43–1.28 (m, 6 
H), 1.06 (br s, 14 H), 0.93–0.86 (m, 11 H), 0.09 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 159.1, 
132.5, 130.8, 129.4, 129.2, 113.8, 106.0, 88.4, 72.5, 70.2, 64.1, 55.2, , 31.7, 29.7, 29.0, 28.9, 26.0, 
25.9, 25.3 (t, JCF = 23.2 Hz, 1 C), 17.5 (2 C), 17.4 (2 C) 16.5, 12.7, 12.6, 0.3 –4.9; IR (film) 3020, 
2934, 1640, 1514, 1474, 1424, 1216, 1133, 1037, 929, 755 cm-1; HRMS (ESI) m/z (M+ + Na + H) 
calcd for C37H58O3NaSi2F7 749.3634, found 749.3632. 
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(R/S,E)-11-(tert-Butyldimethylsilyl)-9-((perfluoroalkylethyl)diisopropylsilyloxy)undec-7-en-
10-yn-1-ol (M-1.42): 
 DDQ (5.90 g, 26.0 mmol) was added to the mixture of compound 1.41R (7.77 g, 10.0 
mmol) and compound 1.41S (7.25 g, 10.0 mmol) in CH2Cl2 (200 mL) and H2O (22.3 mL) at 
room temperature. The reaction was monitored by TLC until completion, and then saturated 
NaHCO3 aqueous solution was added. The mixture was extracted with CH2Cl2 (3 × 150 mL), the 
organic layers were combined, washed with saturated NaHCO3 aqueous solution, brine, dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (hexane/Et2O = 85:15) to afford the title compound M-41, which was 
contaminated with tiny 4-(methoxymethyl)benzaldehyde and was used in the following step 
without further purification. 1H NMR (300 MHz, CDCl3) δ 5.79 (dtd, J = 15.3, 7.8, 0.9 Hz, 1H), 
5.54 (dd, J = 15.3, 5.7, 1H), 4.89 (d, J = 5.7 Hz, 1H), 3.64 (q, J = 6.2 Hz, 2H), 2.23–2.03 (m, 2H), 
2.06 (q, J = 6.6 Hz, 2H), 1.61–1.52 (m, 2H), 1.45–1.33 (m, 6H), 1.18 (t, J = 5.4 Hz, 1H), 1.08–
1.06 (m, 14H), 0.95–0.85 (m, 11H), 0.09 (s, 6H). 
 
OTIPSF7 ,9
I
TBS  
(R/S,E)-tert-Butyl(3-(perfluoroalkylethyl)diisopropylsilyloxy)-11-iodoundec-4-en-1-
ynyl)dimethylsilane (M-1.29): 
 A solution of iodine (5.74 g, 22.6 mmol) in CH2Cl2 (85 mL) was slowly added to a 
solution of triphenylphosphine (5.93 g, 22.6 mmol) in CH2Cl2 (28 mL), followed by a mixture of 
imidazole (1.69 g, 24.8 mmol) and alcohol M-1.42 (crude, 7.14 g, 11.3 mmol) in CH2Cl2 (28 mL) 
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at room temperature. After 2 h, the reaction was quenched with saturated aqueous NaHCO3 (150 
mL). The mixture was extracted with Et2O (3 × 100 mL) and organic layer was washed with 
saturated aqueous Na2S2O3 (100 mL), water, brine, dried over MgSO4, and concentrated in 
vacuuo. The crude product was purified by column chromatography (hexane/Et2O = 99.5:0.5) to 
afford the title comound M-40 (7.33 g, 49%) as yellow oil. 1H NMR (300 MHz, CDCl3) δ 5.79 
(dtd, J = 15.3, 7.5, 0.9 Hz, 1H), 5.52 (dd, J = 15.3, 5.7 Hz, 1H), 4.90 (d, J = 5.7 Hz, 1H), 3.18 (t, 
J = 6.9 Hz, 2 H), 2.28–2.06 (m, 2H), 2.06 (q, J = 6.6 Hz, 2H), 1.86–1.77 (m, 2H), 1.43–1.26 (m, 
6H), 1.19–1.02 (m, 14H), 1.06 (m, 11H), 0.09 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 132.2, 
129.6, 105.9, 88.4, 87.6, 64.1, 33.5, 31.6, 30.3, 28.7, 28.0, 26.0, 17.5 (2C), 17.4 (2C), 16.5, 12.7, 
12.6, 7.0, 0.3, -4.9. 
 
General procedure: asymmetric alkynylation to alkynyl aldehyde. 
In a 25mL round bottle flask, a solution of alkyne (3.0 mmol) and diethylzinc (323.4 μL, 
3.0 mmol) in toluene (1.0 mL) was heated under argon atmosphere to reflux for 1 h. After the 
solution cooled to room temperature, (R)-BINOL (143.2 mg, 0.5 mmol), Et2O (8.0 mL), and 
Ti(OiPr)4 (370.0 μL, 1.25 mmol) were added sequentially, the resulting mixture was stirred for 1 
h. Aldehyde (0.5 mmol) was added to the above mixture and stirring continued for additional 4 h. 
Saturated aqueous NH4Cl was added to quench the reaction. The mixture was extracted with 
CH2Cl2, dried over MgSO4, and concentrated in vacuo. The crude product was purified by 
column chromatography to afford the corresponding propargylic alcohol. The ee of product was 
determined by chiral HPLC (Chiralcel OD column, 4.6 × 200 mm, hexane/iPrOH = 9:1, 1.0 
mL/min) 
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(S)-1-Phenyldeca-1,4-diyn-3-ol (1.44S): 
 General procedure was followed employing phenylacetylene 1.43 (336.2 μL, 3.0 mmol), 
diethylzinc (323.4 μL, 3.0 mmol), (R)-BINOL (143.2 mg, 0.5 mmol), Ti(OiPr)4 (370.0 μL, 1.25 
mmol), and 2-octynal 1.27 (73.5 μL, 0.5 mmol). Purification by column chromatography 
(hexane/EtOAc = 19:1) afforded the title compound 1.44S (102.1 mg, 90%). 78% ee determined 
by HPLC analysis (tminor = 6.16 min, tmajor = 11.03 min), 1H NMR (300 MHz, CDCl3) δ 7.49–
7.45 (m, 2H), 7.34–7.28 (m, 3H), 5.35 (dt, J = 6.9, 1.8 Hz, 1H), 2.35 (d, J = 7.0, 1H), 2.25 (td, J 
= 7.1 Hz, 2.0 Hz, 2H), 1.60–1.50 (m, 2H), 1.43–1.26 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 131.8, 128.7, 128.2, 122.1, 86.7, 86.0, 83.9, 77.4, 52.9, 31.0, 28.0, 22.1, 18.7, 
13.9; IR (film) 3336, 3032, 2917, 1855, 2230, 1599, 1499, 1443, 1378, 1071, 1010, 996, 963, 
942, 756, 691 cm-1. 
 
OH
Si
Ph
 
(S)-1-(Dimethyl(phenyl)silyl)deca-1,4-diyn-3-ol (1.48S): 
 General procedure was followed employing dimethylphenylsilyacetylene 1.45 (540.1 μL, 
3.0 mmol), diethylzinc (323.4 μL, 3.0 mmol), (R)-BINOL (143.2 mg, 0.5 mmol), Ti(OiPr)4 
(370.0 μL, 1.25 mmol), and 2-octynal 1.27 (73.5 μL, 0.5 mmol). Purification by column 
chromatography (hexane/EtOAc = 19:1) afforded the title compound 1.48S (127.1 mg, 90%) as 
yellow oil. 78% ee determined by HPLC analysis (hexane/iPrOH = 49:1, 1mL/min, tminor = 11.01 
min, tmajor = 13.25 min), 1H NMR (300 MHz, CDCl3) δ 7.64–7.61 (m, 2H), 7.39–7.35 (m, 3H), 
5.14 (dt, J = 7.4, 1.9 Hz, 1H), 2.23 (td, J = 7.0, 1.9 Hz, 2H), 2.15 (d, J = 7.4 Hz, 1H), 1.58–1.49 
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(m, 2H), 1.42–1.26 (m, 4H), 0.90 (t, J =7.1 Hz, 3H), 0.44 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
136.4, 133.7, 129.5, 127.9, 104.3, 86.9, 86.0, 77.2, 52.9, 31.0, 28.0, 22.2, 18.7, 13.9, -1.1; IR 
(film) 3368, 3070, 2958,2932, 2860, 2178, 1466, 1429, 1298,1250, 1115, 1034, 964, 838, 782, 
732, 698; MS (EI) m/z 283 (M+ - H); HRMS (EI) m/z (M+ - H) calcd for C18H23OSi 283.1518, 
found 283.1520. 
 
OH
Si
Ph
Ph
 
(S)-1-(Methyldiphenylsilyl)deca-1,4-diyn-3-ol (1.49S): 
 General procedure was followed employing methyldiphenylsilyacetylene 1.46 (660.5 μL, 
3.0 mmol), diethylzinc (323.4 μL, 3.0 mmol), (R)-BINOL (143.2 mg, 0.5 mmol), Ti(OiPr)4 
(370.0 μL, 1.25 mmol), and 2-octynal 1.27 (73.5 μL, 0.5 mmol). Purification by column 
chromatography (hexane/EtOAc = 33:1) afforded the title compound 1.49S (147.3 mg, 85%) as a 
yellow oil. 80% ee determined by HPLC analysis (hexane/iPrOH = 49:1, 1 mL/min, tminor = 15.55 
min, tmajor = 20.78 min), 1H NMR (300 MHz, CDCl3) δ 7.66–7.63 (m, 4H), 7.45–7.34 (m, 6H), 
5.19 (dt, J = 7.6, 2.1 Hz, 1H), 2.24 (td, J = 7.0, 2.1 Hz, 2H), 2.20 (d, J = 7.5 Hz, 1H), 1.59-1.50 
(m, 2H), 1.43–1.26 (m, 4H), 0.90 (t, J =6.9 Hz, 3H), 0.71 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
134.7 134.5, 129.8, 128.0, 105.9, 86.2, 85.3, 77.1, 53.0, 31.0, 28.0, 22.2, 18.7, 13.9, -–2.3; IR 
(film) 3398, 3069, 2957,2930, 2859, 2178, 1466, 1429, 1298,1252, 1114, 1034, 964, 793, 728, 
698; MS (EI) m/z 346 (M+); HRMS (EI) m/z (M+) calcd for C23H26OSi 346.1753, found 
346.1736. 
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(S)-2-(tert-Butyldimethylsilyloxy)-2-methyldodeca-3,6-diyn-5-ol (1.50S): 
 General procedure was followed employing alkyne 1.47 (679.2 mg, 3.0 mmol), 
diethylzinc (323.4 μL, 3.0 mmol), (R)-BINOL (143.2 mg, 0.5 mmol), Ti(OiPr)4 (370.0 μL, 1.25 
mmol), and 2-octynal 1.27 (73.5 μL, 0.5 mmol). Purification by column chromatography 
(hexane/EtOAc = 33:1) afforded the title compound 1.50S (150.6 mg, 86%) as a yellow oil. 90% 
ee determined by HPLC analysis (hexane/iPrOH = 49:1, 0.6 mL/min, tminor = 15.55 min, tmajor = 
20.78 min), 1H NMR (300 MHz, CDCl3) δ 5.10 (dt, J = 7.4, 2.1 Hz, 1H), 2.22 (td, J = 7.0, 2.0 Hz, 
2H), 1.99 (d, J = 7.3 Hz, 1H), 1.57–1.50 (m, 2H), 1.46 (s, 6H), 1.39-1.25 (m, 4H), 0.90 (t, J = 6.9 
Hz, 3H), 0.87 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 89.3, 85.8, 80.1, 
77.2, 66.2, 52.5, 32.7, 31.0, 28.0, 25.7, 22.2, 18.6, 17.9, 13.9, -3.0; IR (film) 3053, 2986, 2254, 
1422, 1265, 1162, 1037, 909, 735, 650; MS (EI) m/z 307 (M+ - CH3); HRMS (EI) m/z (M+ – CH3) 
calcd for C18H31O2Si 307.2093, found 307.2089. 
 
OTBS
OH  
2-(tert-Butyldimethylsilyloxy)-2-methyldodeca-3,6-diyn-5-ol (rac-1.51): 
 n-BuLi (4.1 mL, 1.6 M solution in hexane, 6.5 mmol) was slowly added to a solution of 
alkyne 1.47 (1.29 g, 6.5 mmol) in THF (30 mL) at -78 °C. The mixture was then warmed to 
room temperature and stirred for 1 h. 2-Octynal 1.27 (0.74 mL, 5.0 mmol) was added and the 
resulting mixture was then stirred overnight. Ice was added to quench reaction; the mixture was 
extracted with CH2Cl2 (3 × 30 mL). The organic layers were combined, dried over MgSO4, and 
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concentrated under reduced pressure. The crude product was purified by column chromatography 
(hexane/EtOAc = 97:3) to afford the racemic compound rac-1.51 (1.32 g, 82%) as yellow oil. 1H 
NMR (300 MHz, CDCl3) δ 5.10 (dt, J = 7.3, 2.0 Hz, 1H), 2.21 (td, J = 7.0, 2.1 Hz, 2H), 2.12 (d, 
J = 7.4 Hz, 1H), 1.56–1.48 (m, 2H), 1.45 (s, 6H), 1.39–1.27 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H), 
0.86 (s, 9H), 0.18 (s, 3H), 0.17 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 89.2, 85.7, 80.0, 77.3, 66.1, 
52.4, 32.6, 31.0, 28.0, 25.7, 22.2, 18.6, 17.9, 13.9, -3.1. 
 
OH
OH  
2-Methyldodeca-3,6-diyne-2,5-diol (rac-1.52): 
 Acetyl chloride (1 mL) was added to a solution of compound 37 (1.28 g, 4.0 mmol) in 
MeOH (40 mL) at room temperature. The mixture was then stirred for 10 min at the same 
temperature. The organic solvents were then removed under reduced pressure. The residue was 
purified by column chromatography (hexane/EtOAc = 7:3) to afford the title compound 38 (0.75 
g, 91%) as pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 5.10 (br s, 1H), 3.06 (d, J = 6.7 Hz, 
1H), 2.80 (s, 1H), 2.21 (td, J = 7.1, 2.0 Hz, 2H), 1.58-1.45 (m, 2H), 1.52 (s, 6H), 1.39–1.24 (m, 
4H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 88.4, 85.6, 80.0, 77.0, 65.1, 52.1, 
31.0 (3C), 28.0, 22.1, 18.6, 13.9. 
 
OH
OTIPS  
2-Methyl-5-(triisopropylsilyloxy)dodeca-3,6-diyn-2-ol (rac-1.53): 
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 TIPSCl (0.66 mL, 3.1 mmol) and imidazole (279 mg, 4.1 mmol) was added to a solution 
of diol rac-1.52 (533 mg, 2.6 mmol) in DMF (13 mL) at room temperature. The mixture was 
stirred overnight at the same temperature. Water (20 mL) was added to quench reaction. The 
organic layer was separated; the aqueous layer was extracted with Et2O (3 × 15 mL). The organic 
layers were combined, dried over MgSO4, and concentrated in vacuuo. The residue was purified 
by column chromatography (hexane/EtOAc = 97:3) to afford title compound 39 (813 mg, 87%) 
as pale yellow oil.  1H NMR (300 MHz, CDCl3) δ 5.25 (t, J = 2.1 Hz, 1H), 2.20 (td, J = 6.9, 2.0 
Hz, 2H), 1.96 (br s, 1H), 1.55-1.44 (m, 2H), 1.50 (s, 6H), 1.39–1.26 (m, 4H), 1.17–1.04 (m, 21H), 
0.88 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 87.3, 84.4, 80.9, 78.2, 65.1, 53.3, 31.2, 
31.1, 31.0, 28.0, 22.1, 18.6, 17.8, 13.9, 12.2. 
 
OPMB
OH
Si
Ph
R
 
(R)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-ol (1.54R): 
 In a 50 mL round bottle flask, a solution of dimethylphenylsilyacetylene 1.45 (6.0 mmol) 
and diethylzinc (646.8 μL, 6.0 mmol) in toluene (2.0 mL) was heated under argon atmosphere to 
reflux for 1 h. After the solution cooled to room temperature, (S)-BINOL (286.4 mg, 1.0 mmol), 
Et2O (16.0 mL), and Ti(OiPr)4 (540.0 μL, 2.5 mmol) were added sequentially, the resulting 
mixture was stirred for 1 h. Aldehyde 1.5 (260.1 mg, 1.0 mmol) was added to the above mixture 
and stirring continued for additional 4 h. Saturated aqueous NH4Cl (20 mL) was added to quench 
the reaction. The mixture was extracted with CH2Cl2 (3 × 35 mL), dried over MgSO4, and 
concentrated in vacuo. The crude product was purified by chiral HPLC (semi-preparation 
Chiracel OD column, hexane/iPrOH = 19:1, 8.0 mL/min) to afford the optical pure compound 
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1.54R (269.3 mg, 64%), followed by 1.54S (25.8 mg, 6%). [α]D 25 = +4.3 (c = 1.09, CHCl3). 1H 
NMR (300 MHz, CDCl3) δ 7.64–7.61 (m, 2H), 7.39–7.37 (m, 3H), 7.26 (d, J = 8.7 Hz, 2H), 6.88 
(d, J = 8.4 Hz, 2H), 5.12 (dt, J = 7.5, 2.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.44 (t, J = 6.3 Hz, 
2H), 2.24 (td, J = 6.9, 1.8 Hz, 2H), 2.22 (d, J = 7.5 Hz, 1H), 1.64–1.46 (m, 6H), 0.43 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 158.9, 136.2, 133.6, 130.4, 129.4, 129.2, 127.8, 113.6, 104.5, 86.4, 
85.2, 77.4, 72.3, 69.6, 55.1, 52.5, 29.0, 27.9, 25.3, 18.5, –1.2; IR (film) 3585, 3019, 2986, 2400, 
1613, 1513, 1429, 1215, 1114, 1033, 929, 755; MS (EI) m/z 420 (M+); HRMS (EI) m/z (M+) 
calcd for C26H32SiO3 420.2121, found 420.2109. 
 
OPMB
OH
Si
Ph
S
 
(S)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-ol (1.54S): 
 In a 50 mL round bottle flask, a solution of dimethylphenylsilyacetylene 1.45 (6.0 mmol) 
and diethylzinc (646.8 μL, 6.0 mmol) in toluene (2.0 mL) was heated under argon atmosphere to 
reflux for 1 h. After the solution cooled to room temperature, (R)-BINOL (286.4 mg, 1.0 mmol), 
Et2O (16.0 mL), and Ti(OiPr)4 (540.0 μL, 2.5 mmol) were added sequentially, the resulting 
mixture was stirred for 1 h. Aldehyde 1.5 (260.1 mg, 1.0 mmol) was added to the above mixture 
and stirring continued for additional 4 h. Saturated aqueous NH4Cl (20 mL) was added to quench 
the reaction. The mixture was extracted with CH2Cl2 (3 × 35 mL), dried over MgSO4, and 
concentrated in vacuo. The crude product was purified by chiral HPLC (semi-preparation 
Chiracel OD column, hexane/iPrOH = 19:1, 8.0 mL/min) to afford the optical pure compound  
1.54R (23.4 mg, 5%), followed by 1.54S (294.6 mg, 70%). [α]D 25 = -4.2 (c = 0.96, CHCl3). 1H 
NMR (300 MHz, CDCl3) δ 7.65–7.61 (m, 2H), 7.40–7.35 (m, 3H), 7.26 (d, J = 8.7 Hz, 2H), 6.88 
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(d, J = 8.7 Hz, 2H), 5.12 (dt, J = 7.2, 2.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.44 (t, J = 6.3 Hz, 
2H), 2.28 (d, J = 7.5 Hz, 1H), 2.24 (td, J = 6.9, 2.1 Hz, 2H), 1.66–1.43 (m, 6H), 0.44 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 159.0, 136.3, 133.6, 130.5, 129.4, 129.2, 127.8, 113.7, 104.4, 86.5, 
85.4, 77.4, 72.4, 69.7, 55.2, 52.6, 29.1, 27.9, 25.3, 18.6, -1.2; IR (film) 3585, 3019, 2400, 1613, 
1514, 1429, 1215, 1114, 1034, 929, 755; MS (EI) m/z 420 (M+); HRMS (EI) m/z (M+) calcd for 
C26H32SiO3 420.2121, found 420.2121. 
 
OPMB
O
Si
Ph
O
CF3
OCH3
S
R
 
(S)-((R)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-yl)3,3,3-tri 
fluoro-2-methoxy-2-phenylpropanoate (1.55RS): 
 Alcohol 1.54R (11.0 mg, 0.04 mmol) was added to a solution of (R)-MTPA-Cl (20.4 μL, 
0.11 mmol) in pyridine (0.4 mL) at room temperature. After 4 h, the organic solvent was 
removed under reduced pressure. The residue was purified by column chromatography 
(hexane/EtOAc = 19:1) to afford the title compound 1.55RS (15.1 mg, 80%): 1H NMR (300 
MHz, CDCl3) δ 7.59–7.56 (m, 2H), 7.53 (d, J = 7.3 Hz, 2H), 7.41–7.30 (m, 6H), 7.25 (d, J = 
8.1Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 6.27 (t, J = 2.1 Hz, 1H), 4.41 (s, 2H), 3.80 (s, 3H), 3.57 (s, 
3H), 3.41 (t, J = 6.4 Hz, 2H), 2.24 (td, J = 7.0, 2.1 Hz, 2H), 1.62–1.41 (m, 6H), 0.41 (s, 6H). 
 
OPMB
O
Si
Ph
O
OCH3
CF3
R
R
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(R)-((R)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-yl)3,3,3-tri 
fluoro-2-methoxy-2-phenylpropanoate (1.55RR): 
 Following the same procedure as above, except for using (S)-MTPA-Cl rather than (R)-
MTPA-Cl, the title compound 1.55RR (14.5 mg, 78%) was obtained: 1H NMR (300 MHz, 
CDCl3) δ 7.61–7.58 (m, 2H), 7.53 (d, J = 7.0 Hz, 2H), 7.42–7.31 (m, 6H), 7.25 (d, J = 7.5 Hz, 
2H), 6.87 (d, J = 8.7 Hz, 2H), 6.29 ( t, J = 2.1 Hz, 1H), 4.41 (s, 2H), 3.80 (s, 3H), 3.56 (s, 3H), 
3.41 (t, J = 6.5 Hz, 2H), 2.21 (td, J = 6.8, 2.0 Hz, 2H), 1.64–1.33 (m, 6H), 0.43 (s, 6H). 
 
OPMB
O
Si
Ph
O
OMe
R
S
 
(S)-((R)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-yl) 2-methoxy-
2-(naphthalen-2-yl)acetate (1.56RS): 
 (S)-NMA acid (7.8 mg, 0.04 mmol), DCC (8.9, 0.04 mmol), and DMAP (0.4 mg, 
0.004mmol) was added to a solution of alcohol 1.54R (7.6 mg, 0.02 mmol) in CH2Cl2 (0.3 ml) at 
room temperature. The resulting mixture was stirred at the same temperature overnight. The 
mixture was then filtered through a pad of Celite ®, the filtrate was concentrated in vacuo. The 
crude product was purified by column chromatography (hexane/EtOAc = 17:3) to afford the tiltle 
compound 1.56RS (8.7 mg, 78%): 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.85–7.80 (m, 
3H), 7.60–7.55 (m, 3H), 7.49–7.46 (m, 2H), 7.37–7.32 (m, 3H), 7.24 (d, J = 8.7 Hz, 2H), 6.87 (d, 
J = 8.7 Hz, 2H), 6.13 (t, J = 2.1 Hz, 1H), 4.99 (s, 1H), 4.39 (s, 2H), 3.80 (s, 3H), 3.46 (s, 3H), 
3.35 (t, J = 6.5 Hz, 2H), 2.05 (td, J = 6.8, 2.1 Hz, 2H), 1.51–1.44 (m, 2H), 1.38–1.23 (m, 4H), 
0.40 (s, 6H). 
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OPMB
O
Si
Ph
O
OMe
S
S
 
(S)-((S)-1-(Dimethyl(phenyl)silyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-yl) 2- methoxy-
2-(naphthalen-2-yl)acetate (1.56SS): 
 Following the same procedure as above, except for using alcohol 1.54S rather than 1.54R, 
the title compound 1.56SS (8.2 mg, 74%) was obtained: 1H NMR (300 MHz, CDCl3) δ 7.94 (s, 
1H), 7.85–7.76 (m, 3H), 7.60–7.45 (m, 4H), 7.37–7.24 (m, 6H), 6.88 (d, J = 8.6 Hz, 2H), 6.13 (t, 
J = 2.0 Hz, 1H), 5.00 (s, 1H), 4.41 (s, 2H), 3.79 (s, 3H), 3.47 (s, 3H), 3.41 (t, J = 6.4 Hz, 2H), 
2.21 (td, J = 6.6, 2.0 Hz, 2H), 1.70–1.37 (m, 6H), 0.25 (s, 6H). 
 
OPMB
OH
S
 
(S)-10-(4-Methoxybenzyloxy)deca-1,4-diyn-3-ol (1.57S): 
 TBAF (9.2 mL, 1.0 M solution in THF, 9.2 mmol) was added to a solution of alcohol 
1.54R (1.93 g, 4.6 mmol) in THF (45 mL) at room temperature. The mixture then was stirred for 
1 h at this temperature and quenched with saturated aqueous NH4Cl. The resulting mixture was 
extracted with CH2Cl2 (3 × 70 mL). The organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified by column 
chromatography (hexane/EtOAc = 4 : 1) to give compound 1.57S (1.12 g, 85%) as a pale yellow 
oil. [α]D 25 = +3.71 (c = 1.09, CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 
6.88 (d, J = 8.4 Hz, 2H), 5.09 (dq, J = 7.5, 2.1 Hz, 1H), 4.43 (s, 2H), 3.81 (s, 3H), 3.44 (t, J = 6.6 
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Hz, 2H), 2.53 (d, J = 2.1 Hz, 1H), 2.30–2.25(m, 1H), 2.24 (td, J = 6.6, 2.1 Hz, 2H), 1.66–1.40 (m, 
6H); 13C NMR (75 MHz, CDCl3) δ 159.1, 130.6, 129.3, 113.8, 85.8, 81.5, 77.2, 72.5, 72.2, 69.8, 
55.3, 52.1, 29.1, 28.0, 25.5, 18.6; IR (film) 3422, 3020, 1642, 1514, 1425, 1216, 1089, 1015, 928, 
757. 
 
OPMB
OH
R
 
(R)-10-(4-Methoxybenzyloxy)deca-1,4-diyn-3-ol (1.57R): 
 TBAF (9.1 mL, 1.0 M solution in THF, 9.1 mmol) was added to a solution of alcohol 
1.54R (1.91 g, 4.5 mmol) in THF (45 mL) at room temperature. The mixture then was stirred for 
1 h at this temperature and quenched with saturated aqueous NH4Cl. The resulting mixture was 
extracted with CH2Cl2 (3 × 70 mL). The organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified by column 
chromatography (hexane/EtOAc = 4 : 1) to give compound 1.57S (1.15 g, 85%) as a pale yellow 
oil. [α]D 25 = -3.29 (c = 1.25, CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 
6.88 (d, J = 8.4 Hz, 2H), 5.09 (dq, J = 7.5, 2.1 Hz, 1H), 4.43 (s, 2H), 3.81 (s, 3H), 3.44 (t, J = 6.6 
Hz, 2H), 2.53 (d, J = 2.1 Hz, 1H), 2.30–2.25(m, 1H), 2.24 (td, J = 6.6, 2.1 Hz, 2H), 1.66–1.40 (m, 
6H); 13C NMR (75 MHz, CDCl3) δ 159.1, 130.6, 129.3, 113.8, 85.8, 81.5, 77.2, 72.5, 72.2, 69.8, 
55.3, 52.1, 29.1, 28.0, 25.5, 18.6; IR (film) 3422, 3020, 1642, 1514, 1425, 1216, 1089, 1015, 928, 
757. 
 
OPMB
TMS
OH  
10-(4-Methoxybenzyloxy)-1-(trimethylsilyl)deca-1,4-diyn-3-ol: 
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 n-BuLi (7.5 mL, 1.6 M in hexane, 12.0 mmol) was added dropwise to a solution of 
trimethylsilylacetylene (1.70 mL, 12.0 mmol) in THF (50 mL) at -78 °C. After 30 min, a 
solution of aldehyde 1.5 (2.09 g, 8.0 mmol) in THF (14 mL) was added slowly. The resulting 
mixture was stirred for 45 min, and then allowed to warm to rt. The solution was poured into pH 
7 phosphate buffer and extracted with Et2O (3 × 50 mL). The organic layer was washed with 
brine. The aqueous layer was extracted with Et2O (50 mL) again. The combined organic layers 
were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was 
purified by column chromatography (hexane/EtOAc = 85 : 15) to give the title compound (2.55 g, 
89%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 
8.7 Hz, 2H), 5.08 (dq, J = 7.2, 2.1 Hz, 1H), 4.30 (s, 2H), 3.81 (s, 3H), 3.44 (t, J = 6.3 Hz, 2H), 
2.23 (td, J = 6.9, 2.1 Hz, 2H), 2.21 (d, J = 7.5 Hz, 1H), 1.66–1.40 (m, 6H), 0.19 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 159.1, 130.6, 129.2, 113.8, 102.7, 88.7, 85.4, 77.5, 72.5, 69.8, 55.2, 
52.7, 29.2, 28.0, 25.4, 18.7, -0.3; IR (film) 3419, 2941, 1612, 1513, 1464, 1373, 1302, 1251, 
1174, 1093, 1034, 907, 846, 732; MS (EI) m/z 358 (M+)  
 
OPMB
OH  
10-(4-Methoxybenzyloxy)deca-1,4-diyn-3-ol (rac-1.57): 
 TBAF (14.4 mL, 1.0 M in THF, 14.4 mmol) was added to a solution of 10-(4-
Methoxybenzyloxy)-1-(trimethylsilyl)deca-1,4-diyn-3-ol (2.50 g, 7.2 mmol) in THF (70 mL). 
The resulting mixture was stirred for 2 h at rt. The mixture was diluted with Et2O (50 mL), 
washed with brine (3 × 50 mL), dried over MgSO4, and concentrated under reduced pressure. 
The crude product was purified by column chromatography (hexane/EtOAc = 3:1) to give the 
compound rac-1.57 (1.88 g, 91%) as pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 
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8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.08 (dq, J = 7.5, 2.1 Hz, 1H), 4.43 (s, 2H), 3.81 (s, 3H), 
3.44 (t, J = 6.3 Hz, 2H), 2.54 (d, J = 2.4 Hz, 1H), 2.26 (d, J = 7.5 Hz, 1H), 2.23 (td, J = 6.6, 2.1 
Hz, 2H), 1.66–1.40 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 159.1, 130.6, 129.2, 113.8, 85.7, 81.6, 
77.2, 72.5, 72.1, 69.8, 55.3, 52.1, 29.1, 28.0, 25.4, 18.6; IR (film) 3416, 2941, 1615, 1514, 1464, 
1378, 1302, 1248, 1174, 1095, 1014, 907, 731; MS (EI) m/z 286 (M+). 
 
OPMB
OTIPS  
Triisopropyl(10-(4-methoxybenzyloxy)deca-1,4-diyn-3-yloxy)silane (rac-1.59): 
 2,6-Lutidine (1.5 mL, 13.1 mmol) and TIPSOTf (3.6 mL, 13.1 mmol) were sequentially  
added to a solution of alcohol rac-1.57 (1.85 g, 6.5 mmol) in CH2Cl2 (65 mL) at 0 °C. The 
reaction was monitored by TLC until completion. Saturated NH4Cl (aq) (50 mL) was then added 
to quench reaction. The reaction mixture was poured in a separatory funnel containing CH2Cl2 
(50 mL). The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (3 × 
50 mL). The combined organic layers were washed with brine, dried over MgSO4, and 
concentrated under reduced pressure. The crude product was purified by column chromatography 
(hexane/EtOAc = 92:8) to afford the product rac-1.59 (2.59 g, 90%) as pale yellow oil. 1H NMR 
(300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.23 (q, J = 2.1 Hz, 1H), 
4.42 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.3 Hz, 2H), 2.47 (d, J = 2.4 Hz, 1H), 2.22 (td, J = 6.9, 2.1 
Hz, 2H), 1.66–1.40 (m, 6H), 1.18–1.04 (m, 21H). 
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I
OPMB
OTIPS
+
OPMB
OTIPS
OPMB
OTIPS
OPMB
OTIPS
n-BuLi, HMPA
THF
1.60, 16.5%
1.58 rac-1.59
1.61, 2.5%
1.62, 9.1%
14
14
14
14
 
n-BuLi (0.15 mL, 1.6 M in hexane, 0.24 mmol) was added to a solution of alkyne rac-
1.59 (88.5 mg, 0.2 mmol) in THF (2 mL) at -30 °C. After stirring at the same temperature for 1 h, 
the reaction mixture was cooled to -78 °C. HMPA (0.2 mL) was added to above solution, 
followed by a solution of iodide 1.58 (64.6 μL, 0.4 mmol) in THF (1 mL). The mixture was 
stirred at -78 °C for another 3 h and allowed to warm to rt for overnight stirring. The reaction 
was quenched with saturated NH4Cl (5 mL). The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 × 15 mL). The combined organic layers were washed with H2O 
and brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/Et2O = 98:2) to give three products shown below. 
 
Triisopropyl(1-(4-methoxybenzyloxy)octadeca-6,9-diyn-8-yloxy)silane (1.60): 
Yield: 18.3 mg, 16.5%. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 
Hz, 2H), 5.22 (quint, J = 2.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.25–
2.16 (m, 2H), 1.62–1.41 (m, 8H), 1.26 (br s, 12H), 1.18–1.08 (m, 21H), 0.88 (t, J = 6.3 Hz, 3H). 
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(8-Ethynyl-1-(4-methoxybenzyloxy)hexadec-6-yn-8-yloxy)triisopropylsilane (1.61): 
Yield: 2.8 mg, 2.5%. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.7 Hz, 
2H), 4.42 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.44 (s, 1H), 2.24–2.16 (m, 2H), 1.89–
1.84 (m, 2H), 1.62–1.41 (m, 8H), 1.26 (br s, 12H), 1.10–1.06 (m, 21H), 0.88 (t, J = 6.3 Hz, 3H). 
 
Triisopropyl(9-(7-(4-methoxybenzyloxy)hept-1-ynyl)nonadec-10-yn-9-yloxy)silane (1.62): 
Yield: 12.2 mg, 9.1%. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.7 
Hz, 2H), 4.42 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.44 (s, 1H), 2.24–2.16 (m, 2H), 
1.89–1.84 (m, 2H), 1.62–1.41 (m, 8H), 1.26 (br s, 12H), 1.10–1.06 (m, 21H), 0.88 (t, J = 6.3 Hz, 
3H). 
 
OPMB
OH  
1-(4-Methoxybenzyloxy)octadeca-6,9-diyn-8-ol (rac-1.63): 
n-BuLi (0.28 mL, 1.6 M in hexane, 0.44 mmol) was added to a solution of alkyne rac-
1.57 (57.3 mg, 0.2 mmol) in THF (1 mL) at -30 °C. After stirring at the same temperature for 1 h, 
the reaction mixture was cooled to -78 °C. HMPA (0.1 mL) was added to above solution, 
followed by a solution of iodide 1.58 (16.2 μL, 0.1 mmol) in THF (0.5 mL). The mixture was 
stirred at -78 °C for another 3 h and allowed to warm to rt for overnight stirring. The reaction 
was quenched with saturated NH4Cl (5 mL). The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were washed with H2O 
and brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/EtOAc = 95:5) to give the product rac-1.63 (23.3 
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mg, 59%) as pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 
8.4 Hz, 2H), 5.09 (dt, J = 3.0, 2.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.3 Hz, 2H), 
2.25–2.19 (m, 2H), 2.14 (d, J = 7.2 Hz, 1H), 1.65–1.45 (m, 8H), 1.26 (br s, 12H), 0.88 (t, J = 6.3 
Hz, 3H). 
 
OPMB
OC8H1 7  
1-Methoxy-4-((8-(octyloxy)octadeca-6,9-diynyloxy)methyl)benzene (rac-1.64): 
n-BuLi (0.28 mL, 1.6 M in hexane, 0.44 mmol) was added to a solution of alkyne rac-
1.57 (57.3 mg, 0.2 mmol) in THF (2 mL) at -30 °C. After stirring at the same temperature for 1 h, 
the reaction mixture was cooled to -78 °C. HMPA (0.2 mL) was added to above solution, 
followed by a solution of iodide 1.58 (64.6 μL, 0.4 mmol) in THF (1 mL). The mixture was 
stirred at -78 °C for another 3 h and allowed to warm to rt for overnight stirring. The reaction 
was quenched with saturated NH4Cl (5 mL). The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were washed with H2O 
and brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/EtOAc = 95:5) to give the products rac-1.64 (26.3 
mg, 26%) and rac-1.63 (20.0 mg, 25%) as pale yellow oils. rac-1.64: 1H NMR (300 MHz, 
CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.92 (t, J = 2.1 Hz, 1H), 4.42 (s, 2H), 
3.80 (s, 3H), 3.56 (t, J = 6.6 Hz, 2 H), 3.43 (t, J = 6.3 Hz, 2H), 2.25–2.19 (m, 2H), 1.65–1.45 (m, 
8H), 1.26 (br s, 24H), 0.88 (t, J = 6.3 Hz, 6H). 
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TBS
OTIPS
OH
OPMB
 
(19S,E)-21-(tert-Butyldimethylsilyl)-1-(4-methoxybenzyloxy)-19-(triisopropylsilyloxy) 
henicosa-17-en-6,9,20-triyn-8-ol (1.65): 
 n-BuLi (0.28 mL, 1.6 M in hexane, 0.44 mmol) was added to a solution of alkyne rac-
1.57 (57.3 mg, 0.2 mmol) in THF (0.35 mL) at -30 °C. After stirring at the same temperature for 
1 h, the reaction mixture was cooled to -78 °C. HMPA (0.1 mL) was added to above solution, 
followed by a solution of iodide 1.29S (56.3 mg, 0.1 mmol) in THF (0.05 mL). The mixture was 
stirred at -78 °C for another 3 h and allowed to warm to rt for overnight stirring. The reaction 
was quenched with saturated NH4Cl (5 mL). The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were washed with H2O 
and brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/EtOAc = 95:5) to give the products 1.65 (25.1 mg, 
35%). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 5.79 (dtd, 
J = 15.0, 7.8, 0.9 Hz, 1H), 5.53 (dd, J = 15.3, 5.4 Hz, 1H), 5.08 (br s, 1H), 4.92 (d, J = 5.1 Hz, 
1H), 4.43 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.25–2.16 (m, 4H), 2.04 (q, J = 6.6 Hz, 
2H), 1.65–1.28 (m, 16H), 1.13–1.02 (m, 21H), 0.92 (s, 9H), 0.09 (s, 6H). 
 
TBS
OTIPSF7,9
OH
OPMB OPMB
OH
F7,9TIPS
 
(8S,E)-21-(tert-butyldimethylsilyl)-19-((purfluoroethyl)diisopropylsilyloxy)-1-(4-methoxy 
benzyloxy)henicosa-17-en-6,9,20-triyn-8-ol (M-1.66) and (R)-1-((3,3,4,4,5,5,5-perfluoro 
ethyl)diisopropylsilyl)-10-(4-methoxybenzyloxy)deca-1,4-diyn-3-ol (1.67): 
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n-BuLi (0.27 mL, 1.6 M in hexane, 0.42 mmol) was added to a solution of alkyne 1.57S 
(57.3 mg, 0.2 mmol) in THF (1.0 mL) at -30 °C. After stirring at the same temperature for 1 h, 
the reaction mixture was cooled to -78 °C. HMPA (0.1 mL) was added to above solution, 
followed by a solution of iodide M-1.29 (74.2 mg, 0.1 mmol) in THF (0.5 mL). The mixture was 
stirred at -78 °C for another 3 h and allowed to warm to rt for overnight stirring. The reaction 
was quenched with saturated NH4Cl (5 mL). The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 × 10 mL). The combined organic layers were washed with H2O 
and brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/EtOAc = 95:5) to give the inseparable products M-
1.66 and 1.67 (24.7 mg, 30%). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 4H), 6.88 (d, J 
= 8.4 Hz, 4H), 5.79 (dtd, J = 15.0, 7.8, 0.9 Hz, 1H), 5.52 (dd, J = 15.3, 5.4 Hz, 1H), 5.08 (m, 2H), 
4.89 (d, J = 6.0 Hz, 1H), 4.43 (s, 4H), 3.80 (s, 6H), 3.43 (td, J = 6.0, 0.9 Hz, 4H), 2.25–2.04 (m, 
8H),  1.65–1.28 (m, 28H), 1.13–1.02 (m, 28H), 0.92 (s, 11H), 0.09 (s, 6H); MS (ESI) for M-
1.66-C3F7 m/z 913.3 (M+ + K); M-1.66-C4F9 m/z 963.4 (M+  + K); 1.63-C3F7 m/z 635.2 (M+ + K); 
1.67-C4F9 m/z 685.2 (M+  + K). 
 
SiC3F7
H
 
(4,4,5,5,6,6,6-Heptafluorohexyl)diisopropylsilane (1.69): 
 To a three-neck falsk equipped with adition funnel, thermometer, and Ar gas inlet, t-BuLi 
(14.7 mL, 1.7 M in hexane, 25.0 mmol) was added while cooling with -78 °C bath (a precipitate 
was observed). A solution of 1,1,1,2,2,3,3-heptafluoro-6-iodohexane (3.72 g, 11.0 mmol) in Et2O 
(25 mL) was added dropwise, keeping the internal temperature below -50 °C. The mixture was 
107
  
stirred for 45 min and allowed to warm to -25 °C (internal temperature) and maintained at this 
temperature until the solution became clear. After everything were into solution, the solution was 
cooled to -50 °C, chlorodiisopropylsilane (1.71 mL, 10.0 mmol) was added slowly. The mixture 
was stirred for overnight, during which time it was warmed to rt. The mixture was cooled to 0 °C, 
H2O (12.5 mL) was added quickly and the mixture was stirred for 30 min. The organic layer was 
separated and the aqueous layer was extracted with Et2O (3 × 30 mL). The combined organic 
layers were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The 
crude product was purified by column chromatography (hexane 100%) to afford the title 
compound 1.69 (2.94 g, 90%) as colorless oil. 1H NMR (300 MHz, CDCl3) 3.46 (s, 1H), 2.20–
2.02 (m, 2H), 1.78–1.66 (m, 2H), 0.72–0.66 (m, 2H). 
 
SiC4F9
H
 
Diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silane (1.70): 
 Following the same procedure for 1.69, 1,1,1,2,2,3,3,4,4-nonafluoro-7-iodoheptane (4.27 
g, 11.0 mmol) was reacted with chlorodiisopropylsilane (1.71 mL, 10.0 mmol), the title 
compound 1.70 (3.34 g, 89%) was obtained as colorless oil. 1H NMR (300 MHz, CDCl3) 3.46 (s, 
1H), 2.20–2.02 (m, 2H), 1.78–1.66 (m, 2H), 0.72–0.66 (m, 2H). 
 
O
OPMB
TBS
Si C4F9
 
(R,E)-tert-Butyl(3-(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy)-11-(4-methoxy 
benzyloxy)undec-4-en-1-ynyl)dimethylsilane (1.71R): 
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Trifluoromethanesulfonic acid (neat, 1.9 mL, 21.7 mmol) was slowly added to silane 1.70 
(neat, 8.67 g, 23.0 mmol) at 0 °C. After being stirred for 20 min at the same temperature, the 
mixture was warmed to room temperature and stirred for 15 h. To it CH2Cl2 (24 mL) was added 
at –60 °C, followed by a solution of alcohol 1.37R (6.00 g, 14.4 mmol) in CH2Cl2 (36 mL) and 
2,6-lutidine (3.3 mL, 28.7 mmol). The resulting mixture was warmed to room temperature and 
stirred for further 2 h. Saturated aqueous NH4Cl (75 mL) was then added to quench the reaction 
at 0 °C. The mixture was extracted with Et2O (3 × 150 mL), the organic layers were combined 
and washed with water, dried over MgSO4, and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/EtOAc = 19:1) to afford the title compound 1.71R 
(9.94 g, 87%). [α]D 25 = +1.1 (c = 1.20, CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.4 
Hz, 2 H), 6.88 (d, J = 8.4 Hz, 2 H), 5.79 (dtd, J = 15.0, 6.9, 0.9 Hz, 1 H), 5.51 (dd, J = 15.3, 5.7 
Hz, 1 H), 4.88 (d, J = 6.0 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 H), 3.43 (t, J = 6.6 Hz, 2 H), 2.19–
2.00 (m, 4 H), 1.76–1.69 (m, 2 H), 1.61–1.53 (m, 2 H), 1.43–1.28 (m, 6 H), 1.06 (br s, 14 H), 
0.93 (s, 9 H), 0.79–0.73 (m, 2 H), 0.09 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 159.1, 132.2, 
130.8, 129.6, 129.2, 113.8, 106.3, 88.0, 72.5, 70.2, 64.0, 55.3, 34.5 (t, JCF = 21.8 Hz, 1 C), 31.8, 
29.7, 29.0, 28.9, 26.0 (2 C), 17.6 (2 C), 17.5 (2 C) 16.5, 14.6, 12.7, 12.6, 11.0, -4.8; IR (film) 
3020, 2933, 1514, 1423, 1215, 1133, 1044, 928, 755 cm-1; HRMS (ESI) m/z (M+ + Na) calcd for 
C38H59O3NaSi2F9 813.3757, found 813.3793. 
 
OTIPS
OPMB
TBS  
(S,E)-tert-Butyl(11-(4-methoxybenzyloxy)-3-(triisopropylsilyloxy)undec-4-en-1-ynyl) 
dimethylsilane (1.71S): 
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2,6-Lutidine (3.5 mL, 30.1 mmol) and TIPSOTf (7.9 mL, 29.4 mmol) were sequentially 
added to the solution of alcohol 1.37S (6.90 g, 16.6 mmol) in CH2Cl2 (160 mL) at 0 °C. The 
resulting mixture was stirred for 2 h at the same temperature. Saturated aqueous NH4Cl (80 mL) 
was then added to quench the reaction. The mixture was extracted with Et2O (3 × 150 mL), the 
organic layers were combined and washed with water, dried over MgSO4, and concentrated in 
vacuo. The crude product was purified by column chromatography (hexane/EtOAc = 19:1) to 
afford the title compound 1.71S (8.53 g, 90%). [α]D 25 = -1.0 (c = 0.92, CHCl3), 1H NMR (300 
MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2 H), 6.88 (d, J = 8.7 Hz, 2 H), 5.80 (dtd, J = 15.3, 6.6, 0.9 
Hz, 1 H), 5.52 (dd, J = 15.0, 5.4 Hz, 1 H), 4.92 (dd, J = 5.1, 0.6 Hz, 1 H), 4.43 (s, 2 H), 3.80 (s, 3 
H), 3.43 (t, J = 6.6 Hz, 2 H), 2.04 (q, J = 6.6 Hz, 2 H), 1.61–1.54 (m, 2 H), 1.43–1.28 (m, 6 H), 
1.15–1.06 (m, 21 H), 0.92 (s, 9 H), 0.09 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 159.1, 131.7, 
130.8, 129.9, 129.2, 113.7, 106.8, 87.5, 72.5, 70.2, 63.9, 55.3, 31.8, 29.7, 28.9 (2 C), 26.1 (2 C), 
18.0, 16.5, 12.2, -4.7; IR (film) 3019, 2934, 2864, 1514, 1424, 1216, 1039, 928, 756 cm-1; 
HRMS (ESI) m/z (M+ + Na) calcd for C34H60O3NaSi2 595.3979, found 595.3959. 
 
O
OH
TBS
Si C4F9 OTIPS
OH
TBS  
(R,E)-11-(tert-Butyldimethylsilyl)-9-(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy) 
undec-7-en-10-yn-1-ol and (S,E)-11-(tert-butyldimethylsilyl)-9-(triisopropylsilyloxy) undec-
7-en-10-yn-1-ol: 
 DDQ (7.88 g, 34.7 mmol) was added to the mixture of compound 1.71R (7.89 g, 10.0 
mmol) and compound 1.71S (5.75 g, 10.0 mmol) in CH2Cl2 (250 mL) and H2O (13 mL) at room 
temperature. The reaction was monitored by TLC until completion, and then saturated NaHCO3 
110
  
aqueous solution was added. The mixture was extracted with CH2Cl2 (3 × 150 mL), the organic 
layers were combined, washed with saturated NaHCO3 aqueous solution, brine, dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by column chromatography 
(hexane/Et2O = 4:1) to afford the title mixture, which was contaminated with tiny 4-
(methoxymethyl)benzaldehyde and was used in the following step without further purification.  
 
O
I
TBS
Si C4F9 OTIPS
I
TBS  
(R,E)-tert-Butyl(3-(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy)-11-iodoundec-4-
en-1-ynyl)dimethylsilane and (S,E)-tert-butyl(11-iodo-3-(triisopropylsilyloxy)undec-4 -en-1-
ynyl)dimethylsilane (M-1.68): 
 To a solution of triphenylphosphine (5.44 g, 20.7 mmol) in CH2Cl2 (27 mL) was slowly 
added a solution of iodine (5.26 g, 20.7 mmol) in CH2Cl2 (27 mL), followed by a mixture of 
imidazole (1.55 g, 22.8 mmol) and above alcohol (5.74 g, 10.2 mmol) in CH2Cl2 (80 mL) at 
room temperature. After 2 h, the reaction was quenched with saturated aqueous NaHCO3 (100 
mL). The mixture was extracted with Et2O (3 × 100 mL) and organic layer was washed with 
saturated aqueous Na2S2O3 (100 mL), water, brine, dried over MgSO4, and concentrated in 
vacuuo. The crude product was purified by column chromatography (hexane/EtOAc = 99:1) to 
afford the title comound M-1.68 (5.62 g, 82%):  1H NMR (300 MHz, CDCl3) δ 5.83–5.74 (m, 1 
H), 5.52 (dd, J = 15.0, 5.1 Hz, 1 H), 4.94–4.88 (m, 1 H), 3.18 (t, J = 6.9 Hz, 2 H), 2.19–2.04 (m, 
4H), 1.88–1.70 (m, 4H), 1.47–1.27 (m, 8 H), 1.19–1.02 (m, 17.5 H), 1.06 (s, 9 H), 0.79–0.73 (m, 
2 H), 0.09 (s, 6 H); 13C NMR (75 MHz, CDCl3) δ 131.9, 131.4, 130.1, 129.8, 106.8, 106.2, 88.1, 
87.6, 64.0, 63.8, 34.5 (t, JCF = 21.8 Hz), 33.5, 31.6, 30.3, 28.7, 28.0, 26.0, 18.0, 17.6, 17.5, 16.5, 
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14.6, 12.7, 12.6, 12.2, 10.9, 7.1; IR (film) 2932, 2862, 1464, 1384, 1236, 1133, 1057, 908, 826, 
733; MS (EI) for M-1.68-C4F9 m/z 737 (M+ - C3H7); M-1.68-TIPS m/z 519 (M+ - C3H7); 
HRMS (ESI) M-1.68-C4F9 m/z (M+ - C3H7) calcd for C27H43OF9Si2I 737.1753, found 
737.1748; . M-1.68-TIPS m/z (M+ - C3H7) calcd for C23H44OSi2I 519.1976, found 519. 1993. 
 
TBS
OPMB
OTIPS
OTIPS  
(5S,E)-5-((tert-butyldimethylsilyl)ethynyl)-3,3,18,18-tetraisopropyl-16-(7-(4-methoxy 
benzyloxy)hept-1-ynyl)-2,19-dimethyl-4,17-dioxa-3,18-disilaicos-6-en-14-yne (1.72): 
 2,6-Lutidine (27.2 μL, 0.24 mmol) and TIPSOTf (62.9 μL, 0.24 mmol) were sequentially 
added to the solution of alcohol 1.65 (84.4 mg, 0.12 mmol) in CH2Cl2 (1.2 mL) at 0 °C. The 
resulting mixture was stirred for 2 h at the same temperature. Saturated aqueous NH4Cl (5 mL) 
was then added to quench the reaction. The mixture was extracted with Et2O (3 × 10 mL), the 
organic layers were combined and washed with water, dried over MgSO4, and concentrated in 
vacuo. The crude product was purified by column chromatography (hexane/EtOAc = 19:1) to 
afford the title compound 1.72 (95.6 mg, 93%). 1H NMR (500 MHz, CDCl3) 7.26 (d, J = 8.0 Hz, 
2H), 6.88 (d, J = 8.5 Hz, 2 H), 5.79 (dt, J = 15.0, 6.5 Hz, 1H), 5.53 (dd, J = 15.5, 5.5 Hz, 1H), 
5.22 (d, J = 2.0 Hz, 1H), 4.92 (d, J = 5.5 Hz, 1H), 4.42 (s, 2H), 3.82 (s, 3H), 3.42 (t, J = 6.5 Hz, 
2H), 2.21 (q, J = 7.5 Hz, 4H), 2.06 (q, J = 7.0 Hz, 2H), 1.63–1.21 (m, 14H), 1.20–1.10 (m, 42H), 
0.93 (s, 9H), 0.09 (s, 6H). 
 
TBS
OH
OTIPS
OTIPS  
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(19S,E)-21-(tert-Butyldimethylsilyl)-8,19-bis(triisopropylsilyloxy)henicosa-17-en-6,9,20-
triyn-1-ol (1.73): 
 Ceric ammonium nitrate (CAN, 16.5 mg, 0.03 mmol) was added to a solution of PMB 
ether 1.72 (8.6 mg, 0.01 mmol) in CH2Cl2 (0.4 mL) and pH 7 phosphate buffer (0.04 mL) at rt. 
The orange mixture was stirred at rt for 30 min, CH2Cl2 (5 mL) was added to dilute the mixture. 
The organic layer was washed with saturated NaHCO3 (10 mL). The aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over MgSO4 and 
concentracted under reduced pressure. The crude product was purified by column 
chromatography (hexane/Et2O = 7:3) to give the title compound 1.73 (2.1 mg, 28%) and strating 
material 1.72 (4.4 mg, 50%). 1H NMR (300 MHz, CDCl3) 5.80 (dt, J = 15.0, 6.9 Hz, 1H), 5.52 
(dd, J = 15.0, 4.5 Hz, 1H), 5.22 (m, 1H), 4.92 (d, J = 5.1 Hz, 1H) 3.64 (t, J = 6.0 Hz, 2H), 2.27–
2.21 (m, 4H), 2.05–2.03 (m, 2H), 1.63–1.21 (m, 14H), 1.20–1.10 (m, 42H), 0.93 (s, 9H), 0.09 (s, 
6H). 
 
OMTM  
((Hept-6-ynyloxy)methyl)(methyl)sulfane (1.75): 
 A mixture of Ac2O (71 mL) and AcOH (12.7 mL) was added to a solution of alcohol 1.22 
(3.70 g, 33.0 mmol) in DMSO (102 mL) at room temperature. The resulting mixture was stirred 
at same temperature for 24 h. The mixture was poured into cold saturated NaHCO3 aqueous 
solution. The mixture was extracted with CH2Cl2 (3 × 100 mL). The organic layer was washed 
with saturated NaHCO3 aqueous solution, water, brine, dried over MgSO4 concentrated in 
vacuuo. The curde product was used in next step without further purification. 
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OMTM
O
H
 
8-(Methylthiomethoxy)oct-2-ynal (1.76): 
 To a solution of alkyne 1.75 (4.98 g, 28.9 mmol) in THF (67 mL) was slowly added n-
BuLi (21.7 mL, 1.6 M solution in hexane, 34.7 mmol) at -40 °C. After completion of addition, 
DMF (4.5 mL, 57.9 mmol) was added. The mixture was then warmed to room temperature. After 
being stirred for 30 min at the same temperature, the resulting mixture was poured into a solution 
of 10% acquous solution KH2PO4 (145 mL) and methyl tert-butyl ether (MTBE) (135 mL) at 0 
°C. The organic layer was separated and the aqueous layer was extracted with MTBE (3 × 120 
mL). The combined organic layers was washed with water, dried over MgSO4, and concentrated 
in vacuo. The residue was purified by column chromatography (hexane/Et2O = 17:3) to afford 
the title compound 1.76 (4.11 g, 71%) as pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 9.17 (s, 
1H), 4.62 (s,2H), 3.53 (t, J = 6.0 Hz, 2H), 2.43 (t, J = 6.6 Hz, 2 H), 2.15 (s, 3H), 1.69–1.47 (m, 
6H); 13C NMR (75 MHz, CDCl3) δ 177.2, 99.9, 81.7, 75.2, 67.6, 28.8, 27.3, 25.5, 19.1, 13.9; IR 
(film) 3054, 2987, 1666, 1423, 1265, 1139, 1077, 896, 740 cm-1; MS (EI) m/z 185 (M+ - CH3); 
HRMS (EI) m/z (M+ - CH3) calcd for C9H13O2S 185.0636, found 185.0629. 
 
OMTM
OH
Si
Ph
 
1-(Dimethyl(phenyl)silyl)-10-(methylthiomethoxy)deca-1,4-diyn-3-ol (rac-1.77): 
 n-BuLi (18.5 mL, 1.6 M solution in hexane, 29.7 mmol) was added to a solution of 
(dimethylphenylsilyl)acetylene 1.45 (5.2 mL, 29.7 mmol) in the THF (125 mL) at –78 °C. After 
stirring at same temperature for 30 min, a solution of aldehyde 1.76 (3.96 g, 19.8 mmol) in THF 
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(30 mL) was added slowly. The resulting mixture was stirred for additional 45 min at –78 °C, 
then allowed to warm to toom temperature. The mixture was poured into pH 7 phosphate buffer 
(100 mL) and extracted with Et2O (3× 100 mL). The organic layer was washed with brine, dried 
over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
(hexane/Et2O = 4:1) to afford the title compound rac-1.77 (6.25 g, 97%) as pale yellow oil. 1H 
NMR (300 MHz, CDCl3) δ 7.64–7.61 (m, 2H), 7.39–7.35 (m, 3H), 5.13 (dt, J = 7.5, 1.8 Hz, 
1H), 4.62 (s, 2H), 3.52 (t, J = 6.3 Hz, 2H), 2.25 (td, J = 6.9, 2.1 Hz, 2H), 2.23 (d, J = 7.5 Hz, 1H), 
2.14 (s, 3H), 1.66–1.43 (m, 6H), 0.44 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 136.3, 133.7, 129.5, 
127.9, 104.2, 86.9, 85.6, 77.2, 75.2, 67.9, 52.8, 28.8, 28.0, 25.5, 18.7, 14.0, -1.1; IR (film) 3585, 
3399, 3070, 2942, 2864, 1644, 1429, 1300, 1253, 1113, 1077, 1033, 909, 820, 733; HRMS (ESI) 
m/z (M+ + K) calcd for C20H28O2SiSK 399.1216, found 399.1215. 
 
OMTM
OH
Si
Ph
R
 
(R)-1-(Dimethyl(phenyl)silyl)-10-(methylthiomethoxy)deca-1,4-diyn-3-ol (1.77R): 
OMTM
OH
Si
Ph
S
 
(S)-1-(Dimethyl(phenyl)silyl)-10-(methylthiomethoxy)deca-1,4-diyn-3-ol (1.77S): 
 The racemic alcohol rac-1.77 (6.25 g, 17.3 mmol) was separated by chiral HPLC 
(Chiralcel OD semi-preparative column, hexane/iPrOH = 93:7, 10.0 mL/min) to afford two 
optical pure compounds 1.77R (3.04 g, 49%) and 1.77S (2.99 g, 48%) as pale yellow oils. 
1.77R: [α]D 25 = +5.0 (c = 1.03, CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.64–7.61 (m, 2H), 7.39–
7.35 (m, 3H), 5.13 (dt, J = 7.5, 2.1 Hz, 1H), 4.62 (s, 2H), 3.52 (t, J = 6.3 Hz, 2H), 2.25 (td, J = 
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6.9, 2.1 Hz, 2H), 2.22 (d, J = 7.5 Hz, 1H), 2.14 (s, 3H), 1.66–1.43 (m, 6H), 0.44 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 136.3, 133.7, 129.5, 127.9, 104.3, 86.8, 85.5, 77.2, 75.2, 67.9, 52.8, 
28.8, 28.0, 25.4, 18.7, 13.9, -1.1; IR (film) 3420, 3019, 2942, 2865, 1640, 1429, 1300, 1216, 
1113, 1076, 1031, 956, 756; HRMS (ESI) m/z (M+ + Na) calcd for C20H28O2NaSiS 383.1477, 
found 383.1461. 
1.77S: [α]D 25 = -4.5 (c = 0.99, CHCl3), 1H NMR (300 MHz, CDCl3) δ 7.64–7.61 (m, 2H), 7.39–
7.35 (m, 3H), 5.13 (dt, J = 7.2, 2.1 Hz, 1H), 4.62 (s, 2H), 3.52 (t, J = 6.3 Hz, 2H), 2.25 (td, J = 
6.6, 1.8 Hz, 2H), 2.24 (d, J = 7.5 Hz, 1H), 2.14 (s, 3H), 1.66–1.43 (m, 6H), 0.44 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 136.3, 133.7, 129.5, 127.9, 104.3, 86.8, 85.5, 77.2, 75.2, 67.9, 52.7, 
28.8, 27.9, 25.4, 18.6, 13.9, -1.1; IR (film) 3440, 3019, 2973, 1637, 1427, 1382, 1216, 1159, 
1076, 946, 755; HRMS (ESI) m/z (M+ + Na) calcd for C20H28O2NaSiS 383.1477, found 
383.1460. 
 
OMTM
OH
S
 
(S)-10-(Methylthiomethoxy)deca-1,4-diyn-3-ol (1.74S): 
TBAF (12.5 mL, 1.0 M solution in THF, 12.5 mmol) was added to a solution of alcohol 
1.77R (3.00 g, 8.3 mmol) in THF (80 mL) at room temperature. The mixture then was stirred for 
1 h at this temperature and quenched with saturated aqueous NH4Cl. The resulting mixture was 
extracted with CH2Cl2 (3 × 50 mL). The organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified by column 
chromatography (hexane/Et2O = 4:1) to give compound 1.74S (1.47 g, 78%) as pale yellow oil. 
[α]D 25 = +5.0 (c = 1.20, CHCl3), 1H NMR (300 MHz, CDCl3) δ 5.10 (dq, J = 7.5, 2.1 Hz, 1H), 
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4.62 (s, 2H), 3.53 (t, J = 6.0 Hz, 2H), 2.54 (d, J = 2.4 Hz, 1H), 2.25 (td, J = 6.9, 2.1 Hz, 2H), 
2.22 (d, J = 7.2 Hz, 1H), 2.15 (s, 3H), 1.66–1.43 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 85.7, 
81.5, 77.3, 75.2, 72.1, 67.9, 52.1, 28.8, 27.9, 25.4, 18.6, 13.9; IR (film) 3422, 3020, 1647, 1429, 
1216, 1015, 929, 757; MS (EI) m/z 249 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for 
C12H18O2NaS 249.0925, found 249.0945. 
 
OMTM
OH
R
 
(R)-10-(Methylthiomethoxy)deca-1,4-diyn-3-ol (1.74R): 
 Following the same procedure for 1.74S, alcohol 1.77R (2.99 g, 8.3 mmol) was reacted 
with TBAF (12.5 mL, 1.0 M solution in THF, 12.5 mmol), the title compound 1.74R (1.78 g, 
95%) was obtained as pale yellow oil. [α]D 25 = -4.4 (c = 1.37, CHCl3), 1H NMR (300 MHz, 
CDCl3) δ 5.10 (dq, J = 7.5, 2.1 Hz, 1H), 4.63 (s, 2 H), 3.53 (t, J = 6.3 Hz, 2H), 2.54 (d, J = 2.1 
Hz, 1H), 2.25 (td, J = 6.6, 1.8 Hz, 2H), 2.24 (d, J = 7.5 Hz, 1H), 2.15 (s, 3H), 1.66–1.42 (m, 6H); 
13C NMR (75 MHz, CDCl3) δ 85.3, 81.5, 77.3, 75.0, 71.9, 67.8, 51.8, 28.6, 27.8, 25.3, 18.5, 13.8; 
IR (film) 3420, 3307, 3020, 2943, 1641, 1430, 1216, 1076, 1015, 928, 755; MS (EI) m/z 249 (M+ 
+ Na); HRMS (ESI) m/z (M+ + Na) calcd for C12H18O2NaS 249.0925, found 249.0950. 
 
O
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Si C4F9
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R
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(12R,23R,E)-23-((tert-Butyldimethylsilyl)ethynyl)-29,29,30,30,31,31,32,32,32-nonafluoro-
25,25-diisopropyl-4,24-dioxa-2-thia-25-siladotriaconta-21-en-10,13-diyn-12-ol and (12R,23 
S,E)-23-((tert-butyldimethylsilyl)ethynyl)-25,25-diisopropyl-26-methyl-4,24-dioxa-2-thia-
25-silaheptacosa-21-en-10,13-diyn-12-ol (M-1.78R): 
 n-BuLi (4.0 mL, 1.6 M solution in THF, 6.4 mmol) was slowly added to the solution of 
alkyne 1.74R (679.0 mg, 3.0 mmol) in THF (15 mL) at -30 °C. After stirring at the same 
temperature for 1 h, the mixture was cooled to -78 °C, HMPA (1.5 mL) was added followed by a 
solution of iodide M-1.68 (1.01 g, 1.5 mmol) in THF (7.5 mL). The resulting mixture was stirred 
for 2 h at -78 °C and warmed to room temperature. After stirring at room temperature for 
overnight, saturated NH4Cl aqueous solution (20 mL) was added, the organic layer was separated 
and the aqueous layer was extracted with Et2O (3 × 20 mL). The combined organic layers were 
washed with water, brine, dried over MgSO4, and concentrated in vacuo. The crude product was 
purified by column chromatography (hexane/Et2O = 4:1) to afford the mixture M-1.78R (370.7 
mg, 34%), which was contaminated with some inseparable impurities and was used in the 
following step without further purification. 1H NMR (500 MHz, CDCl3) δ 5.80–5.76 (m, 1H), 
5.55–5.49 (m, 1H), 5.10–5.08 (m, 1H), 4.93–4.88 (m, 1H), 4.63 (s, 2H), 3.52 (t, J = 6.5 Hz, 2H), 
2.23 (quind, J = 7.0, 1.5 Hz, 4H), 2.15 (s, 3H), 2.12–2.06 (m, 1H), 2.05 (q, J = 6.5 Hz, 2H), 
1.78–1.69 (m, 1H), 1.64–1.45 (m, 8H), 1.40–1.25 (m, 6H), 1.10–1.05 (m, 17.5H), 0.93 (s, 9H), 
0.78–0.74 (m, 1H), 0.09 (s, 6H); HRMS (ESI) M-1.78R-C4F9 m/z (M+ + Na) calcd for 
C42H67O3F9NaSi2S 901.4103, found 901.4134; M-1.78R-TIPS m/z (M+ + Na) calcd for 
C38H68O3NaSi2S 683.4325, found 683.4340. 
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(12S,23R,E)-23-((tert-Butyldimethylsilyl)ethynyl)-29,29,30,30,31,31,32,32,32-nonafluoro-
25,25-diisopropyl-4,24-dioxa-2-thia-25-siladotriaconta-21-en-10,13-diyn-12-ol and (12S,23 
S,E)-23-((tert-butyldimethylsilyl)ethynyl)-25,25-diisopropyl-26-methyl-4,24-dioxa-2-thia-
25-silaheptacosa-21-en-10,13-diyn-12-ol (M-1.78S): 
Following the same procedure for M-1.78R, alkyne 1.74S (679.0 mg, 3.0 mmol) was 
reacted with n-BuLi (4.0 mL, 1.6 M solution in THF, 6.4 mmol), HMPA (1.5 mL), and iodide 
M-1.68 (1.01 g, 1.5 mmol), the title mixture M-1.78S (356.2 mg, 33%) was obtained, which was 
contaminated with some inseparable impurities and was used in the following step without 
further purification. 1H NMR (600 MHz, CDCl3) δ 5.82–5.77 (m, 1H), 5.55–5.49 (m, 1H), 5.10–
5.08 (m, 1H), 4.92–4.88 (m, 1H), 4.63 (s, 2H), 3.52 (t, J = 6.6 Hz, 2H), 2.23–2.20 (m, 4H), 2.15 
(s, 3H), 2.14–2.09 (m, 1H), 2.05 (q, J = 6.6 Hz, 2H), 1.76–1.70 (m, 1H), 1.63–1.43 (m, 8H), 
1.40–1.25 (m, 6H), 1.11–1.03 (m, 17.5H), 0.92 (s, 9H), 0.77–0.74 (m, 1H), 0.09 (s, 6H); HRMS 
(ESI) M-1.78S-C4F9 m/z (M+ + Na) calcd for C42H67O3F9NaSi2S 901.4103, found 901.4072; M-
1.78S-TIPS m/z (M+ + Na) calcd for C38H68O3NaSi2S 683.4325, found 683.4296. 
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(12R,23R,E)-23-((tert-butyldimethylsilyl)ethynyl)-12-(diisopropyl(4,4,5,5,6,6,7,7,7-nona 
fluoroheptyl)silyloxy)-29,29,30,30,31,31,32,32,32-nonafluoro-25,25-diisopropyl-4,24-dioxa-2 
-thia-25-siladotriaconta-21-en-10,13-diyne and (12R,23S,E)-23-((tert-butyldimethylsilyl) eth 
ynyl)-12-(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy)-25,25-diisopropyl-26-
methyl-4,24-dioxa-2-thia-25-silaheptacosa-21-en-10,13-diyne (M-1.79R): 
 Trifluoromethanesulfonic acid (neat, 72.4 μL, 0.82 mmol) was slowly added to silane 
1.70 (neat, 359.0 mg, 0.95 mmol) at 0 °C. After being stirred for 20 min at the same temperature, 
the mixture was warmed to room temperature and stirred for 15 h. To it CH2Cl2 (0.8 mL) was 
added at –60 °C, followed by a solution of alcohol M-1.78R (200.0 mg, 0.27 mmol) in CH2Cl2 
(1.2 mL) and 2,6-lutidine (0.13 mL, 1.09 mmol). The resulting mixture was warmed to room 
temperature and stirred for further 2 h. Saturated aqueous NH4Cl (10 mL) was then added to 
quench the reaction at 0 °C. The mixture was extracted with Et2O (3 × 10 mL), the organic layers 
were combined and washed with water, dried over MgSO4, and concentrated in vacuo. The crude 
product was purified by column chromatography (hexane/Et2O = 97:3) to afford the title mixture 
M-1.79R (272.5 g, 99%). 1H NMR (600 MHz, CDCl3) δ 5.81–5.77 (m, 1H), 5.54–5.49 (m, 1H), 
5.21 (s, 1H), 4.92–4.87 (m, 1H), 4.62 (s, 2H), 3.50 (t, J = 6.6 Hz, 2H), 2.23–2.18 (m, 4H), 2.14 (s, 
3H), 2.12–2.03 (m, 5H), 1.80–1.73 (m, 3H), 1.62–1.41 (m, 8H), 1.40–1.33 (m, 4H), 1.31–1.25 
(m, 2H), 1.12–1.05 (m, 31.5H), 0.92 (s, 9H), 0.79–0.75 (m, 3H), 0.09 (s, 6H); MS (EI) M-1.79R-
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C4F9, C4F9 m/z 1275 (M+ + Na); M-1.79R-TIPS, C4F9 m/z 1057 (M+ + Na); HRMS (ESI) M-
1.79R-C4F9, C4F9 m/z (M+ + Na) calcd for C55H86O3F18NaSi3S 1275.5216, found 1275.5110; M-
1.79R-TIPS, C4F9 m/z (M+ + Na) calcd for C51H87O3F9NaSi3S 1057.5438, found 1057.5507. 
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(12S,23R,E)-23-((tert-Butyldimethylsilyl)ethynyl)-29,29,30,30,31,31,32,32,32-nonafluoro-12-
((4,4,5,5,6,6,6-heptafluorohexyl)diisopropylsilyloxy)-25,25-diisopropyl-4,24-dioxa-2-thia-
25-siladotriaconta-21-en-10,13-diyne and (12S,23S,E)-23-((tert-butyldimethylsilyl)ethynyl)-
12-((4,4,5,5,6,6,6-heptafluorohexyl)diisopropylsilyloxy)-25,25-diisopropyl-26-methyl-4,24-
dioxa-2-thia-25-silaheptacosa-21-en-10,13-diyne (M-1.79S): 
Following the same procedure for M-1.79R, the mixture M-1.78S (250.0 mg, 0.34 mmol) 
was reacted with Trifluoromethanesulfonic acid (neat, 79.6 μL, 0.90 mmol), silane 1.69 (neat, 
333.6 mg, 1.02 mmol), and 2,6–lutidine (0.14 mL, 1.19 mmol), the title mixture M-1.79S (277.7 
mg, 85%) was obtained. 1H NMR (600 MHz, CDCl3) δ 5.80–5.77 (m, 1 H), 5.54–5.50 (m, 1 H), 
5.21 (s, 1 H), 4.92–4.87 (m, 1 H), 4.62 (s, 2 H), 3.50 (t, J = 6.6 Hz, 2 H), 2.23–2.18 (m, 4 H), 
2.14 (s, 3 H), 2.12–2.03 (m, 5 H), 1.80–1.73 (m, 3 H), 1.62–1.43 (m, 8 H), 1.40–1.33 (m, 4 H), 
1.31–1.25 (m, 2 H), 1.12–1.05 (m, 31.5 H), 0.92 (s, 9 H), 0.79–0.75 (m, 3 H), 0.09 (s, 6 H); MS 
(EI) M-1.79S-C4F9, C3F7 m/z 1225 (M+ + Na); M-1.79S-TIPS, C3F7 m/z 1008 (M+ + Na + H); 
HRMS (ESI) M-1.79S-C4F9, C3F7 m/z (M+ + Na) calcd for C54H86O3F16NaSi3S 1225.5248, 
121
  
found 1225.5331; M-1.79S-TIPS, C3F7 m/z (M+ + Na) calcd for C50H87O3F7NaSi3S 1007.5470, 
found 1007.5438. 
 
OTIPSF9
TBS
OTIPSF9
OH
OTIPSF0
TBS
OTIPSF9
OH
OTIPSF9
TBS
OTIPSF7
OH
OTIPSF0
TBS
OTIPSF7
OH
 
(8R,19R,E)-21-(tert-Butyldimethylsilyl)-8,19-bis(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoro 
heptyl)silyloxy)henicosa-17-en-6,9,20-triyn-1-ol, (8R,19S,E)-21-(tert-butyl dimethylsilyl)-8-
(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy)-19-(triisopropyl silyloxy)henicosa-
17-en-6,9,20-triyn-1-ol, (8S,19R,E)-21-(tert-butyldimethylsilyl)-19-(diisopropyl(4,4,5,5,6,6, 
7,7,7-nonafluoroheptyl)silyloxy)-8-((4,4,5,5,6,6,6-heptafluorohexyl)diisopropylsilyloxy) 
henicosa-17-en-6,9,20-triyn-1-ol, and (8S,19S,E)-21-(tert-butyldimethyl silyl)-8-((4,4,5,5, 
6,6,6-heptafluorohexyl)diisopropylsilyloxy)-19-(triisopropylsilyloxy) henicosa-17-en-6,9,20-
triyn-1-ol (M-1.80): 
Solid NaHCO3 (324.4 mg, 3.86 mmol) and MeI (9.0 mL) were added to the solution of 
mixture M-1.79R (270.0 mg, 0.27 mmol) and M-1.79S (259.4 mg, 0.27 mmol) in mixture of 
acetone (16.0 mL) and water (0.86 mL). The resulting suspension was stirred in a sealed tube at 
45 °C for 14 h. The mixture was diluted with water (20 mL) and EtOAc (30 mL). The organic 
layer was separated and the aqueous phase was extracted with EtOAC (3 × 20 mL). The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated in vacuo. 
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The crude product was purified by column chromatography (hexane/Et2O = 3:1) to afford the 
mixture M-1.80 (451.0 mg, 90%). 1H NMR (600 MHz, CDCl3) δ 5.82–5.76 (m, 1H), 5.54–5.49 
(m, 1H), 5.20 (s, 1H), 4.92–4.87 (m, 1H), 3.64 (t, J = 6.6 Hz, 2H), 2.24–2.18 (m, 4H), 2.14–2.03 
(m, 5H), 1.78–1.73 (m, 3H), 1.62–1.43 (m, 8H), 1.40–1.24 (m, 6H), 1.13–1.05 (m, 31.5H), 0.92 
(s, 9H), 0.79–0.75 (m, 3H), 0.09 (s, 6H); MS (EI) M-1.80-C4F9, C4F9 m/z 1215 (M+ + Na); M-
1.80-TIPS, C4F9 m/z 998 (M+ + Na + H); M-1.80-C4F9, C3F7 m/z 1165 (M+ + Na); M-1.80-
TIPS, C3F7 m/z 948 (M+ + Na + H) HRMS (ESI) M-1.80-C4F9, C4F9 m/z (M+ + Na) calcd for 
C53H82O3F18NaSi3 1215.5182, found 1215.5067; M-1.80-TIPS, C4F9 m/z (M+ + Na) calcd for 
C49H83O3F9NaSi3 997.5404, found 997.5370; M-1.80-C4F9, C3F7 m/z (M+ + Na) calcd for 
C52H82O3F16NaSi3 1165.5214, found 1165.5240; M-1.80-TIPS, C3F7 m/z (M+ + Na) calcd for 
C48H83O3F7NaSi3 947.5436, found 947.5422. 
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(8R,19R,E)-21-(tert-Butyldimethylsilyl)-8,19-bis(diisopropyl(4,4,5,5,6,6,7,7,7-nonafluoro 
heptyl)silyloxy)henicosa-17-en-6,9,20-triynal, (8R,19S,E)-21-(tert-butyldimethylsilyl)-8-(di 
isopropyl(4,4,5,5,6,6,7,7,7-nonafluoroheptyl)silyloxy)-19-(triisopropylsilyloxy)henicosa-17-
en-6,9,20-triynal, (8S,19R,E)-21-(tert-butyldimethylsilyl)-19-(diisopropyl(4,4,5,5,6,6,7,7,7-
nonafluoroheptyl)silyloxy)-8-((4,4,5,5,6,6,6-heptafluorohexyl)diisopropylsilyloxy)henicosa-
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17-en-6,9,20-triynal, and (8S,19S,E)-21-(tert-butyldimethylsilyl)-8-((4,4,5,5,6,6,6-hepta 
fluorohexyl)diisopropylsilyloxy)-19-(triisopropylsilyloxy)henicosa-17-en-6,9,20-triynal (M-
1.2): 
NaHCO3 (196.2 mg, 2.34 mmol) was added followed by DMP (371.5 mg, 0.88 mmol) to 
the solution of mixture M-1.80 (270.0 mg, 0.29 mmol) in CH2Cl2 (4.5 mL) at room temperature. 
The resulting mixture was stirred at the same temperature for 2 h. Saturated NH4Cl aqueous 
solution (15 mL) was added. The organic phase was separated and the aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed with brine, dried 
over MgSO4, and concentrated in vacuo. The crude product was purified by column 
chromatography (hexane/Et2O = 9:1) to afford the mixture M-1.2 (200.3 mg, 74%). 1H NMR 
(600 MHz, CDCl3) δ 9.76 (s, 1H), 5.82–5.76 (m, 1H), 5.54–5.49 (m, 1H), 5.20 (s, 1H), 4.92–4.87 
(m, 1H), 2.44 (t, J = 7.2 Hz, 2H), 2.24 (t, J = 6.6 Hz, 2H), 2.19 (t, J = 7.2 Hz, 2H), 2.14–2.02 (m, 
5H), 1.79–1.70 (m, 5H), 1.57–1.46 (m, 6H), 1.38–1.33 (m, 4H), 1.31–1.25 (m, 2H), 1.13–1.05 
(m, 31.5H), 0.92 (s, 9H), 0.79–0.75 (m, 3H), 0.09 (s, 6H); HRMS (ESI) M-1.2-C4F9, C4F9 m/z 
(M+ + Na) calcd for C53H80O3F18NaSi3 1213.5026, found 1213.5062; M-1.2-TIPS, C4F9 m/z (M+ 
+ Na) calcd for C49H81O3F9NaSi3 995.5248, found 995.5237; M-1.2-C4F9, C3F7 m/z (M+ + Na) 
calcd for C52H80O3F16NaSi3 1163.5058, found 1163.5133; M-1.2-TIPS, C3F7 m/z (M+ + Na) 
calcd for C48H81O3F7NaSi3 945.5279, found 945.5218. 
 
PMBO
OH  
6-(4-Methoxybenzyloxy)hexan-1-ol (1.82):47 
1,6-Hexanediol 1.81 (14.19 g, 120 mmol) was added dropwise to a suspension of NaH 
(4.80 g, 60 wt% in mineral oil, 120 mmol) in THF (400 mL) at 0 °C. PMBCl (16.4 mL, 120 
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mmol) was then added dropwise followed by addition of TBAI (4.88 g, 13.2 mmol). After 
stirring at room temperature for 1 h, the reaction mixture was heated to 60 °C for 15 h. After 
being cooled to room temperature, the resulting mixture was poured into a solution of saturated 
NaHCO3 and vigorously stirred. The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 × 150 mL). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography (hexane/EtOAc = 3:2) 
to afford the title compound 1.82 (15.45 g, 54%). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.6 
Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.43 (s, 2H), 3.80 (s, 3H), 3.63 (q, J = 5.5 Hz, 2H), 3.44 (t, J = 
6.5 Hz, 2H), 1.64–1.52 (m, 4 H), 1.39–1.36 (m, 4H), 1.23 (t, J = 5.4 Hz, 1H); 13C NMR (75 MHz, 
CDCl3) δ 158.9, 130.4, 129.0, 113.5, 72.3, 69.8, 62.3, 55.0, 32.4, 29.5, 25.8, 25.4; IR (film) 3425, 
2937, 2861, 1613, 1513, 1464, 1302, 1248, 1174, 1090, 1036, 907, 731, 650; MS (EI) m/z 238 
(M+); HRMS (ESI) m/z (M+) calcd for C14H22O3 238.1569, found 238.1575. 
 
PMBO
Br  
1-((6-Bromohexyloxy)methyl)-4-methoxybenzene (1.83):47 
A solution of triphenylphosphine (18.5 g, 70.7 mmol) was added to a solution of alcohol 
1.82 (11.23 g, 47.1 mmol) and CBr4 (18.8 g, 56.5 mmol) in CH2Cl2 (175 mL) at 0 °C. After 
stirring at room temperature for 1 h, the organic solvent was removed under reduced pressure. 
The residue was purified by column chromatography (hexane/EtOAc = 19:1) to afford the title 
compound 1.83 (12.65 g, 89%). 1H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 2H), 6.88 (d, 
J = 8.7 Hz, 2H), 4.43 (s, 2H), 3.80 (s, 3H), 3.44 (t, J = 6.5 Hz, 2H), 3.40 (t, J = 6.8 Hz, 2H), 1.86 
(quin, J = 6.8 Hz, 2H), 1.66–1.57 (m, 2H), 1.50–1.37 (m, 4 H); 13C NMR (75 MHz, CDCl3) δ 
159.1, 130.7, 129.2, 113.8, 72.5, 69.9, 55.3, 33.8, 32.7, 29.6, 28.0, 25.4; IR (film) 3015, 2938, 
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2860, 1612, 1513, 1463, 1302, 1248, 1216, 1174, 1094, 1036, 756; MS (EI) m/z 300 (M+); 
HRMS (ESI) m/z (M+) calcd for C14H21O2Br 300.0725, found 300.0718. 
 
PMBO
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(6-(4-Methoxybenzyloxy)hexyl)triphenylphosphonium bromide (1.12):47 
 A mixture of bromide 1.83 (12.62 g, 41.9 mmol) and triphenylphosphine (22.03 g, 84.0 
mmol) in CH3CN (310 mL) was stirred at 90 °C for 2 days. The organic solvent was removed 
under reduced pressure, the residue was purified by column chromatography (CHCl3/MeOH = 
19:1) to afford the title compound 1.12 with tiny triphenylphosphine (21.23 g, 90%). 1H NMR 
(300 MHz, CDCl3) δ 7.81–7.73 (m, 9H), 7.68–7.59 (m, 6H), 7.17 (d, J = 8.7 Hz, 2H), 6.78 (d, J 
= 8.7 Hz, 2H), 4.33 (s, 2H), 3.73 (s, 3H), 3.68 (m, 2H), 3.34 (t, J = 6.3 Hz, 2H), 1.60 (br s, 4H), 
1.52–1.43 (m, 2H), 1.33–1.29 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 158.3, 134.4 (d, JCP = 2.2 
Hz, 1C), 132.8 (d, JCP = 9.8 Hz, 1C), 129.8 (d, JCP = 12.8 Hz, 1C), 128.5, 127.6, 117.4 (d, JCP = 
85.5 Hz, 1C), 113.0, 71.7, 69.1, 54.6, 29.4 (d, JCP = 15.8 Hz, 1C), 28.5, 25.0, 22.0 (d, JCP = 49.5 
Hz, 1C), 21.8 (d, JCP = 3.8 Hz, 1C); IR (film) 3010, 2937, 2863, 2193, 1702, 1610, 1513, 1462, 
1439, 1302, 1250, 1170, 1113, 1033, 910, 732; MS (EI) m/z 483 (M+ - Br); HRMS (ESI) m/z 
(M+) calcd for C32H36O2P 483.2453, found 483.2418. 
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Methyl 16-hydroxyhexadecanoate (1.84):48 
 16-Hydroxyhexadecanic acid 1.15 (5.60 g, 20.6 mmol) and p-toluenesulfonic acid 
monohydrate (1.25 g, 6.6 mmol) were dried under vacuum for 2 h. MeOH (300 mL) was added 
and the mixture was stirred at room temperature for 16 h. Solid NaHCO3 (1.25 g) was added and 
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the resulting mixture was stirred for further 30 min, then filtered through a pad of Celite. The 
organic solvent was removed under reduced pressure. The crude product was purified by column 
chromatography (hexane/EtOAc = 3:1) to afford the title compound 1.84 (5.89 g, 100%) as 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 3.66 (s, 3H), 3.64 (q, J = 6.5 Hz, 2H), 2.30 (t, J = 
7.5 Hz, 2H), 1.64–1.54 (m, 4H), 1.25 (br s, 22H); 13C NMR (125 MHz, CDCl3) δ 174.3, 62.6, 
51.3, 39.9, 32.6, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 25.6, 24.8; IR (film) 3435, 2927, 2855, 1731, 
1465, 1438, 1202, 1175, 1054, 908, 735, 650; MS (EI) m/z 287 (M+); HRMS (ESI) m/z (M+) 
calcd for C17H35O3 287.2586, found 287.2594. 
 
12
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Methyl 16-oxohexadecanoate (1.85):49 
 To a solution of oxalyl chloride (3.50 mL, 40.8 mmol) in CH2Cl2 (145 mL) was slowly 
added a solution of DMSO (4.35 mL, 61.2 mmol) in CH2Cl2 (30 mL) at –78 °C. After 15 min at 
the same temperature, a solution of alcohol 1.84 (5.85 g, 20.4 mmol) in CH2Cl2 (30 mL) was 
then added dropwise. The resulting mixture was stirred for 15 min and Et3N (14.2 mL, 102.0 
mmol) was added slowly. The reaction was maintained at –78 °C for 15 min, then allowed to 
warm to 0 °C, the stirring continued for further 30 min. Water was added and the mixture was 
diluted with Et2O. The organic layer was separated and washed with brine. The combined 
aqueous layers were extracted with Et2O (3 × 90 mL). The combined organic layers were dried 
over MgSO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (hexane/EtOAc = 9:1) to afford the title compound 1.85 (5.70 g, 98%). 1H NMR 
(500 MHz, CDCl3) δ 9.76 (t, J = 2.0 Hz, 1H), 3.66 (s, 3H), 2.41 (td, J = 7.5, 2.0 Hz, 2H), 2.30 (t, 
J = 7.5 Hz, 2H), 1.69–1.58 (m, 4H), 1.25 (br s, 20H); 13C NMR (125 MHz, CDCl3) δ 202.7, 
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174.2, 51.3, 43.8, 34.0, 32.6, 29.5, 29.4, 29.3, 29.3, 29.2, 29.1, 29.0, 29.0, 24.8, 22.0; IR (film) 
2928, 2855, 1725, 1644, 1465, 1438, 1201, 1175, 908, 735, 650; MS (EI) m/z 285 (M+ + H); 
HRMS (ESI) m/z (M+) calcd for C17H32O3 284.2351, found 284.2338. 
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MeO
O
Br
Br  
Methyl 17, 17-dibromoheptadec-16-enoate (1.86): 
 To a solution of triphenylphosphine (23.6 g, 90 mmol) in CH2Cl2 (60 mL) at 0 °C was 
slowly added a solution of CBr4 (13.9 g, 42 mmol) in CH2Cl2 (12 mL) at a rate to maintain the 
temperature below 15 °C. Then a solution of aldehyde 1.85 (5.7 g, 20 mmol) and Et3N (8.4 mL, 
60 mmol) in CH2Cl2 (12 mL) was added dropwise at 0 °C. After stirring for 35 min at the same 
temperature, the mixture was poured into hexane (120 mL) and filtered through a pad of Celite. 
The solid was washed with hexane (2 × 50 mL) and the filtrate was concentrated under reduced 
pressure. Hexane (40 mL) was added and the mixture was filtered again. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
chromatography (hexane/EtOAc = 49:1) to afford the title compound 1.86 (8.10 g, 92%): 1H 
NMR (300 MHz, CDCl3) δ 6.38 (t, J = 7.2 Hz, 1 H), 3.66 (s, 3H), 2.30 (t, J = 7.5 Hz, 2H), 2.08 
(q, J = 7.2 Hz, 2H), 1.66–1.56 (m, 2H), 1.46–1.35 (m, 2H), 1.25 (br. s, 20H); 13C NMR (75 MHz, 
CDCl3) δ 174.2, 138.8, 88.4, 51.3, 34.0, 33.0, 29.5, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 27.7, 24.9; 
IR (film) 2925, 2853, 1741, 1462, 1436, 1361, 1249, 1197, 1170, 1112, 1016, 911, 799; MS (EI) 
m/z 439 (M+ + H); HRMS (ESI) m/z (M+) calcd for C18H32O2Br2 438.0769, found 438.0782. 
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(Z)-Methyl 17-bromoheptadec-16-enoate (1.14): 
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 A mixture of triphenylphosphine (2.42 g, 9.2 mmol) and Pd(OAc)2 (0.42 g, 1.9 mmol) in 
CH2Cl2 (95 mL) was stirred for 15 min at room temperature to generate a light yellow solution. 
Dibromide 1.86 (8.10 g, 18.4 mmol) and tributyltin hydride (12.9 mL, 47.8 mmol) were 
sequentially added and the mixture was stirred for 45 min at room temperature. After the reaction 
was completed, the mixture was diluted with Et2O and washed with water (3 × 75 mL), brine (3 
× 75 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (hexane/Et2O = 49:1) to afford the title 
compound 1.14 (6.66 g, 100%). 1H NMR (300 MHz, CDCl3) δ 6.15–6.04 (m, 2H), 3.65 (s, 3H), 
2.29 (t, J = 7.5 Hz, 2H), 2.18 (q, J = 6.9 Hz, 2H), 1.66–1.56 (m, 2H), 1.44–1.33 (m, 2H), 1.25 (br. 
s, 20H); 13C NMR (75 MHz, CDCl3) δ 174.2, 134.9, 107.5, 51.3, 34.0, 29.6, 29.6, 29.5, 29.4, 
29.3, 29.2, 29.1, 28.1, 24.9; IR (film) 2928, 2855, 1731, 1463, 1439, 1201, 1174, 908, 734; MS 
(EI) m/z 329 (M+ - CH3O); HRMS (ESI) m/z (M+ - CH3O) calcd for C17H30OBr 329.1480, found 
329.1480. 
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(Z)-Methyl 19-(tert-butyldimethylsilyl)nonadec-16-en-18-ynoate (1.87): 
 tert-Butyldimethylsilylacetylene 1.35 (8.4 mL, 45 mmol) was added to a solution of vinyl 
bormide 1.14 (6.60 g, 18.3 mmol), PdCl2(PPh3)2 (1.52 g, 2.2 mmol), and CuI (0.34 g, 1.8 mmol) 
in degassed piperidine (180 mL) at room temperature. After stirring at the same temperature for 
2 h, saturated NH4Cl aqueous solution (90 mL) was added and extracted with Et2O (3 × 75 mL). 
The organic layer was washed with brine (3 × 75 mL), dried over MgSO4, and concentrated in 
vacuo. The crude product was purified by column chromatography (hexane/Et2O = 49:1) to 
afford the title compound 1.87 (6.86 g, 87%). 1H NMR (300 MHz, CDCl3) δ 5.95 (dt, J = 10.8, 
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7.8 Hz, 1H), 5.48 (d, J = 10.8 Hz, 1H), 3.66 (s, 3H), 2.31 (q, J = 7.1 Hz, 2H), 2.30 (t, J = 7.5 Hz, 
2H), 1.64–1.56 (m, 2H), 1.43–1.35 (m, 2H), 1.25 (br. s, 20H), 0.96 (s, 9H), 0.13 (s, 6H); 13C 
NMR (75 MHz, CDCl3) δ 174.2, 145.5, 109.2, 102.7, 96.6, 51.3, 34.1, 30.3, 29.6, 29.6, 29.4, 
29.4, 29.2, 29.2, 29.1, 28.7, 26.1, 24.9, 16.6, -4.6; IR (film) 2928, 2855, 1731, 1465, 1439, 1251, 
1201, 1174, 909, 838, 735; MS (EI) m/z 443 (M+ + Na); HRMS (ESI) m/z (M+ + Na) calcd for 
C26H48O2NaSi 443.3321, found 443.3309. 
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(Z)-19-(tert-Butyldimethylsilyl)nonadec-16-en-18-ynal (1.13): 
 DIBAL-H (22 mL, 1.0 M solution in hexane, 22 mmol) was added to a solution of ester 
1.87 (6.85 g, 16.3 mmol) in CH2Cl2 (85 mL) at -78 °C. After stirring for 30 min at the same 
temperature, the mixture was poured into a rapidly stirred mixture of saturated aqueous sodium 
potassium tartrate (240 mL) and Et2O (160 mL). The resulting mixture was stirred vigorously for 
1 h, at which time the organic layer cleared. The organic layer was washed with brine (150 mL) 
and the combined aqueous layers were extracted with Et2O (150 mL). The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography (hexane/Et2O = 49:1) to afford the title compound 1.13 (5.98 g, 94%). 
1H NMR (300 MHz, CDCl3) δ 9.76 (t, J = 1.8 Hz, 1H), 5.95 (dt, J = 10.8, 7.5 Hz, 1H), 5.48 (d, J 
= 10.8 Hz, 1H), 2.42 (td, J = 7.5, 2.1 Hz, 2H), 2.32 (qd, J = 6.9, 0.6 Hz, 2H), 1.68–1.57 (m, 2H), 
1.44–1.35 (m, 2H), 1.25 (br. s, 20H), 0.96 (s, 9H), 0.13 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 
202.8, 145.5, 109.2, 102.8, 96.7, 43.9, 30.4, 29.6, 29.6, 29.6, 29.4, 29.3, 29.2, 29.2, 28.7, 26.1, 
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22.1, 16.6, -4.6; IR (film) 2928, 2855, 1721, 1641, 1466, 1389, 1251, 908, 810, 733; MS (EI) 
m/z 390 (M+); HRMS (ESI) m/z (M+) calcd for C25H46OSi 390.3318, found 390.3316. 
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tert-Butyl((3Z,19Z)-25-(4-methoxybenzyloxy)pentacosa-3,19-dien-1-ynyl)dimethylsilane 
(1.88): 
 NaHMDS (30 mL, 1.0 M solution in THF, 30 mmol) was added to the solution of 
phosphonium bromide 1.12 (19.86 g, 35 mmol) in THF (120 mL) at 0 °C. The resulting orange 
solution was stirred at the same temperature for 30 min and then cooled to -78 °C. The solution 
of aldehyde 1.13 (5.86 g, 15 mmol) in THF (55 mL) was then added. The mixture was stirred at 
-78 °C for 2 h and warmed to room temperature for further 2 h stirring. Saturated NH4Cl 
aqueous solution (75 mL) was added, the organic phase was separated and aqueous phase was 
extracted with Et2O (3 × 75 mL). The combined organic layers were washed with brine, dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (hexane/Et2O = 49:1) to afford the title compound 1.88 (8.85 g, 99%). 1H NMR 
(300 MHz, CDCl3) δ 7.26 (m, 2H), 6.88 (m, 2H), 5.96 (dt, J = 10.8, 7.5 Hz, 1H), 5.47 (d, J = 
10.8 Hz, 1H), 5.37–5.28 (m, 2H), 4.43 (s, 2H), 3.80 (s, 3H), 3.43 (t, J = 6.6 Hz, 2H), 2.32 (qd, J 
= 6.6, 0.6 Hz, 2H), 2.07–1.95 (m, 4H), 1.64–1.56 (m, 2H), 1.44–1.33 (m, 6H), 1.25 (br. s, 22H), 
0.96 (s, 9H), 0.13 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 159.1, 145.6, 130.8, 130.1, 129.6, 129.2, 
113.7, 109.2, 102.8, 96.7, 72.5, 70.2, 55.2, 30.4, 29.8, 29.7, 29.6, 29.4, 29.3, 29.2, 28.8, 27.2, 
27.1, 26.1, 25.9, 16.6, -4.5; IR (film) 3054, 2928, 2855, 1612, 1513, 1463, 1423, 1361, 1265, 
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1096, 1035, 895, 826, 740, 706; MS (EI) m/z 595 (M+ + H); HRMS (ESI) m/z (M+ + H) calcd for 
C39H47O2Si 595.4910, found 595.4912. 
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(6Z,22Z)-25-(tert-Butyldimethylsilyl)pentacosa-6,22-dien-24-yn-1-ol: 
 DDQ (5.03 g, 22.2 mmol) was added to the solution of compound 1.88 (8.80 g, 14.8 
mmol) in CH2Cl2 (150 mL) and H2O (16 mL) at room temperature. The reaction was monitored 
by TLC until completion, and then saturated NaHCO3 aqueous solution was added. The mixture 
was extracted with CH2Cl2 (3 × 100 mL), the organic layers were combined, washed with 
saturated NaHCO3 aqueous solution, brine, dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (hexane/Et2O = 3:1) to afford the title 
compound, which was contaminated with tiny 4-(methoxymethyl)benzaldehyde and was used in 
the following step without further purification. 
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((3Z,19Z)-25-Bromopentacosa-3,19-dien-1-ynyl)(tert-butyl)dimethylsilane (1.89): 
 A solution of triphenylphosphine (14.0 g, 53.4 mmol) was added to a solution of 
(6Z,22Z)-25-(tert-Butyldimethylsilyl)pentacosa-6,22-dien-24-yn-1-ol (14.8 mmol) and CBr4 
(14.2 g, 42.8 mmol) in CH2Cl2 (70 mL) at 0 °C. After stirring at room temperature for 1 h, the 
organic solvent was removed under reduced pressure. The residue was purified by column 
chromatography (hexane/EtOAc = 99:1) to afford the title compound 1.89 (4.77 g, 60% for 2 
steps). 1H NMR (300 MHz, CDCl3) δ 5.96 (dt, J = 10.8, 7.5 Hz, 1H), 5.48 (d, J = 10.8 Hz, 1H), 
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5.43–5.28 (m, 2H), 3.41 (t, J = 6.9 Hz, 2H), 2.32 (q, J = 7.2 Hz, 2H), 2.07–1.96 (m, 4H), 1.87 
(quin, J = 6.9 Hz, 2H), 1.50–1.37 (m, 6H), 1.26 (br. s, 22H), 0.96 (s, 9H), 0.13 (s, 6H); 13C NMR 
(75 MHz, CDCl3) δ 145.6, 130.4, 129.2, 109.2, 102.8, 96.7, 33.9, 32.8, 30.4, 29.7, 29.7, 29.7, 
29.6, 29.6, 29.4, 29.3, 29.2, 28.9, 28.8, 27.8, 27.2, 27.0, 26.1, 16.6, -4.5; IR (film) 2926, 2854, 
1650, 1558, 1459, 1251, 1022, 910, 810, 736; MS (EI) m/z 536 (M+); HRMS (ESI) m/z (M+) 
calcd for C31H57OSi 536.3413, found 536.3401. 
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((6Z,22Z)-25-(tert-butyldimethylsilyl)pentacosa-6,22-dien-24-ynyl)triphenylphosphonium 
bromide (1.3): 
 A mixture of bromide 1.89 (4.77 g, 8.9 mmol) and triphenylphosphine (5.82 g, 22.2 
mmol) in CH3CN (90 mL) was stirred at 90 °C for 2 days. The organic solvent was removed 
under reduced pressure, the residue was purified by column chromatography (CHCl3/MeOH = 
19:1) to afford the title compound 1.3 (6.78 g, 96%). 1H NMR (500 MHz, CDCl3) δ 7.87–7.82 
(m, 6H), 7.79–7.74 (m, 3H), 7.71–7.67 (m, 6H), 5.95 (dtd, J = 10.5, 7.5, 2.0 Hz, 1H), 5.46 (dt, J 
= 11.0, 1.3 Hz, 1H), 5.31–5.20 (m, 2H), 3.87–3.77 (m, 2H), 2.30 (q, J = 6.5 Hz, 2H), 1.96–1.89 
(m, 4H), 1.68–1.58 (m, 4H), 1.43–1.35 (m, 4H), 1.23 (br. s, 22H), 0.94 (d, J = 2.0 Hz, 9H), 0.11 
(d, J = 2.5 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 145.6, 134.9 (d, JCP = 2.5 Hz), 133.6 (d, JCP 
= 10.0 Hz), 133.4 (d, JCP = 12.5 Hz), 130.3, 129.0, 118.3 (d, JCP = 86.3 Hz), 109.1, 102.7, 96.6, 
30.3, 30.0, 29.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 28.7, 27.2, 26.7, 26.0, 22.7 (d, JCP 
= 45 Hz), 22.5, 16.5, -4.5; IR (film) 2925, 2854, 1650, 1558, 1458, 1437, 1112, 914; HRMS 
(ESI) m/z (M+ - Br) calcd for C49H72SiP 719.5141, found 719.5121. 
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(10R,21R,E)-21-((7Z,13Z,29Z)-32-(tert-Butyldimethylsilyl)dotriaconta-7,13,29-trien-1,31-
diynyl)-10-((tert-butyldimethylsilyl)ethynyl)-1,1,1,2,2,3,3,4,4,27,27,28,28,29,29,30,30,30-
octadecafluoro-8,8,23,23-tetraisopropyl-9,22-dioxa-8,23-disilatriacont-11-en-19-yne, 
(5S,16R,E)-16-((7Z,13Z,29Z)-32-(tert-butyldimethylsilyl)dotriaconta-7,13,29-trien-1,31-
diynyl)-5-((tert-butyldimethylsilyl)ethynyl)-22,22,23,23,24,24,25,25,25-nonafluoro-
3,3,18,18-tetraisopropyl-2-methyl-4,17-dioxa-3,18-disilapentacos-6-en-14-yne, (9S,20R,E)-9-
((7Z,13Z,29Z)-32-(tert-butyldimethylsilyl)dotriaconta-7,13,29-trien-1,31-diynyl)-20-((tert-
butyldimethylsilyl)ethynyl)-1,1,1,2,2,3,3,26,26,27,27,28,28,29,29,29-hexadecafluoro-
7,7,22,22-tetraisopropyl-8,21-dioxa-7,22-disilanonacos-18-en-10-yne, and (5S,16S,E)-16-
((7Z,13Z,29Z)-32-(tert-butyldimethylsilyl)dotriaconta-7,13,29-trien-1,31-diynyl)-5-((tert-
butyldimethylsilyl)ethynyl)-22,22,23,23,24,24,24-heptafluoro-3,3,18,18-tetraisopropyl-2-
methyl-4,17-dioxa-3,18-disilatetracos-6-en-14-yne (M-1.90): 
 NaHMDS (0.63 mL, 1.0 M solution in THF, 0.63 mmol) was added to the solution of 
phosphonium bromide 1.3 (658.9 mg, 0.82 mmol) in THF (2.1 mL) at 0 °C. The resulting orange 
solution was stirred at the same temperature for 10 min and then cooled to -78 °C. The solution 
of aldehyde M-1.2 (190.0 mg, 0.21 mmol) in THF (1.4 mL) was then added. The mixture was 
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stirred at -78 °C for 2 h. Saturated NH4Cl aqueous solution (10 mL) was added, the organic 
phase was separated and aqueous phase was extracted with Et2O (3 × 10 mL). The combined 
organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by column chromatography (hexane/CH2Cl2 = 9:1) to afford the title 
compound M-1.90 (137.2 mg, 44%). 1H NMR (600 MHz, CDCl3) δ 5.96 (dt, J = 10.8, 7.8 Hz, 
1H), 5.83–5.76 (m, 1H), 5.54–5.47 (m, 2H), 5.38–5.30 (m, 4H), 5.21 (s, 1H), 4.92–4.87 (m, 1H), 
2.32 (q, J = 7.2 Hz, 2H), 2.20 (q, J = 7.8 Hz, 2H), 2.15–2.08 (m, 3H), 2.06–1.98 (m, 10H), 1.79–
1.72 (m, 3H), 1.53–1.47 (m, 4H), 1.44–1.25 (m, 36H), 1.13–1.05 (m, 31.5H), 0.96 (s, 9H), 0.92 
(s, 9H), 0.79–0.75 (m, 3H), 0.13 (s, 6H), 0.09 (s, 6H). 
 
Demix the mixture M-1.90:  
The mixture M-1.90 (137.2 mg, 0.09 mmol) was dissolved in CH3CN/THF (3:2) (6 mL) 
and demixed by semi-preparative fluorous HPLC (FluorosFlashTM PFC8 column, CH3CN:THF 
= 100:0 to 85:15 in 45 min, then 85:15 for further 20 min). The four desired compounds were 
obtained.  
1.90SS: 41.3 mg, t = 20.3 min 
1.90SR: 39.5 mg, t = 25.5 min 
1.90RS: 16.0 mg, t = 42.2 min 
1.90RR: 19.7 mg, t = 52.7 min 
 
OH
OH
12S S
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(3S,4E,14S,21Z,27Z,43Z)-Hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-3,14-diol 
(1.1SS): 
 TBAF (0.24 mL, 1.0 M solution in THF, 0.24 mmol) was added to a solution of 
compound 1.90SS (40.0 mg, 0.29 mmol) in THF (0.6 mL) at room temperature. The mixture 
then was stirred for 1 h at this temperature and quenched with saturated aqueous NH4Cl. The 
resulting mixture was extracted with CH2Cl2 (3 × 5 mL). The organic layers were washed with 
brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was 
purified by column chromatography (hexane/Et2O = 4:1) to give compound 1.1SS (11.4 mg, 
59%). [α]D 25 = +10.5 (c = 0.30, CH3OH), 1H NMR (600 MHz, CDCl3) δ 6.00 (dt, J = 10.8, 7.2 
Hz, 1H), 5.91 (dt, J = 15.0, 7.0 Hz, 1H), 5.62 (dd, J = 15.0, 6.0 Hz, 1H), 5.44 (dd, J = 10.8, 1.2 
Hz, 1H), 5.39–5.31 (m, 4H), 5.09 (dt, J = 7.2, 1.8 Hz, 1H), 4.84 (t, J = 6.0 Hz, 1H), 3.07 (d, J = 
1.8 Hz, 1H), 2.57 (d, J = 2.4 Hz, 1H), 2.32 (q, J = 7.2 Hz, 2H), 2.23 (qd, J = 6.0, 1.2 Hz, 4H), 
2.13 (d, J = 7.2 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.06–1.99 (m, 8H), 1.88 (d, J = 6.0 Hz, 1H), 
1.55–1.49 (m, 4H), 1.46–1.25 (m, 36H); 13C NMR (200 MHz, CDCl3) δ 146.31, 134.32, 130.21, 
130.07, 129.65, 129.31, 128.52, 107.88, 85.02, 84.97, 83.26, 81.13, 80.58, 78.10, 78.10, 74.01, 
62.77, 52.54, 31.76, 30.26, 29.76, 29.68 (3 C), 29.65 (3 C), 29.57, 29.44, 29.37, 29.33 (2 C), 
29.17, 28.87, 28.72, 28.56, 28.54, 28.49, 28.19, 27.92, 27.23, 27.13, 27,09, 26.65, 18.64, 18.63; 
IR (film) 3054, 2986, 2929, 2855, 1422, 1265, 909, 740; MS (EI) m/z 678 (M+ + Na + H); 
HRMS (ESI) m/z (M+ + Na) calcd for C46H70O2Na 677.5274, found 677.5321. 
 
OH
OH
12S R
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(3S,4E,14R,21Z,27Z,43Z)-Hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-3,14-diol 
(1.1SR): 
 Following the same procedure for 1.1SS, the compound 1.90SR (38.0 mg, 0.027 mmol) 
was reacted with TBAF (0.22 mL, 1.0 M solution in THF, 0.22 mmol), the title compound 1.1SR 
(10.4 mg, 59%) was obtained. [α]D 25 = +9.5 (c = 0.25, CH3OH), 1H NMR (600 MHz, CDCl3) δ 
6.00 (dt, J = 10.8, 7.2 Hz, 1H), 5.91 (dt, J = 15.6, 7.2 Hz, 1H), 5.62 (ddd, J = 15.6, 6.0, 0.6 Hz, 
1H), 5.44 (dd, J = 10.8, 1.2 Hz, 1H), 5.39–5.31 (m, 4H), 5.09 (dt, J = 6.6, 1.2 Hz, 1H), 4.84 (t, J 
= 6.0 Hz, 1H), 3.07 (d, J = 1.8 Hz, 1H), 2.57 (d, J = 1.8 Hz, 1H), 2.32 (q, J = 7.2 Hz, 2H), 2.23 
(qd, J = 6.5, 1.2 Hz, 4H), 2.11 (d, J = 7.2 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.06–1.99 (m, 8H), 
1.87 (d, J = 6.0 Hz, 1H), 1.56–1.49 (m, 4H), 1.46–1.25 (m, 36H); 13C NMR (200 MHz, CDCl3) δ 
146.32, 134.33, 130.21, 130.07, 129.65, 129.31, 128.51, 107.87, 85.03, 84.98, 83.26, 81.12, 
80.58, 78.09, 78.08, 74.02, 62.78, 52.54, 31.77, 30.26, 29.76, 29.68 (3 C), 29.66 (3 C), 29.58, 
29.44, 29.37, 29.33 (2 C), 29.17, 28.87, 28.72, 28.56, 28.54, 28.50, 28.20, 27.91, 27.23, 27.13, 
27,09, 26.65, 18.65, 18.63; IR (film) 3054, 2986, 2929, 2855, 1423, 1265, 909, 736; MS (EI) m/z 
678 (M+ + Na + H); HRMS (ESI) m/z (M+ + Na) calcd for C46H70O2Na 677.5274, found 
677.5267. 
 
OH
OH
12R S
 
(3R,4E,14S,21Z,27Z,43Z)-Hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-3,14-diol 
(1.1RS): 
 Following the same procedure for 1.1SS, the compound 1.90RS (12.5 mg, 0.008 mmol) 
was reacted with TBAF (0.07 mL, 1.0 M solution in THF, 0.07 mmol), the title compound 1.1RS 
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(2.1 mg, 41%) was obtained. [α]D 25 = -9.0 (c = 0.16, CH3OH), 1H NMR (600 MHz, CDCl3) δ 
6.00 (dt, J = 10.8, 7.2 Hz, 1H), 5.91 (dt, J = 15.0, 7.2 Hz, 1H), 5.62 (dd, J = 15.6, 6.0 Hz, 1H), 
5.44 (dd, J = 10.8, 1.2 Hz, 1H), 5.39–5.31 (m, 4H), 5.09 (dt, J = 7.2, 1.8 Hz, 1H), 4.84 (t, J = 6.0 
Hz, 1H), 3.07 (d, J = 1.8 Hz, 1H), 2.57 (d, J = 1.8 Hz, 1H), 2.32 (q, J = 7.2 Hz, 2H), 2.23 (qd, J = 
6.9, 1.8 Hz, 4H), 2.10 (d, J = 6.6 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.06–1.99 (m, 8H), 1.85 (d, J 
= 6.0 Hz, 1H), 1.56–1.49 (m, 4H), 1.46–1.25 (m, 36H); 13C NMR (200 MHz, CDCl3) δ 146.33, 
134.35, 130.22, 130.08, 129.66, 129.31, 128.52, 107.88, 85.05, 85.00, 83.26, 81.12, 80.58, 78.08 
(2 C), 74.02, 62.80, 52.55, 31.77, 30.27, 29.77, 29.68 (3 C), 29.66 (3 C), 29.59, 29.45, 29.38, 
29.34 (2 C), 29.18, 28.88, 28.73, 28.57, 28.55, 28.51, 28.21, 27.92, 27.24, 27.14, 27,09, 26.66, 
18.65, 18.63; IR (film) 3053, 2986, 2929, 1423, 1265, 909, 736, 706; MS (EI) m/z 678 (M+ + Na 
+ H); HRMS (ESI) m/z (M+ + Na) calcd for C46H70O2Na 677.5274, found 677.5307. 
 
OH
OH
12R R
 
(3R,4E,14R,21Z,27Z,43Z)-Hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-3,14-diol 
(1.1RR): 
 Following the same procedure for 1.1SS, the compound 1.90RR (18.5 mg, 0.011 mmol) 
was reacted with TBAF (0.09 mL, 1.0 M solution in THF, 0.09 mmol), the title compound 
1.1RR (5.1 mg, 69%) was obtained. [α]D 25 = -11.2 (c = 0.20, CH3OH), 1H NMR (600 MHz, 
CDCl3) δ 6.00 (dt, J = 10.8, 7.2 Hz, 1H), 5.91 (dt, J = 15.6, 6.6 Hz, 1H), 5.62 (ddd, J = 15.0, 6.0, 
1.2 Hz, 1H), 5.44 (d, J = 10.8, 1H), 5.39–5.31 (m, 4H), 5.09 (dt, J = 7.2, 1.8 Hz, 1H), 4.84 (t, J = 
6.0 Hz, 1H), 3.07 (d, J = 1.2 Hz, 1H), 2.57 (d, J = 1.8 Hz, 1H), 2.32 (q, J = 7.2 Hz, 2H), 2.23 (qd, 
J = 7.2, 1.8 Hz, 4H), 2.11 (d, J = 7.2 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 2.06–1.99 (m, 8H), 1.86 
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(d, J = 6.0 Hz, 1H), 1.56–1.49 (m, 4H), 1.46–1.25 (m, 36H); 13C NMR (200 MHz, CDCl3) δ 
146.33, 134.35, 130.22, 130.08, 129.66, 129.31, 128.52, 107.88, 85.04, 84.99, 83.26, 81.13, 
80.58, 78.09 (2 C), 74.03, 62.79, 52.55, 31.77, 30.28, 29.77, 29.69 (3 C), 29.66 (3 C), 29.59, 
29.45, 29.38, 29.34 (2 C), 29.18, 28.88, 28.73, 28.56, 28.54, 28.50, 28.20, 27.92, 27.24, 27.14, 
27,09, 26.66, 18.65, 18.63; IR (film) 3054, 2986, 1423, 1265, 909, 735, 705; MS (EI) m/z 678 
(M+ + Na + H); HRMS (ESI) m/z (M+ + Na) calcd for C46H70O2Na 677.5274, found 677.5295. 
 
OR-MTPA
OR-MTPA
12S S
11 17 21
 
(2R,2'R)-((3S,4E,14S,21Z,27Z,43Z)-hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-
3,14-diyl) bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate) (1.91SSR): 
To a solution of alcohol 1.1SS (1.0 mg, 1.5×10−3 mmol) in CH2Cl2 (0.5 ml) was added 
(R)-MTPA acid (1.8 mg, 7.6×10−3 mmol), DCC (1.9 mg, 9.2×10−3 mmol), and DMAP (0.2 mg, 
1.5×10−3 mmol) at room temperature. The resulting mixture was stirred at the same temperature 
overnight. The mixture was then filtered through a pad of Celite ®, the filtrate was concentrated 
in vacuo. The crude product 1.191SSR was obtained: 1H NMR (700 MHz, CDCl3) δ 7.55 (d, J = 
7.0 Hz, 2H), 7.52 (d, J = 7.0 Hz, 2H), 7.43–7.39 (m, 6H), 6.21 (t, J = 2.1 Hz, 1H), 6.05 (dtd, J = 
15.4, 7.0, 1.4 Hz, 1H), 6.02–5.98 (m, 2H), 5.60 (ddt, J = 15.4, 7.0, 1.4 Hz, 1H), 5.44 (ddt, J = 
10.5, 2.8, 1.4 Hz, 1H), 5.39–5.29 (m, 4H), 3.59 (s, 3H), 3.55 (s, 3H), 3.06 (d, J = 2.1 Hz, 1H), 
2.59 (d, J = 2.1 Hz, 1H), 2.32 (qd, J = 7.7, 1.4 Hz, 2H), 2.22 (td, J = 7.0, 2.1 Hz, 2H), 2.20 (td, J 
= 7.0, 2.1 Hz, 2H), 2.07 (q, J = 7.0 Hz, 2H), 2.03–1.99 (m, 8H), 1.52–1.46 (m, 4H), 1.42–1.38 
(m, 4H), 1.36–1.25 (m, 32H). 
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OS-MTPA
OS-MTPA
12S S
11 17 21
 
(2S,2'S)-((3S,4E,14S,21Z,27Z,43Z)-hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-
3,14-diyl) bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate) (1.91SSS): 
Following the same procedure for 1.91SSR, the compound 1.1SS (1.0 mg, 0.027 mmol) 
was reacted with (S)-MTPA acid (1.8 mg, 7.6×10−3 mmol), DCC (1.9 mg, 9.2×10−3 mmol), and 
DMAP (0.2 mg, 1.5×10−3 mmol), the title compound 1.91SSS (10.4 mg, 59%) was obtained. 1H 
NMR (700 MHz, CDCl3) δ7.55 (d, J = 7.0 Hz, 2H), 7.52 (d, J = 7.0 Hz, 2H), 7.43–7.39 (m, 6H), 
6.21 (t, J = 2.1 Hz, 1H), 6.03 (m, 1H), 6.00 (m, 1H), 5.99 (m, 1H), 5.49 (dd, J = 15.4, 7.0 Hz, 
1H), 5.44 (d, J = 10.5 Hz, 1H), 5.37–5.29 (m, 4H), 3.59 (s, 3H), 3.58 (s, 3H), 3.06 (d, J = 1.4 Hz, 
1H), 2.63 (d, J = 2.1 Hz, 1H), 2.32 (q, J = 7.0 Hz, 2H), 2.23 (td, J = 7.0, 2.1 Hz, 2H), 2.22 (td, J 
= 7.0, 2.1 Hz, 2H), 2.04 (m, 2H), 2.03–1.99 (m, 8H), 1.53–1.50 (m, 2H), 1.48–1.44 (m, 2H), 
1.43–1.38 (m, 4H), 1.36–1.25 (m, 32H). 
 
OR-MTPA
OR-MTPA
12S R
11 17 21
 
(2R,2'R)-((3S,4E,14R,21Z,27Z,43Z)-hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-
3,14-diyl) bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate) (1.92SRR): 
Following the same procedure for 1.91SSR, the compound 1.1SR (1.0 mg, 0.027 mmol) 
was reacted with (R)-MTPA acid (1.8 mg, 7.6×10−3 mmol), DCC (1.9 mg, 9.2×10−3 mmol), and 
DMAP (0.2 mg, 1.5×10−3 mmol), the title compound 1.92SRR (10.4 mg, 59%) was obtained. 1H 
NMR (600 MHz, CDCl3) δ7.55 (d, J = 7.0 Hz, 2H), 7.52 (d, J = 7.0 Hz, 2H), 7.43–7.39 (m, 6H), 
6.21 (t, J = 2.1 Hz, 1H), 6.06 (dtd, J = 15.4, 7.0, 1.4 Hz, 1H), 6.01 (m, 1H), 6.00 (m, 2H), 5.60 
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(ddt, J = 15.4, 7.0, 1.4 Hz, 1H), 5.44 (ddt, J = 10.5, 2.8, 1.4 Hz, 1H), 5.38–5.29 (m, 4H), 3.59 (s, 
3H), 3.55 (s, 3H), 3.07 (d, J = 1.4 Hz, 1H), 2.59 (d, J = 2.1 Hz, 1H), 2.32 (q, J = 7.0 Hz, 2H), 
2.23 (td, J = 7.0, 2.1 Hz, 2H), 2.19 (td, J = 7.0, 2.1 Hz, 2H), 2.08 (q, J = 7.0Hz, 2H), 2.04–2.00 
(m, 8H), 1.53–1.50 (m, 2H), 1.48–1.44 (m, 2H), 1.43–1.38 (m, 4H), 1.36–1.25 (m, 32H). 
 
OS-MTPA
OS-MTPA
12S R
11 17 21
 
(2S,2'S)-((3S,4E,14R,21Z,27Z,43Z)-hexatetraconta-4,21,27,43-tetraen-1,12,15,45-tetrayne-
3,14-diyl) bis(3,3,3-trifluoro-2-methoxy-2-phenylpropanoate) (1.92SRS): 
Following the same procedure for 1.91SSR, the compound 1.1SR (1.0 mg, 0.027 mmol) 
was reacted with (S)-MTPA acid (1.8 mg, 7.6×10−3 mmol), DCC (1.9 mg, 9.2×10−3 mmol), and 
DMAP (0.2 mg, 1.5×10−3 mmol), the title compound 1.92SRS (10.4 mg, 59%) was obtained. 1H 
NMR (600 MHz, CDCl3) δ7.55 (d, J = 7.0 Hz, 2H), 7.52 (d, J = 7.0 Hz, 2H), 7.43–7.39 (m, 6H), 
6.21 (t, J = 2.1 Hz, 1H), 6.02 (m, 1H), 6.00 (m, 1H), 5.99 (m, 1H), 5.49 (ddt, J = 15.4, 7.0, 1.4 
Hz, 1H), 5.44 (ddt, J = 10.5, 2.8, 1.4 Hz, 1H), 5.38–5.29 (m, 4H), 3.59 (s, 3H), 3.58 (s, 3H), 3.07 
(d, J = 0.7 Hz, 1H), 2.63 (d, J = 1.4 Hz, 1H), 2.32 (qd, J = 7.0, 1.4 Hz, 2H), 2.21 (td, J = 7.7, 2.1 
Hz, 2H), 2.20 (td, J = 7.0, 2.1 Hz, 2H), 2.04 (m, 2H), 2.03–1.99 (m, 8H), 1.52–1.46 (m, 4H), 
1.42–1.38 (m, 4H), 1.36–1.25 (m, 32H). 
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APPENDIX  
NMR SPECTRA 
1. 1H and 13C NMR spectra of M-1.68, 1.74R/S, M-1.78–M-1.80, M-1.2, 1.3, and M-1.90. 
2. 1H and 13C NMR spectra of petrocortyne A four isomers 1.1 and COSY, HMQC, and HMBC 
spectra of 1.1SS 
3. 1H, and TOCSY spectra of Mosher esters 1.91SSR/SSS and 1.92SRS/SRR 
146
IO
TIP
S
F0,9'
TBS
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
0.753
0.764
0.787
0.928
1.056
1.082
1.101
1.351
1.374
1.394
1.703
1.724
1.737
1.764
1.789
1.812
1.834
2.043
2.066
2.126
2.159
2.185
3.156
3.180
3.203
4.878
4.896
5.485
5.502
5.519
5.535
5.552
5.741
5.762
5.787
5.811
7.261
5.76
1.59
10.14
19.33
7.92
4.04
3.82
2.00
0.85
0.90
0.88
B
S4P204 CDCl3 301b BinS 11/27/07
147
IO
TIP
S
F0,9'
TBS
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm 14.11
14.62
16.48
17.51
17.54
17.59
17.61
17.98
22.65
26.00
26.05
27.96
28.67
28.73
30.29
30.32
31.66
33.48
33.51
34.21
34.50
34.79
63.81
63.95
76.58
77.00
77.43
87.58
88.06
106.24
106.75
129.76
130.13
131.41
131.88
B
S4P204 13CNMR CDCl3 301a BinS 11/28/07
148
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.448
1.455
1.471
1.485
1.492
1.504
1.514
1.521
1.533
1.546
1.557
1.569
1.573
1.581
1.590
1.613
1.635
1.657
2.152
2.226
2.232
2.251
2.256
2.272
2.278
2.539
2.546
3.506
3.527
3.548
4.626
5.072
5.079
5.086
5.094
5.096
5.104
5.111
5.118
7.260
7.69
2.89
3.14
0.66
2.15
2.00
0.72
B
S4P198 CDCl3 301 BinS 11/16/07
O
M
TM
O
H
 
149
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
13.82
18.45
25.31
27.81
28.62
51.78
67.78
71.94
75.00
76.58
77.00
77.27
77.43
81.53
85.32
B
S4P198 13CNMR CDCl3 301 BinS 11/16/07
O
M
TM
O
H
 
150
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1.457
1.472
1.487
1.494
1.505
1.516
1.523
1.535
1.548
1.561
1.571
1.592
1.614
1.636
1.659
2.153
2.204
2.221
2.228
2.234
2.251
2.257
2.273
2.280
2.539
2.547
3.507
3.529
3.549
4.627
5.074
5.080
5.087
5.097
5.105
5.112
5.119
7.261
7.55
2.74
3.13
0.64
2.16
2.00
0.71
B
S4P197 CDCl3 301 BinS 11/15/07
O
M
TM
O
H
 
151
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
13.93
18.57
25.44
27.90
28.78
52.06
67.89
72.10
75.16
76.58
77.00
77.25
77.43
81.50
85.65
B
S4P197 13CNMR CDCl3 301 BinS 11/15/07
O
M
TM
O
H
 
152
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H
O
M
TM
R
O
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F0,9'
TBS
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.091
0.124
0.927
0.946
1.046
1.054
1.061
1.067
1.080
1.086
1.099
1.300
1.313
1.359
1.374
1.388
1.403
1.432
1.450
1.468
1.475
1.482
1.488
1.496
1.512
1.526
1.534
1.538
1.547
1.562
1.579
1.593
1.608
1.622
2.042
2.057
2.060
2.075
2.152
2.202
2.205
2.216
2.220
2.229
2.232
2.243
2.246
2.257
2.260
3.510
3.523
3.536
4.625
7.260
5.60
0.56
9.80
16.61
5.96
8.96
0.65
2.51
0.47
2.70
3.72
2.18
2.00
0.24
0.47
0.65
0.72
0.71
B
S5P28 SM CDCl3 500 BinS 01/10/08
153
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H
O
M
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8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.088
0.122
0.923
0.943
1.033
1.043
1.051
1.064
1.076
1.084
1.096
1.121
1.132
1.144
1.297
1.308
1.359
1.371
1.383
1.395
1.457
1.465
1.472
1.477
1.483
1.496
1.508
1.520
1.547
1.555
1.559
1.572
1.593
1.605
1.617
2.041
2.052
2.087
2.099
2.144
2.151
2.204
2.216
2.230
2.233
2.242
2.245
2.254
2.257
3.510
3.521
3.532
4.625
7.260
5.50
0.50
8.99
16.04
5.50
8.91
0.65
2.77
3.22
3.43
2.13
2.00
0.22
0.45
0.75
0.69
0.67
BS5P29 SM CDCl3 600 BinS 01/11/08
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O
TIPS
F9'
O
M
TM
R
O
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F0,9'
TBS
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.085
0.097
0.749
0.761
0.777
0.921
0.926
1.030
1.047
1.055
1.062
1.073
1.082
1.093
1.119
1.129
1.142
1.282
1.293
1.346
1.357
1.369
1.446
1.453
1.458
1.463
1.472
1.484
1.524
1.536
1.549
1.560
1.575
1.587
1.599
1.756
1.763
1.771
1.779
2.031
2.043
2.104
2.141
2.191
2.204
2.216
2.226
2.228
3.492
3.503
3.514
4.615
5.205
7.260
5.70
2.56
9.07
29.72
1.95
3.09
3.67
4.49
2.56
6.99
3.63
2.07
2.00
0.22
0.46
0.97
0.71
0.68
BS5P33 CDCl3 600 BinS 01/28/08
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O
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F7'
O
M
TM
S
O
TIPS
F0,9'
TBS
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.085
0.097
0.748
0.760
0.776
0.921
0.926
1.055
1.063
1.072
1.082
1.094
1.119
1.130
1.142
1.282
1.294
1.358
1.369
1.447
1.459
1.464
1.472
1.484
1.497
1.524
1.536
1.549
1.560
1.575
1.588
1.599
1.754
1.761
1.768
1.776
2.032
2.044
2.056
2.078
2.092
2.106
2.142
2.180
2.192
2.204
2.216
2.227
3.493
3.503
3.514
4.616
5.205
7.260
5.60
2.56
9.11
29.69
1.96
3.14
8.16
2.60
6.94
3.60
2.09
2.00
0.21
0.45
0.93
0.69
0.66
BS5P34 CDCl3 600 BinS 01/28/08
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O
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O
H
O
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F0,9'
TBS
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.086
0.097
0.748
0.761
0.777
0.921
0.927
1.031
1.046
1.055
1.063
1.073
1.083
1.094
1.119
1.131
1.142
1.250
1.283
1.294
1.359
1.369
1.430
1.438
1.446
1.452
1.458
1.463
1.472
1.485
1.497
1.527
1.540
1.552
1.558
1.571
1.582
1.762
1.770
2.033
2.045
2.092
2.106
2.181
2.193
2.205
2.214
2.226
2.238
3.626
3.636
3.647
5.204
7.260
5.77
2.63
9.42
30.50
3.43
3.22
4.10
4.36
2.65
4.25
3.64
2.00
0.22
0.45
0.96
0.70
0.68
BS5P35 CDCl3 600 BinS 01/31/08
157
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F7',9'
O
O
TIPS
F0,9'
TBS
10
9
8
7
6
5
4
3
2
1
ppm 0.084
0.096
0.744
0.758
0.765
0.773
0.920
0.923
0.924
1.030
1.042
1.052
1.061
1.069
1.081
1.093
1.107
1.118
1.129
1.142
1.281
1.293
1.344
1.356
1.368
1.381
1.470
1.483
1.532
1.545
1.558
1.716
1.729
1.741
1.752
1.765
2.031
2.043
2.092
2.191
2.203
2.236
2.245
2.247
2.256
2.259
2.431
2.443
2.455
5.199
5.202
5.205
7.260
9.757
5.99
2.63
9.76
31.54
2.06
3.29
1.76
2.46
4.85
4.36
1.61
2.10
2.00
0.21
0.46
0.97
0.71
0.69
0.81
BS5P36 CDCl3 600 BinS 02/02/08
158
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1.5
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0.5
ppm 0.108
0.113
0.907
0.912
0.938
0.941
0.942
1.230
1.266
1.291
1.306
1.320
1.335
1.376
1.389
1.402
1.629
1.899
1.914
1.932
1.947
2.297
2.312
3.808
3.816
5.277
5.449
5.452
5.468
5.471
5.473
7.261
7.675
7.678
7.686
7.690
7.693
7.700
7.702
7.706
7.763
7.777
7.820
7.823
7.829
7.832
7.839
7.845
7.848
7.854
7.857
7.864
7.868
7.871
5.14
8.41
27.55
3.97
3.97
1.84
2.00
1.94
0.79
0.87
5.62
2.97
6.02
B
S4P42 CDCl3 500 BinS 05/01/07
12
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S
P
h
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r
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190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
−4.62
16.53
22.50
22.54
22.90
26.03
26.65
27.16
28.67
29.14
29.19
29.27
29.35
29.53
29.58
29.61
29.67
29.85
29.97
30.29
76.75
77.00
77.26
96.59
102.71
109.11
117.97
118.66
128.98
130.28
130.36
130.46
133.57
133.65
134.91
134.93
145.55
B
S4P42 13CNMR CDCl3 500 BinS 05/01/07
12
TB
S
P
h
3 PB
r
 
160
O
TIPS
F0,9'
TBS
O
TIPS
F7',9'
TBS
12
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 0.087
0.127
0.750
0.764
0.779
0.910
0.922
0.939
0.955
1.050
1.057
1.064
1.074
1.083
1.095
1.110
1.120
1.132
1.144
1.157
1.253
1.283
1.326
1.345
1.356
1.369
1.391
1.403
1.414
1.426
1.438
1.473
1.485
1.498
1.510
1.523
1.771
2.005
2.015
2.026
2.092
2.181
2.193
2.206
2.219
2.314
2.326
5.206
5.328
5.342
5.348
5.357
5.489
7.260
11.42
3.11
19.02
38.29
44.14
5.11
3.05
10.43
2.92
4.38
2.00
0.30
0.65
1.00
3.83
1.89
0.98
0.89
BS5P32 CDCl3 600 BinS 01/20/08
161
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.252
1.286
1.293
1.308
1.320
1.337
1.343
1.349
1.354
1.360
1.371
1.375
1.385
1.398
1.403
1.410
1.424
1.437
1.450
1.504
1.516
1.528
1.532
1.540
1.545
1.576
1.873
1.883
2.005
2.017
2.029
2.041
2.055
2.069
2.081
2.125
2.137
2.210
2.213
2.222
2.234
2.243
2.245
2.314
2.326
2.567
2.571
3.067
3.070
5.335
5.345
5.351
5.355
7.260
39.32
4.36
0.77
10.63
0.82
4.21
2.00
0.69
0.66
0.82
0.83
3.95
0.83
0.89
0.88
0.87
BS5P40 peak 1 Rf(0, 3)  After deprotection  CDCl3 600 BinS 02/16/08
O
H
O
H
12
S
S
162
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm 18.63
18.64
26.65
27.09
27.13
27.23
27.92
28.19
28.49
28.54
28.56
28.72
28.87
29.17
29.33
29.37
29.44
29.57
29.65
29.68
29.76
30.26
31.76
52.54
62.77
74.01
76.79
77.00
77.21
78.10
80.58
81.13
83.26
84.97
85.02
107.88
128.52
129.31
129.65
130.07
130.21
134.32
146.31
BS5P40 peak 1 Rf(0, 3)  After deprotection 13CNMR CDCl3 600 BinS 02/16/08
O
H
O
H
12
S
S
163
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.253
1.289
1.293
1.309
1.320
1.338
1.344
1.349
1.354
1.360
1.371
1.375
1.386
1.398
1.405
1.410
1.424
1.438
1.451
1.504
1.517
1.529
1.532
1.546
1.571
1.862
1.872
2.006
2.018
2.029
2.042
2.055
2.069
2.081
2.109
2.121
2.211
2.213
2.222
2.224
2.234
2.243
2.246
2.315
2.327
2.567
2.568
2.570
3.067
3.070
5.345
5.352
5.356
7.260
38.93
4.30
0.72
8.24
2.26
0.86
4.12
2.00
0.65
0.66
0.79
0.81
3.91
0.82
0.83
0.85
0.87
BS5P40 peak 2 Rf(0, 4)  After deprotection  CDCl3 600 BinS 02/19/08
O
H
O
H
12
S
R
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190
180
170
160
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110
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90
80
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60
50
40
30
20
10
0
ppm 18.63
18.65
26.65
27.09
27.13
27.23
27.91
28.20
28.50
28.54
28.56
28.72
28.87
29.17
29.33
29.37
29.44
29.58
29.66
29.68
29.76
30.26
31.77
52.54
62.78
74.02
76.79
77.00
77.21
78.08
78.09
80.58
81.12
83.26
84.98
85.03
107.87
128.51
129.31
129.65
130.07
130.21
134.33
146.32
BS5P40 peak 2 Rf(0, 4)  After deprotection 13CNMR CDCl3 600 BinS 02/19/08
O
H
O
H
12
S
R
165
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.252
1.287
1.309
1.320
1.337
1.343
1.349
1.354
1.360
1.371
1.375
1.385
1.398
1.404
1.410
1.424
1.438
1.451
1.504
1.517
1.520
1.529
1.533
1.541
1.546
1.555
1.842
1.852
1.993
2.006
2.017
2.029
2.042
2.055
2.069
2.081
2.093
2.104
2.211
2.214
2.223
2.233
2.235
2.244
2.247
2.315
2.327
2.568
2.572
3.067
3.070
5.346
5.352
5.356
39.93
4.43
0.68
10.82
4.08
2.00
0.61
0.66
0.74
0.78
3.90
0.79
0.79
0.80
0.84
BS5P40 peak 3 Rf(4, 3)  After deprotection CDCl3 600 BinS 02/17/08
O
H
O
H
12
R
S
166
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm 18.63
18.65
26.66
27.09
27.14
27.24
27.92
28.21
28.51
28.55
28.57
28.73
28.88
29.18
29.34
29.38
29.45
29.59
29.66
29.68
29.77
30.27
31.77
52.55
62.80
74.02
76.79
77.00
77.21
78.08
80.58
81.12
83.26
85.00
85.05
107.88
128.52
129.31
129.66
130.08
130.22
134.35
146.33
BS5P40 peak 3 Rf(4, 3)  After deprotection 13CNMR CDCl3 600 BinS 02/17/08
O
H
O
H
12
R
S
167
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.254
1.283
1.290
1.295
1.310
1.322
1.338
1.345
1.350
1.361
1.373
1.387
1.399
1.412
1.426
1.440
1.452
1.505
1.520
1.530
1.541
1.547
1.558
1.853
1.863
2.007
2.019
2.031
2.043
2.046
2.057
2.071
2.083
2.108
2.120
2.211
2.214
2.223
2.226
2.232
2.235
2.244
2.247
2.317
2.329
2.568
2.571
3.068
3.070
5.337
5.346
5.353
5.356
7.260
31.00
8.56
4.45
0.70
8.27
2.18
0.76
4.14
2.00
0.62
0.67
0.77
0.82
3.94
0.82
0.82
0.82
0.87
BS5P40 peak 4 Rf(4, 4)  After deprotection 13CNMR CDCl3 600 BinS 02/18/08
O
H
O
H
12
R
R
168
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm 18.63
18.65
26.66
27.09
27.14
27.24
27.92
28.20
28.50
28.54
28.56
28.73
28.88
29.18
29.34
29.38
29.45
29.59
29.66
29.69
29.77
30.28
31.77
52.55
62.79
74.03
76.79
77.00
77.22
78.09
80.58
81.13
83.26
84.99
85.04
107.88
128.52
129.31
129.66
130.08
130.22
134.35
146.33
BS5P40 peak 4 Rf(4, 4)  After deprotection 13CNMR CDCl3 600 BinS 02/18/08
O
H
O
H
12
R
R
169
O
H
O
H
12
S
S
 
ppm
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
7 6 5 4 3 2 1
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SINE
SF          600.8700137 MHz
M
C2                  QF
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SINE
SF          600.8700137 MHz
SI                 1024
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QF
SW                8.001 ppm
F
I
D
R
ES        66.773506 Hz
SFO1           600.8724 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72
N
D0                   1
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z2              10.00 %
G
P
Z1              10.00 %
G
P
Y2               0.00 %
G
P
Y1               0.00 %
G
P
X2               0.00 %
G
P
X1               0.00 %
G
P
N
A
M2       SMSQ10.100
G
P
N
A
M1       SMSQ10.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO1        600.8724034 MHz
P
L1                8.00 dB
P1                 8.24 usec
P0                 8.24 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
I
N0          0.00020800 sec
D16          0.00020000 sec
d13          0.00000400 sec
D1           1.48689198 sec
d0           0.00000300 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 294.1 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.00 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 104.000 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 143.7
AQ            0.2130420 sec
F
I
D
R
ES         2.347506 Hz
SWH            4807.692 Hz
DS                   16
NS                   32
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2048
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
c
o
s
y
g
p
qf
P
R
O
B
H
D
 
 
 5 mm TBI 1H−BB
I
NSTRUM           spect
Time              18.32
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20080216
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8
N
A
M
E
 
 
 
 
 
 
 
 
 
 
 
 
 
BS5P40
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
BS5P40 peak 1 Rf(0, 3)  After deprotection COSY CDCl3 600 BinS 02/16/08
170
O
H
O
H
12
S
S
 
ppm
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
140
120
100 80 60 40 20 0
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          151.0888820 MHz
M
C2                  QF
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          600.8700137 MHz
SI                 1024
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QF
SW              165.453 ppm
F
I
D
R
ES       195.312500 Hz
SFO1           151.1002 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128
N
D0                   2
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z3              40.10 %
G
P
Z2              30.00 %
G
P
Z1              50.00 %
G
P
Y3               0.00 %
G
P
Y2               0.00 %
G
P
Y1               0.00 %
G
P
X3               0.00 %
G
P
X2               0.00 %
G
P
X1               0.00 %
G
P
N
A
M3         SINE.100
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO2        151.1002126 MHz
P
L12              16.72 dB
P
L2               −1.00 dB
P
C
P
D2            100.00 usec
P3                13.00 usec
N
U
C2                13C
C
P
D
P
R
G2            garp
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
SFO1        600.8724034 MHz
P
L1                8.00 dB
p2                16.48 usec
P1                 8.24 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
I
N0          0.00002000 sec
D
E
L
T
A1       0.00222428 sec
D16          0.00020000 sec
d13          0.00000400 sec
d12          0.00002000 sec
d2           0.00344828 sec
D1           2.00000000 sec
d0           0.00000300 sec
C
NST2       145.0000000
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 293.6 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.00 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 104.000 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16384
AQ            0.1065460 sec
F
I
D
R
ES         4.695012 Hz
SWH            4807.692 Hz
DS                   16
NS                   96
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1024
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 hmqcgpqf
P
R
O
B
H
D
 
 
 5 mm TBI 1H−BB
I
NSTRUM           spect
Time              14.42
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20080217
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
N
A
M
E
 
 
 
 
 
 
 
 
 
 
 
 
 
BS5P40
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
BS5P40 peak 1 Rf(0, 3)  After deprotection HMQC CDCl3 600 BinS 02/17/08
171
O
H
O
H
12
S
S
 
ppm
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
140
120
100 80 60 40 20
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SINE
SF          151.0888820 MHz
M
C2                  QF
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SINE
SF          600.8700137 MHz
SI                 2048
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QF
SW              222.079 ppm
F
I
D
R
ES       296.965027 Hz
SFO1            151.104 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113
N
D0                   2
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z3              40.10 %
G
P
Z2              30.00 %
G
P
Z1              50.00 %
G
P
Y3               0.00 %
G
P
Y2               0.00 %
G
P
Y1               0.00 %
G
P
X3               0.00 %
G
P
X2               0.00 %
G
P
X1               0.00 %
G
P
N
A
M3         SINE.100
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO2        151.1039665 MHz
P
L2               −1.00 dB
P3                13.00 usec
N
U
C2                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
SFO1        600.8724034 MHz
P
L1                8.00 dB
p2                16.48 usec
P1                 8.24 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
I
N0          0.00001490 sec
D16          0.00020000 sec
d6           0.05000000 sec
d2           0.00344828 sec
D1           2.00000000 sec
d0           0.00000300 sec
C
NST13       10.0000000
C
NST2       145.0000000
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 294.0 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.00 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 104.000 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16384
AQ            0.4260340 sec
F
I
D
R
ES         1.173753 Hz
SWH            4807.692 Hz
DS                   16
NS                  240
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4096
P
U
L
P
R
O
G
 
 
 
 hmbcgplpndqf
P
R
O
B
H
D
 
 
 5 mm TBI 1H−BB
I
NSTRUM           spect
Time              19.52
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20080216
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9
N
A
M
E
 
 
 
 
 
 
 
 
 
 
 
 
 
BS5P40
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
BS5P40 peak 1 Rf(0, 3)  After deprotection HMBC CDCl3 600 BinS 02/16/08
172
O
H
O
H
12
S
S
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.290
1.309
1.324
1.339
1.350
1.356
1.363
1.368
1.373
1.380
1.394
1.401
1.407
1.412
1.418
1.427
1.469
1.480
1.482
1.494
1.506
1.513
1.517
2.030
2.039
2.046
2.051
2.053
2.065
2.077
2.196
2.200
2.205
2.208
2.211
2.216
2.220
2.223
2.304
2.306
2.317
2.858
2.862
3.298
3.300
3.303
3.393
4.880
5.007
5.337
5.340
5.343
5.346
5.352
5.357
43.13
10.35
4.12
2.00
0.83
0.80
0.90
0.91
3.97
0.89
0.94
0.94
0.93
B
S5P40 Peak1 MeOD 700 BinS 08/26/08
173
O
H
O
H
12
S
S
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
2 8 . 0 2
2 8 . 0 4
2 8 . 1 4
2 9 . 2 1
2 9 . 5 7
2 9 . 6 7
2 9 . 7 1
2 9 . 8 4
2 9 . 9 2
3 0 . 0 4
3 0 . 2 6
3 0 . 3 0
3 0 . 4 1
3 0 . 4 2
3 0 . 5 4
3 0 . 6 1
3 0 . 7 2
3 0 . 7 6
3 0 . 8 2
3 1 . 1 3
3 2 . 9 3
4 8 . 5 7
4 8 . 7 1
4 8 . 8 6
4 9 . 0 0
4 9 . 1 4
4 9 . 2 8
4 9 . 4 2
5 2 . 6 1
6 3 . 1 6
7 4 . 5 3
7 9 . 8 6
7 9 . 9 3
8 1 . 2 4
8 2 . 7 2
8 4 . 3 6
8 4 . 4 7
8 4 . 7 7
1 0 9 . 3 4
1 3 0 . 5 5
1 3 0 . 7 6
1 3 0 . 9 8
1 3 1 . 1 0
1 3 4 . 0 5
1 4 6 . 4 2
B
S5P40 Peak1 13CNMR MeOD 600 BinS 01/26/09
1 7 4
O
H
O
H
12
S
R
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm 1.299
1.318
1.334
1.348
1.360
1.366
1.372
1.377
1.389
1.411
1.417
1.422
1.428
1.448
1.460
1.464
1.479
1.484
1.491
1.503
1.515
1.522
1.527
2.027
2.039
2.049
2.055
2.075
2.087
2.207
2.210
2.218
2.221
2.226
2.229
2.237
2.314
2.326
2.870
2.874
3.308
3.310
3.313
3.405
3.408
4.894
5.013
5.016
5.346
5.350
5.356
5.361
5.367
5.373
5.376
43.86
10.55
4.08
2.00
0.69
0.74
0.83
0.82
3.92
0.83
0.85
0.87
0.87
B
S5P40 peak 2 Rf(0, 4)  After deprotection MeOD 600 BinS 01/24/09
175
O
H
O
H
12
S
R
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
ppm
2 7 . 7 1
2 8 . 0 2
2 8 . 0 4
2 8 . 1 4
2 9 . 2 1
2 9 . 5 7
2 9 . 6 7
2 9 . 7 1
2 9 . 8 4
2 9 . 9 3
3 0 . 0 4
3 0 . 2 6
3 0 . 3 1
3 0 . 4 1
3 0 . 5 5
3 0 . 6 1
3 0 . 7 2
3 0 . 7 7
3 0 . 8 2
3 1 . 1 3
3 2 . 9 3
4 8 . 5 7
4 8 . 7 2
4 8 . 8 6
4 9 . 0 0
4 9 . 1 4
4 9 . 2 8
4 9 . 4 3
5 2 . 6 1
6 3 . 1 6
7 4 . 5 2
7 9 . 8 6
7 9 . 9 4
8 1 . 2 4
8 2 . 7 2
8 4 . 3 6
8 4 . 4 8
8 4 . 7 7
1 0 9 . 3 4
1 3 0 . 5 6
1 3 0 . 7 4
1 3 0 . 7 6
1 3 0 . 9 9
1 3 1 . 1 0
1 3 4 . 0 6
1 4 6 . 4 2
B
S5P40 peak 2 Rf(0, 4)  After deprotection 13CNMR MeOD 600 BinS 01/24/09
1 7 6
O
RM
T
PA
O
RM
TP
A
12
S
S
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1 . 2 5 1
1 . 3 1 3
1 . 3 2 3
1 . 3 3 2
1 . 3 3 8
1 . 3 4 3
1 . 3 4 6
1 . 3 5 3
1 . 3 6 5
1 . 3 7 6
1 . 3 8 6
1 . 3 9 4
1 . 3 9 6
1 . 4 0 3
1 . 4 7 9
1 . 4 8 3
1 . 4 9 0
1 . 4 9 4
1 . 5 0 0
2 . 0 0 6
2 . 0 1 2
2 . 0 1 6
2 . 0 2 1
2 . 2 0 1
2 . 2 0 4
2 . 2 1 7
2 . 2 2 0
2 . 5 8 8
2 . 5 9 1
3 . 0 6 3
3 . 5 4 6
3 . 5 4 7
3 . 5 8 6
5 . 3 4 0
5 . 3 4 8
6 . 2 0 8
7 . 2 6 0
7 . 3 8 2
7 . 3 9 2
7 . 3 9 2
7 . 3 9 4
7 . 3 9 7
7 . 3 9 9
7 . 4 0 2
7 . 4 0 4
7 . 4 2 1
7 . 4 2 4
7 . 4 2 6
7 . 4 2 8
7 . 4 3 1
7 . 4 3 3
7 . 5 4 2
7 . 5 5 2
7 . 5 6 0
7 . 5 6 5
4 9 . 3 8
6 . 7 0
3 . 3 9
4 . 1 8
8 . 7 5
2 . 0 8
4 . 1 1
2 . 0 0
0 . 8 9
0 . 9 4
3 . 2 0
3 . 6 3
4 . 2 1
1 . 0 2
0 . 9 6
1 . 9 8
0 . 9 6
1 . 0 1
1 1 . 4 8
7 . 5 7
B
S5P150 SS+R 700 CDCl3
1 7 7
O
SM
TP
A
O
SM
TP
A
12
S
S
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1 . 2 5 2
1 . 2 9 9
1 . 3 1 0
1 . 3 1 3
1 . 3 2 1
1 . 3 3 2
1 . 3 3 8
1 . 3 4 2
1 . 3 5 2
1 . 4 0 5
1 . 4 1 8
2 . 0 0 3
2 . 0 1 3
2 . 0 2 3
2 . 0 3 2
2 . 1 8 4
2 . 1 8 7
2 . 2 2 9
2 . 2 3 2
2 . 3 1 5
2 . 3 1 6
2 . 3 2 5
2 . 3 2 7
2 . 6 2 8
2 . 6 3 1
3 . 0 6 2
3 . 0 6 3
3 . 0 6 3
3 . 0 6 5
3 . 0 6 6
3 . 0 6 7
3 . 5 8 6
3 . 5 9 0
5 . 3 4 0
5 . 3 4 8
6 . 0 0 6
6 . 2 1 1
7 . 2 6 0
7 . 3 7 8
7 . 3 8 0
7 . 3 8 2
7 . 3 8 7
7 . 3 8 9
7 . 3 9 0
7 . 3 9 1
7 . 3 9 3
7 . 3 9 5
7 . 3 9 7
7 . 3 9 9
7 . 4 3 1
7 . 5 1 8
7 . 5 2 8
7 . 5 4 0
7 . 5 4 2
7 . 5 5 2
4 0 . 2 5
4 . 4 4
2 . 5 4
3 . 0 1
1 0 . 4 5
2 . 1 2
2 . 0 5
2 . 0 0
0 . 8 9
0 . 9 1
6 . 1 3
4 . 1 5
0 . 9 9
0 . 9 8
2 . 8 7
0 . 9 9
7 . 3 4
4 . 8 6
B
S5P151 SS+S 700 CDCl3
1 7 8
O
RM
T
PA
O
RM
TP
A
12
S
R
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1 . 2 5 3
1 . 3 1 5
1 . 3 2 5
1 . 3 3 4
1 . 3 3 8
1 . 3 4 4
1 . 3 4 8
1 . 3 5 4
1 . 3 6 5
1 . 4 0 6
1 . 4 2 0
2 . 0 0 6
2 . 0 1 6
2 . 0 2 4
2 . 0 2 6
2 . 1 2 4
2 . 1 9 0
2 . 1 9 3
2 . 2 3 3
2 . 2 3 6
2 . 3 1 7
2 . 3 1 8
2 . 3 2 7
2 . 3 2 9
2 . 5 9 0
2 . 5 9 3
3 . 0 6 5
3 . 0 6 6
3 . 0 6 8
3 . 5 4 8
3 . 5 4 9
3 . 5 8 8
5 . 3 4 2
5 . 3 5 0
6 . 0 0 8
6 . 0 0 9
6 . 2 1 1
6 . 2 1 4
6 . 2 1 7
7 . 2 6 0
7 . 3 8 2
7 . 3 9 2
7 . 3 9 5
7 . 3 9 7
7 . 4 0 0
7 . 4 0 3
7 . 4 0 5
7 . 4 0 6
7 . 4 0 7
7 . 5 2 1
7 . 5 2 4
7 . 5 3 3
7 . 5 4 2
7 . 5 4 4
7 . 5 5 4
4 6 . 5 5
8 . 0 5
1 . 9 3
2 . 1 0
2 . 0 0
2 . 0 0
0 . 8 5
0 . 9 1
2 . 8 4
3 . 1 3
3 . 9 8
0 . 9 8
0 . 9 0
1 . 8 6
0 . 8 7
0 . 9 5
6 . 9 6
4 . 3 5
B
S5P148 SR+R CDCl3 700
1 7 9
O
SM
TP
A
O
SM
TP
A
12
S
R
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
ppm
1 . 2 5 2
1 . 3 2 4
1 . 3 3 3
1 . 3 4 0
1 . 3 4 4
1 . 3 4 7
1 . 3 5 4
1 . 3 9 4
1 . 3 9 6
1 . 4 0 4
1 . 4 7 2
1 . 4 8 3
1 . 4 9 4
1 . 5 0 4
2 . 0 0 6
2 . 0 1 3
2 . 0 1 6
2 . 0 2 2
2 . 0 3 0
2 . 2 0 0
2 . 2 0 3
2 . 2 1 3
2 . 2 1 6
2 . 3 1 5
2 . 3 1 7
2 . 3 2 6
2 . 6 3 1
2 . 6 3 4
3 . 0 6 6
3 . 0 6 7
3 . 0 6 8
3 . 0 6 9
3 . 5 8 7
3 . 5 9 1
3 . 5 9 2
5 . 3 4 2
5 . 3 4 9
6 . 2 1 0
7 . 2 6 0
7 . 3 8 2
7 . 3 8 5
7 . 3 8 7
7 . 3 9 0
7 . 3 9 3
7 . 3 9 5
7 . 3 9 8
7 . 4 0 0
7 . 4 0 7
7 . 4 2 2
7 . 4 2 5
7 . 4 2 7
7 . 4 3 0
7 . 4 3 2
7 . 5 1 8
7 . 5 2 8
4 3 . 0 2
4 . 6 2
5 . 6 0
2 . 0 4
2 . 3 5
1 0 . 4 2
3 . 9 1
2 . 0 0
0 . 8 5
0 . 8 8
6 . 1 4
4 . 0 4
0 . 9 5
0 . 9 1
2 . 7 5
0 . 9 2
9 . 4 6
5 . 8 9
B
S5P149 SR+S CDCl3 700
1 8 0
O
RM
T
PA
O
RM
TP
A
12
S
S
ppm
8
7
6
5
4
3
2
1
0
ppm
8 7 6 5 4 3 2 1 0
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300176 MHz
M
C2       echo−antiecho
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300215 MHz
SI                 4096
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
E
cho−Antiecho
SW                8.304 ppm
F
I
D
R
ES        22.710829 Hz
SFO1           700.1327 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 256
N
D0                   1
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z2              30.00 %
G
P
Z1              30.00 %
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO1        700.1327375 MHz
P
L10W        1.25512731 W
P
L1W        13.05232048 W
P
L10              12.57 dB
P
L1                2.40 dB
P17             2500.00 usec
P7                52.00 usec
P6                26.00 usec
P5                17.34 usec
P2                16.12 usec
P1                 8.06 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
L1                   30
I
N0          0.00017200 sec
D16          0.00020000 sec
D12          0.00002000 sec
D11          0.03000000 sec
D9           0.06000000 sec
D1           2.00000000 sec
D0           0.00000300 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 293.7 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86.000 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 406
AQ            0.3523060 sec
F
I
D
R
ES         1.419422 Hz
SWH            5813.954 Hz
DS                   16
NS                   16
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4096
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
mlevetgp
P
R
O
B
H
D
 
 
 5 mm PATXI 1H−
I
NSTRUM           spect
Time              11.19
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20081023
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
N
A
M
E
 
 
 
 
 
 
 
 
Bin_BS5P150
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
B
S5P150 SS+R CDCl3 TOCSY 700
1 8 1
O
SM
TP
A
O
SM
TP
A
12
S
S
ppm
8
7
6
5
4
3
2
1
0
ppm
8 7 6 5 4 3 2 1 0
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300201 MHz
M
C2       echo−antiecho
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300209 MHz
SI                 4096
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
E
cho−Antiecho
SW                8.475 ppm
F
I
D
R
ES        23.177950 Hz
SFO1           700.1327 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 256
N
D0                   1
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z2              30.00 %
G
P
Z1              30.00 %
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO1        700.1327424 MHz
P
L10W        0.91556209 W
P
L1W        13.05232048 W
P
L10              13.94 dB
P
L1                2.40 dB
P17             2500.00 usec
P7                52.00 usec
P6                26.00 usec
P5                17.34 usec
P2                13.78 usec
P1                 6.89 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
L1                   66
I
N0          0.00016855 sec
D16          0.00020000 sec
D12          0.00002000 sec
D11          0.03000000 sec
D9           0.12000000 sec
D1           2.00000000 sec
D0           0.00000300 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 295.0 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84.267 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 645
AQ            0.2589172 sec
F
I
D
R
ES         1.931492 Hz
SWH            5933.544 Hz
DS                   16
NS                   16
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3072
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
mlevetgp
P
R
O
B
H
D
 
 
 5 mm PATXI 1H−
I
NSTRUM           spect
Time              11.19
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20081008
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5
N
A
M
E
 
 
 
 
 
 
 
 
Bin_BSSP151
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
B
S5P151 SS+S CDCl3 TOCSY 700
1 8 2
O
SM
TP
A
O
SM
TP
A
12
S
R
ppm
8
7
6
5
4
3
2
1
0
ppm
8 7 6 5 4 3 2 1 0
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300227 MHz
M
C2       echo−antiecho
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300215 MHz
SI                 4096
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
E
cho−Antiecho
SW                8.475 ppm
F
I
D
R
ES        23.177950 Hz
SFO1           700.1328 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 256
N
D0                   1
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z2              30.00 %
G
P
Z1              30.00 %
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO1        700.1327585 MHz
P
L10W        1.26382732 W
P
L1W        13.05232048 W
P
L10              12.54 dB
P
L1                2.40 dB
P17             2500.00 usec
P7                52.00 usec
P6                26.00 usec
P5                17.34 usec
P2                16.18 usec
P1                 8.09 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
L1                   30
I
N0          0.00016855 sec
D16          0.00020000 sec
D12          0.00002000 sec
D11          0.03000000 sec
D9           0.06000000 sec
D1           2.00000000 sec
D0           0.00000300 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 293.0 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84.267 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 645
AQ            0.3452063 sec
F
I
D
R
ES         1.448619 Hz
SWH            5933.544 Hz
DS                   16
NS                   16
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4096
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
mlevetgp
P
R
O
B
H
D
 
 
 5 mm PATXI 1H−
I
NSTRUM           spect
Time              17.44
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20081021
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
N
A
M
E
 
 
 
 
 
 
 
 
Bin_BS5P149
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
B
S5P149 SR+S CDCl3 TOCSY 700
1 8 3
O
RM
T
PA
O
RM
TP
A
12
S
R
ppm
8
7
6
5
4
3
2
1
0
ppm
8 7 6 5 4 3 2 1 0
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300213 MHz
M
C2       echo−antiecho
SI                 1024
F1 − Processing parameters
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.00 Hz
SSB                   2
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 QSINE
SF          700.1300209 MHz
SI                 2048
F2 − Processing parameters
F
n
M
O
D
E
 
 
 
 
E
cho−Antiecho
SW                8.304 ppm
F
I
D
R
ES        22.710831 Hz
SFO1           700.1328 MHz
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 256
N
D0                   1
F1 − Acquisition parameters
P16             1000.00 usec
G
P
Z2              30.00 %
G
P
Z1              30.00 %
G
P
N
A
M2         SINE.100
G
P
N
A
M1         SINE.100
=
=
=
=
=
=
 
G
R
A
D
I
E
N
T
 
C
H
A
N
N
E
L
 
=
=
=
=
=
SFO1        700.1327760 MHz
P
L10W        0.90508169 W
P
L1W        13.05232048 W
P
L10              13.99 dB
P
L1                2.40 dB
P17             2500.00 usec
P7                52.00 usec
P6                26.00 usec
P5                17.34 usec
P2                13.70 usec
P1                 6.85 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
L1                   30
I
N0          0.00017200 sec
D16          0.00020000 sec
D12          0.00002000 sec
D11          0.03000000 sec
D9           0.06000000 sec
D1           2.00000000 sec
D0           0.00000300 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 292.8 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86.000 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 645
AQ            0.3523060 sec
F
I
D
R
ES         1.419422 Hz
SWH            5813.954 Hz
DS                   16
NS                   16
SOLVENT           CDCl3
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4096
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
mlevetgp
P
R
O
B
H
D
 
 
 5 mm PATXI 1H−
I
NSTRUM           spect
Time              13.45
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20081022
F2 − Acquisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
N
A
M
E
 
 
 
 
 
 
 
 
Bin_BS5P148
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
B
S5P148 TOCSY 700 SR+R
1 8 4
